var title_f20_41_21136="Malignant mesothelioma III CT";
var content_f20_41_21136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant mesothelioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 317px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE9AUMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACtHQ9GvdbvBbafCXb+JzwiD1Y9AKu+FfDdxr07tvFvYw8z3LDIQegHc+1eggx2lidP0eBodPyPvH55T/fY/0oAzdK8Padozyq2NQv0wRKRiOM+w7/AFq/E0t4kkaFpDvw3PH1+lbNh4ennQDZgOud47+1bGl2VjpTG2MP26+ZeIU6KfegDP0jwtdajbk+X+7x8ztxgV09n4Qso7YCNPPueqhRxkVqWNpcqVOq3XkoFybZCAqirM2tW+nEGzhyTxntigC3ofhC0t5lv9ReONQuXhHJ+ldtZ+MNN0kNBpunx7oxw54JzXAHW2YPu2MMZZj0HtWRfNvufOMjDcuRg9aAPXD44v5pFVPLRXHBxUEmvX9xKYprmXywd24dD7V5na62sFsPMDhYz8xbrWnp/iuGN5ElRxuGQxFAHZx3jyOySTs8bj5ST0+tZlyi+bNIzFUHX/aqjL4x0qyiLfZQ7J1bNcbq/i6Oe4kaF2VJiOh4HtQB2qanFatukkyh5BB7VX1LxppNtCGW6DSg4KKe1cS1zpt7ZMZr3/TT+7MWegrhdU0VLJZZ4Zy7ngDPUUAe7+A9YPjq5a1Miw2MBLOzH7wB6V3kviEWcwttFtUSGL5duOtfJ3hzXrrRBJ9hnaNwNzIpxkVcvfizrIkDWWQxXAyfvUAfWSeInFuGvIY5iFztUcg1Sl1nTdTl8iS3ijUAllNfK2neOvG8SNPeXSiBm3DPBx6V2Nl4xeWeGR8RyOv7zac5oA9p1Xw611pr3OiRxgIOUU/eryrWdfvdNk8pIl89Dzz0PvWF4g8Za3e3YstN1KWxidcZVucVwxe5tWnS5vDNLJJzMWzQB6np2tajclDcGNXY5JPauqs5ioB3g4GSpHQ14E2qX0EYa1nJYHA3+nrU0fiXWrSV5hqIO5flBPAoA9/S7RQ887bnUYK46+1VNV8QAlAtwkAI4Cn+fvXhlt4q1cRNFJdBi3zM27GfcVCNcuUSRXulYkHLMc4+lAHui+I1S3dEumkI+/z19ia5vUfEs9xJIkNm0m0bSwry/T9V1O7RUtb+OOJiQc9frVqZ9fZWZ9YUKOu1cbvegDp4ZdVtSZfspkkY5Vm/rVq31DxKJc2gVUT5miY9a871G/1qzgluH1SWc4Hy9OK5VvHeto/+j3BjAP1J9jQB9B2uo3NzChe1a0uw2S6n5WPvWja67umSHUYjEzHYueh989q+dbb4meI4Pl+0RumclSld/wCFvirpmqPHY+IrZLLdwLkHcuff0+tAHovibw/ZamjxbI0kA+V1HB+teS6vpEul3gMm4KpwGAwSPWvVUuRNOsWm3lvdQ4+do5A7KO2AO1R6tY2+qQBJEXenygydx6igDxfVtKtvEQZEEdvqUYxFIeBN/st7+hrzu5gltriSC4Ro5Y2KsrDkGvYdc0WWzui0q7Ez+7AGM+9c94v07+3bSS/giCajaKBKij/WoP4vqP5UAedUUUUAFFFFABRRRQAVueE/D83iDUfJVxDaRjfcXDfdiT+pPQCs/SdPuNW1K3sbJN9xO4RB/U+w6mvXtP0iLT4U0PTyXiRs3M6/8tpO+PYdBQAWccTKmn6dA0FhAMRofvSn++3qTXXaT4fSzX7RqoURbMqD0x71paDoscOZLnCqo+TI5H1pt3az+I7gRzlrbT4m2nnrigCql9NqKi10iFoYHG0zkdvQVIP7O8LRqCQ87c792WrUvNtpbizs1CAD5WHTH+NYS6FGH8+/czTbs4Jzg9qAJZp7nVro3DhlidMFh3FXDaBbaNXIbAwo7H3qyHAiKRELkYKYqJG2SLuG84wuDxQBE0CLHll+/wAOueGoYOkcm9AVwFyT0FSOWaLY2Q/3sehqvMxYBSMFfvA9D7/SgBZ4dqlgy+SQM7ucj2qOeMBkMeWUsFwT0FPiKsWDYI/hz0FRyRKLqNHyJME5J+U0AEkS+cwUBgeD6VSk06B53YhiMfdxwPpVuNQsLbPlYvuc01phEXZn3278gDsaAMSXRY5izKNkoORtrn9dmuLaCZnAaE4Ax1HrXau8ssG5l2j+Bh3+tYXia1JsY1Z484+ZQODQB5nLfM0hdh5aAYXHvXQ+GLKOG0e+vVDSA4ijI6e9Z40xTdQfIXAbkdq6cI91M0NrGBHtxkDkUAOQNc3BkuTuiC4jRRxmtGz0+d5BIyrHgYI7j0rQtLaO1iUFASP5+tTbcv8A6wcfeNAFW306FbpBMxeZv4h0qeSztC2xoF+U8AjgmleUhcIhYDnd7U/a+3exJDDKjPSgCKbT7Lyh58KqT94Lztrn9Y8P2dxIFjjdQVyPTPtXSuAsYYN1HzDrmiyjIm82UBgF49qAPPpvBE8jLtnlRU6D1+lN/wCEA1dAz5Lr25r0RWBLBmLY/h/wrQjnkIVmb92goA89tvB92sIjmDRSMMh17j2rRsvC13HBGTdvndxv6AV2pnkeVUbJULtA7getRgbjneXQHJHbNAHNT6I9zGTJHlV+XPr71xeveBFiRpbPc5JJPbH0r1mQeYEVm2KT0HYU+4RZGVPkbso9RQB813ulXNrG0rRnyVbbuPFZ9e0fEDw8PswkgjLpnLqP4a8j1GykspFWTA3cgelADdPv7vTrqO5sbiWCdDlXjbBFe0eBviMmuyQ6drXlW+p8LDc5wkx9G9G9+hrw2lBwcjrQB9a3WkDWbVreZFDof4+vvXnOs2c2h6sdq/cOQWHDD0NL8KvHEmrCHSdSuGXU4h+4nY/65B/Af9oD8wK9Tm8MDxNp73G1t0J43DrQB8yeOdLigvBf2Eey0ufmZAOIn7rXLV7j4m0RrFpbK/I+x3HyZ2/dPY14/ruly6RqMlrKQwHKOOjqehoAzqKKKACiiuo+Huhw6zrofUONLsx592x6FR0T6seKAO48CaM/hrQl1G4jVdW1OMiEsObeA8Fsdmb+Vd34c0zz4o9g2vn5COprHja41fURMx2qzD5McKgGFUfQAV7d8M/DVtqUEl5NHss4f3aBOC7Y5P60Ac1JaNHaETMd2MDIwc+lZEzMqpExIUjkepr1bxp4fis7WG4hkMkIOCrdfz715XqaCKUMWIVzvH+zQAzcnmKANxHBJqFpMuVkVQucjHf6024ePcuMqH4BPY01yMuzoVIGCD/FQA2OSIBlKvk/OGJ+99KhuJlS385w0YToPX2pNzLCQwK7jlG9KwtcvhsK53FTyexoA0ItVDOAoOJOhBzz6VY+3RTYdUPyjEgrhrXUxCjiZjGUyY/QE9q0dB1eKVGXO0ucOrdDQB1Vosk4VMLtP8IPSieXKO74yvBx14rGuNRlRWWKFvMU8YqtdzX9xGEwFJHbjbQB0z4VAwGBMgLfT3qBzF9oVPvQJ3/h+lY9qk0YY3EjEIgK5br71z+seJbqyuESCHcv8TGgDtJ5gsbLuzufgDjA9K5zVpvtCNESGVCRisMa3cXMcwyzSysOTwMVZkmWOExZ3s/DA880ATW0BuUhWwTaE+VyR1966K2tYrUQtjLk4OP61S0aK4VBEwCIeQF7+1aLxrFGxkbk5yM0AKGdpJXjiC7W28njnvQY1I2kn5Ty57mljbzEVV3KCP8AJpoCshMbEgHOD60AO2jYNrFUPVVGc06YgtEgOCwwMdKj3KG8yP55GG1R0FKcxLGoyZ3PzMRwPpQArEKVUbQ3Q+/vUw3hMs4Bz9wdhTYcm5dpNhZPve49aeHI2iFcysSTkdKAIo40PmHJCqD19asKB5SSLJhMYOTksfpTEzJIflyhPU9M0pIS5knEQCgYIx/KgBZHbzG2thT8hbvih5FWMrkeWvBGcEmofMywR0xEB1PVjSErIoGQoX160ATJK8srbAAyr3qSGZEwy/O/Qn0PrUIP7ncpAwfxNOgViWLAZ7JjFAFryGvA8c+NjcDjqPWvHfi5p4sdUthHGqxFSAw717Ik291MjMp4AVRXnPxrs5XsrS8ZVwshUkfwg9BQB5FRRRQBJbzSW88c0LFJEYMrA4IIr7m+Gni7TPEngbT7myCwxKgS7jJ5SYABsn35I9q+Fa9Q+Avi1NB8TPpd/K66Zqq+QRn5UmyNjn8ePxoA+hfH3h9dT0uWa2CsoGV4yce1eAeItBa+sjYyMiTwgvbu3f1UnsDX0dpV/Jp3iL+ztUIyWMTp2B6flXJ/FfwaNM1B5AoFvKPMQoMFvpQB8kspRirAhgcEHtRWnraxtq92fuEyHj0ooAywCxAAyT0Ar2/TNPTw7oFtocCf6bcAXOoucMQx+6g9gMfjXFfCXRku9an1i7X/AELR0+1HPR5R/q0PsSP0r0C1d9RluLwj/TJn3uD6eg9qANzwvaYbzChcEhV28kmvozw/c2OiaRY6OZAl2652+hbua8q+Fujx3moC4nBWxs1852HALDnBqaOa91/xXPLbb2klkKoF/hWgD1zxDpCXdugvL3yLSMZkdiOa8A1S6gn1S5Ntl7ZHKRsfY11PxC1eW1t00S1uHkKczsWyA3pXCu4LoxYDA4XoKAJCS0oUklW4I7qaLifMnlJllQY92NNeVfODpnLDDKKiuWTcJQCvOMnuKAGlmkd48nOeAf4R6isu6tAUUxDzNxwdw/WtJ08ycMHLbRnj+QpYDvMryLuU/wB04KmgDlH8PnLIWwC3y5GSp9av6T4fitm8qVDK+c+d03Gt+RcW4cuonU5xjjFMZwrIFDYJ3N6DNADTHHBFufPynBA5qjqO1YkEJLeYcL/snvmtRogu9E2uPv5zn86otDHHcJMN2CeYz2oAhnQOpRg3+rAxnoazrqw+0WUhmtsNERg56j1rq0VGfgEFjjAHU024iiJ82PDHkFR92gDy28b7PsG1WuJDxg4UD6Vt2FinlJJkEH7/AH5qvdaXbX2vypvaKMLuGOQDW9axBI0twoWToOOvvQBoQ/NBFGh2tn5f8aUosszJwmw5OenvU1vGImk83IO3BalmbG0kLll+8aAI5GDHzh8io3lhO7D1qOVkMnluvl85+XhqVVD7F24Yd2PAHrmkg+eeRs4WMHAPUn2oAWVSY1LACMcAL1FIWLGCPnJ/i7LSHY2B8xJOTS5JjdWXywe46mgBQBEQqfPIeGNT4CKiI3yj5mYHk+1RoGETpGT2Az0p/lxuoiib/VkMz+poAZcybINsS4P3iPSo3kEYdnyq7fmp9yyqdsZPmyNy3UH2qKR0cuZR5pP3UoARD+7Lr8wYZH0pZpIi6MFCkjBPUUwuSokkARU/hBpchneVwoQDKgc0ASM53RqqgAdD6+9WNwEmyWUliO/OfxqrG3myIY4ixIz7f59quRogCoADJ3ZetAFi0EaRhAp355PcfjXJfGK2jTwqSc8yKwYtnJ/ya6+2dQ5QcuOGz2FcB8bpFOjWQ8twxlODnjHvQB4zRRRQAUoJBBBwR3pKKAPpTwD4rj8deE7W3uLgJ4r0dMSMeHu7YfdYHuyjAPc9a9u0ho/HXhCTT7ra2q2QzHI3VvTn9Pyr4J0jUrvSNRgv9OneC6gbckiHkV9GfAr4s28niq1ttRQWs9w/lYU/I4OOB70AeLeNLIJ4r1RQkcYE7Db0xRXT/HK1if4t+KGTfg3ZPA46DNFAGnY2Q0jwbpuiKrLPdD7feE8EN0VD9MfrW5ZDybaCRtqFhzEv8X41mKYtQ1CV/MfdI25u+QPSuv8ADdhDq+t2cJyIkYNIoHQD1oA9P06KLw/4Cgt4ji6viHmB647VsxtD4L8G3GtzIn9pzpthVh1J6DA/OsWKNNe8TRWrbkjiYL8v9xfWsP4p+If7Z1VLG0cLY6edqhTku3TNAHHieWd55b98zTsZXIHfNVpJFR/LYgtjIGO31p4dGdRk4PXd0zTcgZlIBUZVvegBYSXYxoAzMeB6UlxMAjh2yc7enX3+lVLm7SyjeTIDKMBc84rIurwXB8wvhWG4Ad/agDZa/gQqzFlQ/KMDvQ17bNliSQ3Bx61zk1wGjGM5boDzj2oZiH8tYmDMAcZoA6qG4gmIjZh5YXJz1NSxPvjbKhVxwPUVyEcm5pVlLKFGSPSrUd4RIiI8q5ABzQB0lsX2ERptYkbT/eqV4IxMTcKzKoAO3t71StroXEht2OGiAII9far927SFigYyEcg+tADZITJGWSTcCMAA8he5+tVbmVIgsscocRqVI6AjFWvLRQZFlAcjBXt71HNZxXFttlQhc/KRxzQByXh2QwarPLAquWPJbnbWxKhXUzIZBuyMgf0rN01UsNUkSaMx7G3dc5FbjhY5nkaM5b5847e1AFqebchfZl8YOOhqsYSY4zK3zbvlA4C/WnxBwGX5SzAMoJ6VPIP9CYnLuRw2ODQBAY5JZSjgKFG4Af40yNWdZMhUB4XnlqecxWzYBZ84PpimRRrDtZizSHq56KPSgARPMcxsCEjXLMOppIs3NwyKMRIvB7GgqrrKSxGOAB/FTogjhV3FU24AAxz6UAKXygSMgZPzBaWa5SMLHb87s73xwKepESoDGv2kgg46CoCFiRdrBpzyxxxQBWRn87C/MEYsM96cEwGZ+cnHy9Rnv9KGlLKViALdlPFOYiNWyz7gMFsdj6UARr5KSFmV3ReGx3PanlzJJl0wij5Qoxj2pybIlztBTsD/ABU4kybfLBKjl6AHKREocMd2fugdRUkaqincxEjc/N0AqGHbJIuMkZyoNWznzWRFErt1LdFoAmVQkADLubsVHNeefGx1bTNNOCCzkgV6NDtiKbQ27OACc7j/AErxr40agLrxQtqjlktYwpHYMeT/AEoA8/ooooAKKKKACnxu0UiSRsUdSGVlOCCOhFMooA6K58UXN9O9zqAFxdyHMkrHlz6miudooA9/8PCNLVC8WHHceldr4IlNrcX16oAZlCKcc471x1krSkBWAVfu11+ms0GnFJAA5/5aZxx6UAdXZanHo+j3+oISt1MDGuev1Fef72D+eCWeTLMwHB5rV1m7aVYLchfKVep9ayi0scTcYGcOme3qKAGTSFpWSOEg4DZJ4/CqWp3bQQEKyq7fMwHar0jKrGSLpjGCc4rkdWm826LsC2MgDOPxoAZO7yO8jKz55y3Qe1V0BjkRDzn5sdhToXZLPy5X3szblOeMehobIx5bYyc8jvQBOzYuWC7CrDOfQ01mleXYwIcdDmoVQlZFdigbknvu9fpU5yIVJbIxzjvQA6EhJHMz7pXbByOB/jV2K2yqCVy0gbJwOo7VTY+W0eEyrDgN29zV+1zGwWWVnb7wI6/SgC3agpdSSFPlxhWHat2KRsrKpZs8hVFZtqk3lOEC7XP3T1NW7BDCyyRynZCDuB6A0AWJTbmMeWoPPU9jTWEihULHjkA/w0sceYjxuVmy3t71PADcRsD84XIDY5FAHN3lsZL0zopL4wSeh96ntZpDIYmkBkjGcseMH1qSWTDrHuJK8OcfdGaieIPJGY0DpnnPO4e9AFuS1ZoxIhCoMDIPX6UkBE8jPCz+XGMAdAaUnzIypXOOm3jHtUmSHCRyDeF4j6Ae9ADC8sYEjqP8KbOzswhJHlt8wPpUsoWPy2nYeYp5HUMfSqUhbzMznDbjkdselAEwaQzgJ0xjBHX3FTZVIRuwAeg9KrwF3farfLngtVi5TfN5b7dqYPFAACrhHY4UHoRURXMzg4TAyKlv5tsao45Tk4HJ9hVVk/cPJI3ydcdzQAQlJcyHCkf3u/0pVRRA8jKxz1JPHtilKo0ZcgnAyuelIzYhRhIGjc7dg9aAEKbYAWAAf7q55FJk+WERiJG4L4wAPSpGQSFmYALGM5PrSW5Esqq44PIoAfuaGIcHPQ8dPerC7bWMbdu+QfezUUkbnIU4GcYzmpolQEI43tnv0FAFmJkgWSVmQLEheRh0RQP518z6/fnVNavb0k4nmZxnqATwPyr2b4sa+uk+Fzp9tIPtepNhsDkRDqc+5xXhNABRRRQAUUUUAFFFFABRRRQB9D6FB5kKlXHl7crIe1dLIu6GNZmAdVAGP0rmtPj2bOfMTjeg7H1Fb07b4lUkAngOO3tQBBJLvlxIm/acHI6n1qB5TLKUH3/u7mpdzed52PlTgxg9feolJkfhcrvyDQBX1IeTbSCMeWUHzY5z71zqhpRiXBLcoT0NdDqUi7Csw5YkYz0rlogjt874lGVBB4xQA/KLcmPaDCxyQOzU8qcOGXJXn5TxioUXyUZjlyvc0rZCRDcQJeW29KAHx5aQyKd3y/xVPMqxQBg42EfNnjFNCqQkfLArh9vAFOt4lLrDIN0W04YnlqAEhiD/ADIpZTwMnGfpWnagC6him+U5wuPWqEBMYQSELFkgf0FbGkon2fKozsWzhuTn2NAGtbRAOZAR8rbWH9RTzGsdwE/5Yk7mBp0IJzCG4PVuhNWFk8pjDI6uV5yRyR6UAKykK/BSP+FQcbqYk6xWyOhAX7r44zTPNiDvldkZOcdStVtVBtSvlqyxkbsGgCjcsXknKMAztwoHJFSQHagx+7GMEf8A16pWLD7YGVdiPypPODWgIXdnWIgkNkntQA6NWilaEpviblRjGalB3+YGQeWvy7qGZXkjmaTocADgGmPvMkbynagbK46H60AMVhJIdpKuvAVh196lZfOieNQQM5ZmHAomZJZmIBI243dBn2qOUu0TxzMWUDaGHUmgDMZbjzCiOG2nJfPAFayxOZRMGaUY+8o61l3eLe6FuAdzp83oR9a0bWWf7MNk+wAbUVu9ABsSJmlJZ3blc9qiuCSXlKbivAGeBU6gRRkAmTcMBPSmENhvuqSwwgFAEJUhERhknk+gpUUHkfdXj0oIEbMVBZielCq7tjIKY3IvSgCS6IWIRmQMoPTHWpNhKBsKzMMZA4UfSolOQ0kwyQflU1YXEaM7DGRnGePpQARqu5VBOEPU9Ks20SyMQYzyScj+EDqTVcecyhd48k8v2OPSuU+Jfip9B0v7HpkiLd3yFGKnmOLv+J6UAeXeO9bk17xJdXLEGCNjDAF6CNTgH8etc9RRQAUUUUAFFFFABRRRQAUUUUAfRdmSt4g24cjO/wBKuTx/vFLysVbqRU95prRR2kxD+XuwWPGabcEggShCp+9ngigCJXyG2jCn7v1qKYsrRjYVJPDDsfepT5RUtCjfIO36VCLgrGQ5fHVsjpQBl6yTLKqycMM4wep9TWK8kccKxv8APnjIGPzq/wCInPmAqdgYfK2OT7VnAK8CyIoTbwwPUn2oAeRv3spbOABjnI9MU4F1Pl7TtUZUnp9M02zkYsAieQOQ+4849qkQubZ1AICHALd/egCVvldYQQGI3Fj6e9LHvTbtXMhPC46/SlhSN2R5Achcbu5pyzu/ysQCp+Vl6gUASBBMfNnQLEDgx45Bq/pry+e4kbYmMKFHT3qsjAS538SDv3qawfLOApZUPDetAHS2sa+TGXHzjIobzYlYzlMdFyOWpgkH2FN7fODlG7N7VPKhumWSYhlRAcDp9KAI1VCFdQPOQc7uh/xrC8UNNDYqZMtCG3nbzW20ysjPJF+5Pyj1WmXtktxayRsdyAZ2eooAxNDuY7q0ScAMmSpRf5itUooC7Cfs8Y49z71znh+CTSHnKMht5GO0E/d/Ct5nYiMxMA3UgdMev1oAktyhCxyADAJIHrUStIISqk4ZvlY8ipJhsLGLc8j46jHFPx54CqpRQRz79zQA2RkeFY1zgY6Dr/hUgLujbFCODuGehx2pJWhtS0cbBZJBhfXHrWedVtoz9leXfL90FT1NAENzC83mSo++VDTdPuWGoKhP7sD77dM+gqyEWSI26ZCj7xTkn8ayr6FoLdkjJMW7gHqfxoA6HCxF2G7ngn0pmzEpJIVFG73xWVY3bLbzGTdsAAXvn2zVg320qkS+W5UA554PagCa3kWbzZgxMedpxUgCqu/aQCmB7H1qOzaIBwrDbkgt6GpZJ1QKSRuxxjoPrQA5E2RKZgTgggehq20UgIym5nGEXsPfFVTNHbopmly7jp2/Cop9WisVkmuptkSpuZx2AoAm8RX9voNhJc3+BBAvA7yMeiivnXXNSl1fVbi9nAVpWyFHRR2H5Vr+OvFM3ibVTL86WcfywxE9B6n3NczQAUUUUAFFFFABRRRQAUUUUAFFFFAH3r4i8OgeD7tQSJbc+bgjsK8mnR/MWQld4Gfm6GvqOOKO7tPKlXMU8Ww5HUGvmbxQEtNav7OYhhbzGNQP4cGgDOkdnkDFsMey9qi3gs3kfMy/eB70rsZCu1lCKO3DGmWmBKzREeYOc+9AGFrkMkd7HIWI3DJz0X2rPRGlMkzuqleVH+NaWtSGO4VGBCZOWY5HNZYjXyWCZ4PI/vCgB5HnPlTuYjJB4xVmANKCtsM+WOWY8N71WR3lCGNFKIMehanSJvWJ4NwP3WA4waAJlfldzYweAP51bkClYwF8tuev8dU1R0Ekr7WONpx2qwFR4gkjbg42qwoAk3boVaPGI+GHUj6VcgkaIRKdowNyMOPwNZyDyo28obmjPznPb1qaGRJtkicoT34zQB0dldx/NwORl+4Bq8qlRGrbvs54GeNxrkrOUQXFyyLw33lNbWnakHeKCZ/kA+VjzQBquFVVjA8zc2SfT2pdoiJSdiz/AMATooPrUrMsjsYPu4wMd/emRuoXcAWGcYxyMUAcxqOjTzXbSRgJIflWIHqfWn2FvqNvOttOg8sL/rB1FdIyASyXBbDbcgk8g0oEn3mJZyBu9SKAIZEnNvGkYVWAxk1BbxP5TRvISVbJwP61dbBicEMxJ+XB6D3qOUF2EbcRY/h7igDC1jS5LyQLC/llRjcDyR7VxOoadJb6rDDhpMnIcnBPvXp0jrHEsgUuWGxAeqiqGr6fHNHkxhpgMq+eRQBi2U0lpavHIxjB5Vv73tRfkz2oEcg3FhjPT3pXgfyDG4JZehxkLVO8eSz2oEElunzE0AXreaJoikfCZ/1fqe5pl7P5WAg3zEdccD2rIXUkjvY5oV2oDliRV651mOXzCqqkZPD9qAB7jbp6LIdpkOGxxg1UR51lZirIUXARjx9asNqNs8wEoD7eSuOKwPFXimG3Xy4eZf7uO1AE2o61HbOfMYsYxl2Pb2FcN4h8Qz6qxjBKQZ+6D970zWbfX013IzSMcE5xmqlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH6ZeGL0ah4Z0q/Ry3nQK+/1NeK/GvSotO8eJcJ8q6hB5o9PMBwf0Fd18BtWGpfDq1tGbdPprfZ27YXtWX+0PAn9laHemIFkmMZkzyoI4oA8edTJud49yjjcOuackZgUhGBc/PtUd6YSinGXIH3j0x+FSxDdAPs5BkzkZHX60AY/iBd8MQbbGq/M+O1Y8bBHBXdtboBWvrRExB4XnDLnvWSrxnfJk7oxsLetADpmQAorFWXlNvFTBwFWROJthLDsxqBkIk8vZ+7YYB7k1LHuaUq+ASMR+oxQAoRWVC5IlxlgKmgLSkrszHCOMdM0xVkNuqsMkkkt3pVl8u2CwsQc4dcdaAJ7dw0Tu6qGk4wehpsCnPmMqhs7QvQDHpRcoIFts4ZFORg9c06cmaMhgUZTlQB94f40AOmDrdI2AzS/IoPQmpXPlo8LMoCHqvUH0+lRuFZBh9zD5v+uZpXPP7yM5Izgfxn1oA0tL1KWzhEbnO7O1R1ArZinjmVGV9gI5welctAUjTcQ2Cv3z/D7U+3maONtgJ3nCv60AdmZYCqsyZxxxzUcm0CVycl/U9KwYbh4SHVs4X5geg96kjuvtE6hm+VvmJ/xoA2QBJFIOiKuBg8t9KjdSAhUOAqYxSxkblzICDxkDoajluegVG8zPQ8igB4iCeY08iKhIOOnNcr4h8d6HpEckYkN9eodvlw/d/FqX4hWVxq2iSosrrOOQifxe1eCyQyRymORGWQHBUjkUAeteH/ihYy3Lw63ZNDbyH/WRHdj6j0+ldZq9uotIbu3lhuYLpcwlDlWB7187FSvUEV33ww12WO4/sebEkErb4d3PlvnnH1oA6W9sZgNhiLI3UiqL2UcJhS4yu1sbc9RUXxG8WXem6rJpOlvGixAebKFySxGcD0xmsDwbJqPiHVxZPK0rbDJvJ5UDGaANjWdXtNMFy1qoLDARW/iNedXE0lxM8szFpGOSa6DxxOn9qNaxLgw8Oc9WrmqACiiigAooooAKKKKACiiigAooooAKKKKACiiigD7K/Z51RLLXr7R87Yr+LzAMf8tFz3+hr0T4vWEWqfD66kVRLLZyCRDnAUg814P4A1F9I8V6XdxZVQ2xgw6A16nr2tF01vTDJugnzIsfYHFAHj0fyRh1zKGwRgdTVkKuN4GA3oehqNYSCyyKUk5+U9BSoWEYOBuXgjsaAMbXSkjgnAmQZVugrISVoh5koCu7fd/hIrd1xUDruQKwGcDnPtWC7SSPGkqDB6Y7H3oAshVeEKD/ALRNKAs21mBHln5cHk/WmKA7yLjIAAK55qSN1SKQuAoXAAHWgBWcoGAwSfm9wPSpd7RtvUfM+NyY+6KZH+7RpY1DNJyxb+H2p0EYDmV2JwPuf1oAlSLKERkPuO5SBwtSvi5Rcv8AMvVs9CPSoU3Lc5hZU3Lk+1KqRvF8gAj37ifWgCzIUwXDKN42soXGKJEadYI3HCHcnOCB7+1MiL3ErBgi7fukfxCnqxBfePYv6ewoALlfMXygGCs2dvoR/SkjlXaWYbQ38LcYxTnO6PezEoh+Ujg0hdl3ibDKpBHGCBQA9j5pQuSYWHBHb2NXskbGhX/RsfvBjlaz4j5jhCRCn/oVW7WUoxiKsccMp7j2oA1Ld2kkV1XEarzj+L3p8t3BCxlVwHVT8hHQf41RtZNpOCRH08urEn2aVFMuAzNtIPcUAZt9qEtzbCGzjPmNz5/XI9qmt9Dgvx9nvYIpCEGZAnP51rxmKOYwW6BVCgRr9amPl2yG3i3k7sM/YGgDm9T8D6ZcW0ymMDb/AKvb2FcReeCZ7HUra60ssgjcMDn7vvXrbysbnKI3kAYyTg5pLjakZlZN+47Qq8Y9zQB434o8D6zqM8+rabA12khzLGnMisBydvccZqp8Oz/YN7qGraissAtIGRUZSpdz0XB/CvZ7eaS0uDGkqo0h6qeo/pXiXxP10aprj21u263tiVL/APPR+5/pQBymoXcl/f3F3NjzZnMjY6ZJzVeiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA98tppFa0uC2VRxhe/wCNdZf6kZZw0fLSKCxx29q42GYx2iqke/jBz1ra0y5jdIVdGE+NuSelAEswDmTyi27cCzN6Uk8m50DKAAO3f3p9xt2hclgDwAOfrSYCzoQR93p1xQBi66HjhRo8FzwM84rDRpCxjzhweVI/UVt61HMYw3OQcqvoKxxtadowd2PmB/nzQA1owpkeTcB0UjqT/hQYhBEWkfeHAJQc5FG1UdcSbjuIwed3tUqqAxaBsOnylfUUAOt9zyq4wFC4xmp1LSOFcEA5G4VDBFE0qk5EQBL7fWnj/UNH8yljlnznA7UAKriKN2Qbih2H3NXJlfidXVJWUIyY4P4VF5yxM1sYssUHI/nTUjZhtZ1JjYOM/wAVAFh8rcIqRgKuOAfzNS4RnlZizIV2jHc0hYCcStHtEnHXoD3pkSu0qCFNqA4Vs53e9ADbTEiyQvgugyR2J9Kmt2EwZ3Rt6ptOegPao5FAIhBAkP35R2pryHy/LZyFXoR69iaAHPIJQm5fnQc8YxUpY7oZmbcD6Uhd2jjnbAlU4IxyRVdN8U54+Y/Minp9DQBctpsbl4d2OeTjip0y05d8IAPk7gVmylJLSOVWAy/J7j1FWkYF8KcKw+Xd3FAGxHIJGjLx4OOmepq7ZsxtyZmJBBIT0rGtg8j7/mwV2KMcfnWmwOIXDEqi4Ze4oAnAjEgSTcXxv3E9BTZZvOuXWUhYwgddvQ1Cz+bGkjIQw43f7PvTJ3ZmVkIIAxtHQigDD8YXDWej3N5EimTBAOegxXgDsXdmY5LEk17F8RL23W0+yjeTICQB6e9ePSIUYgj6UAMooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPoCC2illUqzoCMHHQ1YjheKdoyMgevf8a09CgSW9iTOxHXaAehNdZqvhC5m8OzXtvGy3Fkcui871PegDjldxtyxyB8u8dfpTY3kCHy41MpOQx7Vat7lHhQ+WJVxjPoap+Vucl2aMdxjO72oASWJblGVSWx/rH/oK5nULMWjCMqSjklWH9a6pGcHy49gQjJ9D+NQXMMMoG5Ts24waAORSWQOA0aEKd25R2/xqeIYkKxgnahKv6+1PubMWsj8PHHnBB6U2SSR18yJQEjPysO9ACh1WESL8jMw3gdqfAjReaYzhCcjvUag7GLofM6k08O7bdoyFGOOMUALEVCfxM8jfNKPSrD/ACK8jJ5jJ8m0dwe9MjwY4xBlt2SwPp7UIpETSqShzgk9h9KALGCLdIyGZmP3fakAzEfLkKqPTrSQM7Esm5VAwzN0IqNn/fIgykRH3160AWYJg6y7CoRV5J7mmTLvt90fEoAOw9MetRmJJEKspESnnHf0NETrJG4k3Ryg7SOxHY0AMWXYT5gI3DPXmpJyqBFnLgS9JP7vtSlXltQGCkoc7hxu9qazrOu2dmKccAfdNAEsbbbz5gu0LtDsOKnit1mkG1shT0bjI9qrskjwmA7QqcgjqPSr+ko1w7PK3I4OBwKANO2k8qQRKGTA+UdsetErKzQGJtrPncD0apFLNHLGqfu40wjjrio4Y1eAhgqzqOM+nrQBI8qJF5e5vLPBJ7n0FVpGWIsm0oqjOBUssguLVCo/1fy8nqaqQyb4HeYESdMUAcxN4fe8uZbm6c4wQF+tPufh/p+oaetnbymCbb5kcrDO1/Q+xrpwQ4QKOBycnrVqBtsiuuGj5Az1BoA+dNd0TUNCvGtdUtngkHQkfKw9Qe4rNr6mvrKw1jSV0/WrcXNp1PZ0J/iRuxr5y8X6K/h7xHf6Y+8rBIRG7DG9P4W/EUAY1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH0dFceSsJIbdGQVGe1fTXhCeLUfD+l6nEOZIfLlTsw9CK+WQ0VzYQywybXxn3r1v9nvxKrT6j4YuZi0wH2m2yeCP4gP0oAyfid4dXwtru60H/Erv8yR4/5Zt3XP61x8qnDAMQBgjP8AFX0Z420WHxZ4XvdLjLNIAZIZkGVWReQuffpXzYvnbpI7nMcsDGNx6EcHFADogjT+RGOD8zHsKdLtEzyKd0Y6H3qF8MmIzgOfmcHtTnUSAKw/dg8AdTQAT2jXMY8z5n+8FbjI9a5q9t2t7hUwyKMszdvxrq45fnDHcwC7G/2RWdrlqXtw4yXQ8e4oAxDOxw2/csvy8e1SndCmVViuM/KcZHvQmw38eU8vcu3ZjhTTYklRB84J3Y+Xp+NADwoWNJEOCBnaDwPakkBldHQFEXkqT1FQrLlPImhJQP8AO4qeUxyMshJEQ4wO9AD3JKSKm5InXBA5yaDvjMCyhWLKRmmRAvFGWm2nf8g/u/WpFeSRzJPtBBwCe59aAGSSYtJYt6lgcFj1/KpWd1ECKoaYICzdse9IwilOHjIdTl29qkSGNUk2s27OUHTetADJCz4kkAGG+6en1pchUk2MTGxzkdBUMThVkZgysx+VW6CpiqKgRWBkcjf9KAJYlka6XEYCMvzD+971t21u9rasAPlHOB/Wqmlw5umjLbowMDf29hW2CIi6xxsyBcHHUUARpKq2hmjjPQKwz1qJOI3yR5h5Geqj0qzHtRpJIz5sCoD5fTr61m6iwtLaaa5mRI5EzGD2PoaAOV8Y64bWaKzgdChYF0H8X0Nb26Iw2s8JPEeWB615FrdxNNqayS8jdwfb2r03w3dpe6JHwGZF2sOhoA145N5jZ4zuY53DpVrGGUoPMUNkx9z9KqWbG3RGcfIRsPfirEDPEzkMfJzgYGT9RQBoqzeWys4APC+31ryP49QKniewmDMzyWSBs9OPT869XtNrZTh0HCoe5/xryD433KTeKoIY3Y+RbKrIf4TQB53RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB7z4UMi2UtnKFdo+Bnt+NWmuLzQtRtdY0zMd1YybgyHkqfvD8qUxDT7qCYqfJnGJMDke9X5445o3i67xlcdKAPqTw7rNvrmg6dq+nEG1uoxIuBjB7gj65rxL4z+HH0zxUNZiYfYtQXAwMBJO+frWX8B/GS6B4jn8K6zPt0zUpN1kWOBFMeNn/AALA/GvXvG9rDqui3+haltNwq+bav3IH9aAPnYRkxvERtJ6qvX61JGzyKFjUrGoxu7mkw4mmBHzxfJg9eKVdhC4PyEZYZ6mgCKEtEpYMwbOQvr70t1ctKIo2B2A8sB1P+FOZJSskhKKh4APamFfKtdokIZeenB9qAMK+B+0GXHzKcE54NQMzOxeJxHERyfU1LfYknk2HY3TBqtcKRawq+Cm7nFAFz5kVInfbEfuk9TTogEdg+FYfMCe/tiq0cglIdtxUdAf4AKVpFfLKWALbtzdQKAHogkHCkZPJHI/GpJJ1lw0pZREMK471GsqkkYKwr/EPX1pEkLxqr48sEgEj71AFmIPPtZZ0yT6cAU3zN8kjOxOwYi2+lQxnyi0nllSo+b3qRxsZiScsNwx1FAFjzAbdPOKiRf4Pb1pAoBLKcs2M0yPDuWkIfIyvtTFlDM4jGN9AHSaY8aXDiZwY9uF9z6VrQjy5DGrEOFJZW9D3rOsIsWcchZXjK/dxytWXZtpkViZ8bcHutACtIZN6NsUdeeM1x/jy4U2QgJG7cAo7k11kJAikErqUA446Y75rzjV2/tPxOUX5lB/dqOSW9KAM7W9FjW0hlSczylOI15I9q6DwP4O8TiQXtvZTRQso+WUHD59BXtPwn+E8NkkGraxEJJJhuWF84WvZ1jtreNIUREToB6fSgD5mj0HVoFKXFlIvPIPQ+wqOWaS1neKRdrD7oxwor6WnmtmRkuYI5WQ8EjmsbWfDGla0uXto1yuX2cYoA+cdX8QRWFoziSLzh9wDrn1FeKeNZbi416W5ugQ8yh+fSvon4kfC2fTLK5urBUuI+SgwcpXzn4pa4+0wx3Ry0a7Rkc0AYlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH0hYNHqWkxyebuR03D1U0y2kMkf2OVAssHU55cVgeCbmWw1O40DVUUKDmPI2lvTmuo1KzIuFmgjbzI+SB1Pt9KAOc8RWf76Ge2cmaBg4foUYdCPpXqdt44fxP4UtrmedR4g08bGA4Myev1rz+6Bu7aQoqq46g9qwNNmltr79z8joenqKAO2kmW5lMwRRczZLLjvVOeAxfM23fg8Co4Zy7qFxuY7sd/ep5wJDtGNozgH1oArxy7lCSpmNeR7mpG5ZkKDkdQe9RyArER/GTwD/ShgGmjZwNic8cYPvQBkajZqbkR8MAPmI/lWVIvl7mByQcY9BXSajHtG9zkk5VB1+pNc9dDM8iHCso3bPU0AEZP2bcW+XOCKYr7lZ5CQo4we49qdC7MZFkwoZcH29/rUSEhiqqWUDJPXigC2rEFYhgB1zkjjH+NMdBJa+Wdww3B7j3ppZX8pFfCAE4PWnRO25SeTIMbj1VaALLuCkayEscZLj/CmRbgBtcMzggA9VFRxtIZQqqrj+Fv8aVnVW84qOpVgOM0ATKVLbUOwqu0+9KkzNKqyIsa4+6veon/AHTrH3kGVPpSrIVhiVsb1bIf1oA62zcS2cSk7dg59c+9WMkyIJWQrjJI/lVDTJEns2TKoWOTnrVoRloUEmQ27Cle496AJJNwkLeTmEpyg6H3rW+CHgODUPENxq1yh8qA7kRxnvWNONsbGOXYydu30r3j4R2UcPhMz7wTNndj+GgDfnlufLCWihUUHG7sPaue3PcSyeczBxzjptPrVXxHcau1wpsJE+zR8JtPU1Lo0lxeW0rajG0bJ1ZRyT9aAFxOhY5ZiDgHHLGnRzzQYaXcH53E8cVNJqqyGJrWBjdxt8z9FUe4qhf30tw4NwiNcBjuMR+Tb2/H1oA6XS5YtTje3niWVZE4LfyNfJf7UnhZdJ1TTdQtbZIbeUyRSbR/GMEf1r6MtLuQXO+33IykfLnH41zv7R2hNrnwz1SUKpmt1W+ViOfl+8B9RQB8O0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAes6VdDxj4ajuoXP/CUaOAJFXrc246OPVl5z+Fd14W1iPWdOVWcrdRphs8H8a+fNB1e90LVrfUdMmMN1A25T2PqCO4PQivYbS7t9WtP+Eo0BViYEf2jZKcmB/UDup7GgDV1hZbGYC3Qtu52n+L1rnri6S8lMsR8qaHhoscmuvtbu21ezjd2JmOduDyK4vxTplxYTJq1sdzI22VEHX60AbFmzTyx3MUmTtxx1X61sKVijRWHmZ6P7muN8Mags1wyt+6V8l8Hv6V0yPNGUMsbKrH5fTHrQBaX5psD5j644FEmDGyum5M/j9fpSWzbi8kLghxgg9hUzZZtzjdgUAR7cyIXAKkYXPQCsLV7bF0JEGwH+Kt6NSIlZhh8kE9hUNzEk8gzIrFB9zPJFAHLGOVZNpQYxyTTVMixIv3U38H+efWtO5spIWe55MeCMelZJY/Z9zEnnoOMUAPlIRnX5iWP3sYxS3A3oFjk3NGvT19qfMSsGQ+1QB8rclqIyhdyylWZskAcUAOAAtB5ZMRH3wDnj0qPylmZUEmFYZwetGFNuyqpXLcsDniiB2iPmIu7+EGgCVpDvjUodudqlu1OlO2QiTDj+EgU0H/WeYysud7egNJJcEjzQRh8AAdhQBt6YysgQDheQD3rZi3QozD7p5Kn+lYej4kMsDqzYXK/Sty3k3GMAfL0bA6UAR3USzWsnz7FB546V9AfCtkfwd5KttKp0xz35rwK6lCxvhQWYHI9fevVvg1f/bdP8u0lG4DbJk8j2NAGxeSeXOuAW2E8etSS3ErBIo3JjU79o45q3rVs8V1uEaqV/In1p2mWH2mZ55/kIGAg6mgDIn84l5HXaGIG1e9FvbSJKyufuDKg8mum/sx0Mb+XtwfmB5zV9tIhMpdgEkAB+ToaAOMt1M1yXQ7QvD/StfxFY/2r4dmtmj8yKeF4sseGyK2LjQxtcx+WgAyT6mqmqM0Hhe7dmRUtlbe+cADHJoA/OPVLSTT9SurSdQssErRsB2IOKq16V478NW99/aOsaO+50kaSWIHO5SfvD+tea0AFFFFABRRRQAUUUUAFFFFABRRRQAUVKtvMygrE5B6ECigCKtnwr4gvPDeqLeWRVgRslhflJUPVSP8AOKxqKAPd4JrY2MGu6AfM0uc4mQnL20ndGHb29RWy8NvqNuW4cTDjB/nXi/gLxVJ4a1JhPH9p0q5/d3ds3R1/vD/aHUV6hfRDQLq2vbR2vdBvF863uYzlQP7p9COhFAHMzWo8Ja2TJEZbGdssTyFHrXs2laXZ65Z27rK01hKo8q4jPEZ9DXJSxWevafIgRTHMvfnFZnw38TXHw58RLYaqrXPhe5l2ybv+WWe9AHWeINDu/D9z9nuk/dvzHOF4cVmxqM75N+SeQOMV9Iahouk69okEJ23ej3KboLiNtxiz0IPpXh3jLwhqnhOQwXJkuLKRsw3qrlT6K/pQBz5b524JU84FJHl3YlFVF4VgOT/9apGDZaTKqgUDHdj61CSyxMvzDvxQAs6rcQPFgbByfY1ymoRGKQRhCFPLE9q6lRkxhDy3zA/41U1SzE0UrgAStyBnrQBz6s26NmAO04+buKGYIrs2/wA1xgjtj1qMpJuERiOR96iAEZjGQV5KnuPSgBVkUD7/AM7gA896cHMTsrRhgTtK7sc+tQvslgRjFtCtxipFZcrvXaWPBP8AWgB8ZCyzIn/LRfunkGo0O+SEbQdvAU8fjUyDdEyBQrl87wegpMgqxX7zHapz1oA09Nk2O2MbQ2Bg11UBMQLBGywyTjrXL6SiCSONG+XPLMK6KEOIACxyGyP9oelADpMeTuDDByrepzW58IfEsGj6zfW+V2SFV+Y9eawYt0krrGcBPmOR0PvXCzSNdXFzDHM0N2rnDrxzQB9mapLDM8F1KcQSjAOeK0NPtYVtkIwAnzb2Pb3rxf4IeL59T0hvDniLbNcRcQThgSea6P4zeKf+EX8KDRrOdxqN2hUsvVVI5oAl8ZfFzRNLmlsbAteTIfnMfQ+wNc1ZfHpEu4kn04tZk7S5bBWvGtKtYoZBK7s7Ov50awkCxOdm1RyMdjQB9d6X4m0jxDpguNPuY3yuTHu+Ye1ea/tAazJp/g+20GwDCW/YmRgeijnBrzT4J2eo6p4qWOxuG+yqwMu3OENfQHxL8DQ+LNIjWIhb+1U+W3Tfx0NAHx7plrLZi4LTKuAQEz19Qa4PXNNWOR7izU+ST8yf3D/hWvqxl03WdR027aVJYpWXDZBBBqjapfXICDO3PHHWgDnKK27zRpVR5Nvlup5Qjg/Q1kNFIpIZGGOvFAEdFFFABRRRQAUVZ06wvNSulttOtLi7uX+7FBGZHP0AGa9q8Efs6eItUtE1HxVKmg6dgNsk+a4dcdl/hPs3PtQB4pYWVzqF0ltY28txcOcLHEhZj+Ar1Lw18MRZtFdeJCrvkEWaHIH+8R/IV7Vpfgjw/wCDrAvpNu0CgfvdQnOZXHpnoPwxXFax4ktHumWxZXRW+ULyTQB5D4qQx+Ib5NrRbXwEXoowOBRVbxO09xr97NMNkjyZK7unFFAHL0UUUAFeh/DHxlbabDN4c8R7n8PXzgtIOWtJOnmL7eo/GvPKKAPcNRtb3wLrSRmUXVjMBLDOnKvGejD2INbF3BZa/p8ihlMbJlkGDk+1cP8ADbx7Z29j/wAI14xRrjQ5DiG5AzLZn2PdPUdu1b2t6Xf+DNQiMUqXekz/ALyG4gO5GU9MGgDsPhD8SbjwBfx+H/EQZ/Ctw+ILls7rM+h9VJ/Kvp9hbXtiFbyrzT7lOOjpIp7ivkOOWx8Q2YVzGXI+dDzx710XgPx3qvw7k+yyxSan4Ykb/j23EyWo9UPp7UAd74++GNxbRtf+Ew1zBGdzWB++v+4e4HpXlouhcPKhRo5gcPDIu1lI9Qa+pPDWvaZ4k0qHVfD94l5aOBgqfmQ/3WHUEehrG8XeBNE8Vs0s0QtdWI+S7h4Zseo7igD5y3+UmX+8xx8o5pZkHlbnG1B2z3rS8T6NqvhnVhZ6vCd2T5cyr+7lX1BrH3xSviQMiZ+UGgCpLZiUMA+G7Vj6jby2sR+X5yQAc5ro4vL3PlhlT8oAqK4SN9nA4POe5oA5gwsiKSGIbkqfX1qMyny3BU8nIX0rp3tkbchAds5U9MUkVpAEVfLyVODxzz3oA57ftSPcjOvQ1YhtGSWIorBDyFPbNbUdvEqk7ejcH6VOT5tzmPAUigCCzhkgxv2nnCnFaz3PyIv8SNwO496gWTe2UKqgON1Nd18ky7dzKeG9fagCLXtVj0+CSaQ7mbAAXgn3rzrVNZeKcumwynkkdhXQeMLa7lhBIYzvjbER933rkG8NaiWddhkk/i9qAPXv2Z4ZvEHxHM6g/ZtOi8yR16Fuw/Ovp7xZ4Y0vxXbCHUk2yRnKTIBvX2+leU/so+Cp/DXhfVNTvo2S71CQKm7geWvT9Sa9X8U+KdB8K20dx4k1a109GOE3nlj9Bk0AeGeOfhHrulyzz6Io1CwALqsfEi47Y7/hXmmi6HrnjHXItE0uwull37biaaJkjiTPzMSRz+FfWWhfEDwlrU6RaR4hs5ppeUQsU3fQMBXUKhXICIjHrgYz7k0AYfgrwrpfg7QLbSdGhWOKJQJJsfPM3dmPqa3l4Xdjao5yTjFcN8SPH9n4O0gG2KXepXBKW8QPyg+p9hXzJ4u8ceLdeuZH1DWLpo8bRbWh8qMj3A60Aa3xv07SvFvxQurzQ2WQxQCKVo8BZZB1IPf0zXnujQ/Zo5oLkEEPt2kcit/wqJ7e6S4uBvB/5Zj+E+9b3imwiuLqK+t4drkYkAGBQBzEttDLbGB4ncHqMcn8at+GPD2m3c3lPGEUHDK3OanXzCoRHYEHgj+VRhdhMtsziZTwFPBPvQB2lj8E/AetA79XvdPuOrCLBUfgc4rVj/ZY8NzhWt/FWoMh5B8mM5/GuR8OeKtS0e8UmBJJT/eGQ3tXrlh8ZGhtEW50IBwAB5TgL/KgDm0/ZT8MjHmeIdYJ74SMf+ymut8Mfs9/D/RBG82nzatcRnIlvJ2Iz/urhT+INTx/GO1lg8xdHnLjgqXGarr8YpSONCG7sfN4A9+KAPTLHR9O03DaPpVhZyD5d0NuqYX/AICKr68mnWkEl94gu1+zRDcEdtoH0Hc15Brnxb16X5bGK1sEA++B5hP5ivMPEWtahfXMl1qupSXan7zStgD6LQB0Xjzxg/iiaaK3ha10pMrHED98etedwW9loG6dmzIeUDHpVqw/tfVrkQaDZS3KH/lqRwPz7U/VdK8O+G3S68bauL68GGGnWLh3+hP3R+NAHkWuXT3Wr3U/9980Vb13xAl9q91c2NjBa2sj5jhI3FF7An1ooAwKKKKACiiigAr0D4efESbw9ay6NrNv/afhu4P7y2f78B/vxE9D7dDXn9FAHuV34V2x/wBu+A7tdU0mT55Ah/eRf7Lr1Bp2j+IYNQR47r/RrhDt2PXkXhnxHq3hnUVvdEvJLWbgMFOVkH91l6MPY138/jKz8VW73N7oFvb6pGo33NrMY1kPrsxgfnQB2uiXOqeFtRk1bwteeRducyQ/8sbkf7a/1r3Xwd4/0Xx9bjTdQLaPry4P2fzMEsB96Nu49q+QIfGd3pcjRCLzh6u/P8q0pvGUd7CgfSkjmTlZY5yrA+o4oA+qfHsN6dNOn+KbUXlkDmHUoRhk/wB4eteM6zpv9mToUkE0DH93L2I96Z4F/aF1awYaHrWlR6zbKuEknuCsgGOjHaQ35Vp+KfGmj3kZMPhhIFODsF6xUE85xtoAwTGwzgqWHI2njFMMeArFMoec+grlrzxgbO7YW9igjDH5TKT+uKJfHW1go0xMHg/vjzn8KAOnDM0RwBhhyMcn2pnmgJ5sJYHgbT61zz+LF+VRp4GO4mP+FVZfFygBV05AC3/PU/4UAdcrMg3OoYIOfxp0EG1TKWyydQeBg1zkXinzpUi+xKoB5PmHJ/SvRPBceizM15qelz3gj5WE3jIhPuAOaAMTS7G91e4Wz0LTbnUPmwQi4Rc9yT6V69ofw9svDGlpfeJpTd6i2fKtI/uBuw96dpXxYtLMSWtj4YhtokH3YrkKD+UdUPFnxqWw0i6uY/DcMk0aBkMl1kAnv9ygDlvFulXNtLPqd6scaEfLHjlT6CuR8JaZJquuwJC7Z8wNID93bnvWHqXxHu/ENwtxqdoH3c+WsxCg/TFafgnxWlpqksyaeNrfeQTEc+ucUAfSfjHU7bTPCEdvYXQURJgiM89K+UvEV3J4j8Qteam0kxjGyPfkjjvXea747Eul3aNpuS3Qm4Jx+lcM3jWK205o00aA7u5lJx+lAGZPHbyRSQykLIWGyYHDRnsQa+nvgL4uvde8OXmgatcNLqWnxbY7nq0sRGAT7jgV8marq0U7qfsYUOMkeYev5V3HwV8dz+HvGsDC1a4jkjMJQzleCevQ5oAv+M9WmvPFF1GWMsVgfKCkd+9KkWnWsUcqAG7cZ2E9vXFZ3xL1q3Xxrq1za6f5AumLsgmyA3r0rh7jxPJbXFrcrbhnGF5c9PyoA76NmS6W4hHR9xjPcV1WteLUv9B+xR6bDCSBvmByxx7V5lb+LDvCmyHJzkSkH6dKWPxeNkgOnqVJyB5p45+lAHSblYKLYGPHBx3NOWyVXaRMxyD73oa46XxlIzmOKyjiUfNw/U/lUg8UXVyAzKRxggPx/KgDsETZjdIgj67iehqW2mimRc3G1EOcA9a811PVHa2k2h15GP3nSqyas0McQ8tnVhkhpDQB68mo21tmQXEe4cFDzuqrc66ruRaR7n7BOd1cros1k7pJd2T3AHO0zED+VP1H4qRaKZrPQPDNjZ3EZ+W5lkMzA+uCAKAOrg0fxDqo3CGO0hP/AC3uWEaj6ZrF1S+8D+G7jz9UvpvE2qr8ptrUlIFI67m/wzXl3ifxhr/ieTdrep3Fyg5WItiNfoo4Fc/QB6J4p+LOvavby2Ol+VoulNwLayAVsehk+8a88ZizFmJLE5JPU0lFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows right sided circumferential pleural thickening and accompanying pleural effusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21136=[""].join("\n");
var outline_f20_41_21136=null;
var title_f20_41_21137="Endobronchial bx asthma High";
var content_f20_41_21137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histology of asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 192px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADAAR8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDOtfLwsIG1nVjGSSPn67Tnnnp+VQTB2DDc8TkYAPP1wOnrWXZava2Rt1mBtniY7IpsLjbzgdQQOmfat/TtP1HWD5llGwj3ZLSAqoU5PB719NNqOsmCdtehXExgKeXIGlY53cfJx6/jTbCCe5uFxC8i5wQgJBUH/P5V2Wm+CLNE/wBOkkmwR8qsVGfqOaZ4g8W2WhR/YdAtLa/1FJBG8QYiODsfMYdweNgO76VyvEpu1NXIdZX5YatmD4y8SXnhLR1sNMgCzshleVUz5YJ4xxjeSe+e5xxg8xc6Gt54FkvriWS1e5n2ssinzJCGJZs9Tk88+ldX/ZM2pwCyuJJZbqRxJJJ1ZstlnIIOACcAdsAVe8Z+EtQuNPtP7GuSos4x+6Y/fK5OcerDg1LnCDUW99/68yYWj6s5r4eadKurzrDawfZzbOTKIxv8zjCE9cEZ4Ofwqv8ACMDXLyW41JfLtrXE0ZGNjvznOeeMj9Ku6Tfat4eS+WRFjhmKhJHx50TDHEi5xxkrkHjgnNO80XFk4tYfKluDumFvxkEnLgjgnp1q3GUr2dkzR6ttHcDxFo41OeDSBBcanKMyGIDGBxuYj06etc3438cRQLZ2NvfW63jXCC6iiJJRMZ5PYZrb0yXSNGBkihUzFAC4XkkDnJ798muU8VaPpmsW1xeS26W9/d8GRFwSB9388AfQ1jTpJSTS+8xjFc3kDar/AGnHDeWsjmVxu4XGeSNw9Qev4108umwQ2bJJmWaVckE9c+ma870iC+t/DSXMd8j3ioI7NCFMaIACVPryMDPA/HNddFc3t7JayM8ILJhinCox68EkjH1/xrolB6WdjTXZBH4bitJFljsxYxMAZFhDKH9CVBwe3an28UpuomikYqspUFF2l1P94H72O3epUutRe1ZbwKSrjYqkY2j1JqLw3ew3Gr3k7LvtNPOAjj+Mk7WODweDgYBA+tS+ZRbfQrm01OE8TaF4pu/E9pcaQsdxcwszwm24I+bq27j2Ofl4568+j6Tpd54a8N3Gp+LtTthcuBsEcahbd2OPLGPvEZxx79QM0uhrPYytdiOONjlFYHcNpOcZ9eB+VV/H9zYeIdMtobjM/kyidbeNzh2wRhvbPX6VhONRz0enUW7sjE827vpoY4tVZUiZ3e4DHzgu0j933BILAHpnFU5dStrnVpNYuYZLO2WMW8LXBCyKxY5Dp1Un5cN0I7+nNXGp3t/qNvp0cqQ3sgIuDAnCKAD2x6EY/wAa9W8NeFobnTyNYgEtuVUsJT94A55wexANdFSUaa5rmsrRdzzfxGt5HrNnLIgGjTsB56qWSBjgEHbkgZwR/vHHtu6PcXdvpsdvqrxLdKDG7CQAfKcBh9QBxXY+IfFmkGxuI9JkvrXUFjk+dLE4Uqpxv3DGD615db64yWt1fXduohKhzHkbYiX7Z74boPb3NVSnOSfOrCiuZOVtjVTR2tfE9zqDj7I73CGN2O4SuoyQwPA5yMe3ajUdJhv5JLKzlht5p2KvFHbtKl4xPBwPut15GPrW/wCPrq2s/Bulai8QeWaP7QYpR98lRwR27VT8L6NputaE+oaTcw2tyX3Jbxs3D/7POR1qozi43f8AX/AJ037klzpsWpXEFvZ2z3sUEawTpbggW7xYXAAOcgAf1rlr2z1HTprjVNOIu3hnaWJvJCmAsRu46eme5yasRaPJpUyTrdTR6mszlbvz8SCR+i+nJz9e/WtLxbrV1qraO2mGIxEPHLKzkIbmMfNHKBjGcrg8cn0p2krdiuZqylZ9Cx4Z1jVl8RRWGr6cbiZz5kktsCI4Qy52N6gY6/zrW+3WF1qkmkrYXKyRYZsofLCtySG6dzwfQ1hah4hm0qScXMT25hj2tcu7eV5hz5aLgZbIGSc8DNJoEl1FbNcXaxXmsSSZYQM2DHgYyCdoI9h0H4lNXYkmdBBpPhe38QLBBZW/nRx+YVwVXHQMQMKTzjoetaHiSe2sLJr9oZEsy6RO0Sbgu44Bx9SOgzzXLabeabc3puL0/wDExaQ2TW7uAPLDZDhevJwc16qdDt7nSjZ3A8+3lXJMnJz2Pv61y1v3LTYm9dWee24lmuyZZ2iQvhWbkMuACP6fnWFH4R06DXje27bYC24xGMbGYHgr75H/ANYVz2oa7f6f4hvLKa6CGOd44fMty/mYYgFSD3GD0zmuwsdQE032e6tLi2dRtkaRGRUbso3AZyCSOo/St01J80Wbtdy/JciS5EKowhUfMx+636frxUiu1xNJBfwR+QxAKyJuVQCOnUH1/n2qSD7LcbZLS4juG8zKxqQWBPAGP0rCvpo/DJFyVuZ7Nzi4jWYvHCNy/OAcnI6YH94fgtNmTZdEdZNc6fam9gmLC6hjMsTv0cYz8vOf/wBVYlvNqrwQTperE7xKJlZQyyOec5AypwQcjjHas2w8QWGsi9uSbgXktqwsoCdrTvjhBweT0/XtT7PTdfu/DCJPb3Oj3MUKW8RBU7yqgbiB0BwOfrTUVHd/15EKy0f9bGhZ6pqMV3icRCeM5j2ksx5OTk4wMeg/GumstWZrtop2so5Qu45lUEE9Afw5rxq28M69p5d4Vhv7yZzmNpTvI7nr6nmunl8O6pF4f+33Xh2A61FN8sbPkOjcEk9MjnjPrRJU38Wg5wVrrc7fwb4St9JsLVb5Ib3UITvFwyA7X/2PQDp+Fauqa9o+lv5V3fQpcnJWEMDI/P8Ad+teTeJPEWpeLbewisbiWzjunMcMcYYCUKRvJ9cZxk8ZyKS0/sYafc6mxEv2N3jz5eCrKPmwfTnt1rH6rd803d/11OX2blrNmv4i8aX94qWcgFla3EiRxJbFjNMT2Zx9xfUDk+tSReH7q0lhWwsicHe7vKkSIw4xg8kfQfWqGjaejSz63eyzCFIk8rAAWJmYEBB3bjBOehPsKxNS159f165utNkuZr5cyLaGRkQRAfMFJ6HHORzXQoqLtHRItrl0hoezaHc2FlYxxyXNqJjJ5bSKw2u7DcACfr0qfxHqc2nWtvLaQed5shQkdFAUnP5j+deWXuuadZzSW+oRx30MsUZazlzlgZFTcM9WXqBnPH4ja1e61CO2lvtIjzZWissURyYpc8YOD97n26ckVzPDLnuzN09dTI8SXd9r2s6fba5ocltb2Tie4Md0uTtU7mPAyMKPcAVHq2ueHtW16O00SaaJr75ZDZkKqY5yOOM9Dj9KpawtzrviTT553naxGyXY1kI0hdSQU5Y7Qcg8n5u+eK2ha6ZpNzd6zHaCOZ0SGK3HyrG+WJAHoDn/AD125OWScTSEXtYt29rb2eoSSNdKXWMKkTsVKjOeeMZJ981Zu2e7sjKgUBRtESjOD6GuR8P/ANpXklxeah5Xz8QwoSEAyepx1J747CujW4S2lgtzK7NKx2ejEAnn04561q49S2mnruV9Ms4Y7UQxW0KIvzpCowGNR29/9mt5brWY/wCz0jfCqzbl+g/vf/XrfiCpGdoX18zOCR+Pf6VyVxbp9qF7epHJeE4X0iGTtA9yMZNEdU0OPvyOhjma5IUyoiYyewxim6Fc2NlLfXDGKbSr5Yn3u2BIdpVs56cBPx5rnItesRqUNikvmXEjFE2DIDA4KmprnSrfUdOe02NCnmCVkU4IYdcYyOeelJwTVmW4J6JlD4i+HpbWaBtKurp7Yx7kuAT1z9x/cYHPfr61h6R4juLGWW31NWa4bafvDGB0AHUn8a9Y03y59PgsbgMVgj2pJneW2jGG9cj+lNhsraN/OihhaZeAzRLuAPXBx6UlNx33Iu1o9zkvh1o/2oajfXVpKdQVTiIgqORkLvIxz+ldhY+MbrTJRBrVtAQ7bYRCGP8AwHnO7HPPFdE9uL7Q7iKG4KMVbaT8oBx7Vwc2kRQCOOSeXeUkCSHLmMnGSOwxnI9M1lBxqtqaJi1N6mm4i1HVJntLS3tIbqAkxleS2cfdHABByffpXJ/EfQ/sR8P6b5uIZ8PO4XGxI/vFvqXzg98e1dDoWlQWugbdMlultJ4mjhuCxMjZPJJGOc88Y/rUuu2uozeFbbSNMl+0TmWPzbu8bczqHBIHtkDgnoMVT0dlsVJytZbHM/EK+Ly3jOk5vYst5IUhU8xQQIzn7i8jjuDXC6PpV/qMdrsR0mdvLEyybGhjOOSM5IOWOO9dHBY6gLbxQ0vnapEsrWFtI7+ZI8m8qMD+EfNu/KrzeDrgaidTiuP7Nkd1d4T8zw/KMxlhxwe+OlaJqVkVzX0Z0Go2ol0+TTZ7rzrNYGM084SNSepYngArkc+vWtHwnp0WkaeJ3MjqWM8aOFzK5UKrsAewUnnBye2K4zwXqMsurahpyX4v7BOfNkjDhwemdx4+gGOK6C+vtQvPMj0r7HKEB8y4mlLeWRzgKB1A61clzInle3Qht7pru3nuPEen2rmE5CSPuiiUDOcnp1wa1HuHvPCst7pU8ChpTbM1sgBibZu3ux7YI+ua5XwX9hvvttuEnv7aUqWkvfuyvnLHy+mBwByeTWhp2s6bqP2ixEH2e0jmaNBbxAbj0JAAAH1zninytu8Qk+hzngWK113xNMkKySTwqZBKyA8qcBt4PG49iPxOOfUtP8azWurW1gbS3bS1ZYZtSlvFCpM2T5Yxnc3HQc9ewrhfB3h/TYoNYks7ua7sd5jki3nbgEHDLxluvP5VHbNcy3039maO0VzdXAhtbRkCDIU/vGHRfl5OB04zzWM6ftFaoS1zLc9sW3077W9zaQRu7sS0qY4P1rl/E0U3k3UNzcfuHJdf3WOAMAZ71haNb/2JI/2LV4XmD4uVhgMhaTG4qZC+fwxgVqTeIbi9QR3lmZ4Y+dyjIzngc4PY1hDDyhK8df68zOM2nfoZHwt8I6Zf6df3ctxcTSieSFFMgYIgb5SQO5GOD+ma1NZ0aHTbVLT7OrLEGCuzYO30HrgU23lOnD7ZpcQto7ksDGrYXeO+3GQfXIrROqQajpdrY37H7e2VG5D+9YDJ+b1I/OqcZqXNujRVXzXvoYmkGe3hZYbSOO2jJIdTncw/D3xxUOnajJPd3AvYJofInA+fIVo+u4HvwR06VpJIyQyIU8pem3d90jHPPvjr/wDWqSV2a2wyfIw/1gbLds+/StPQ0c7vVHV6fYaZrFuzWssywspjYxSEYz1GetXPDujL4c082enrPPCHLqs0u9yT2BOOO9clpVxc6e8bwSMyg58s/LuJ9cV2vh7UJdQgkmkSNPm+UK2TiuCvCcb2funPJdTx3T9PtNYvv7UhiktN8K7Id+3bGQQmADhe/b9al1/QLCTSRZNKY4wY/wB0FJzhhwceuDmptMs/s+7y1ZbiQl57jGN3J5/oABgY4rW0PT7q+1VZQAbSKVJJpZlyr45AX/Pse1ehOXKm29F0Htrcj8PvFpumX1nrax3JgcTLGyrIIGcsBGSDySE3Y/hH1rKna0h0/wC3RRuERvJkSOIysCem3jI6EEDjgVsePGVbu3tNKNqtxKGmboRliB5jAdcc/wAu9J4bWz0LSb63uoDJG2ZpN2Tv9SCeM5JPH6VEXpzrd9Av7vO92YFlaq4Emo2Vo0mBJAjQkSK24ck54OOw4znmmWPh+y0SyguZrhkvHZj5mxg5DHgZHDHnkkA4xWx4Xn1KBlF3bJCZA52yMhJGSUAXcWztxn8cZpt1a22t/bbRpWMDSeXPCsmSsgw4ZW52tj6H602/ebG53ehYghVopTBckqzhxGIyCSR1I/EVnXcia7pz/ZGDQ3ELqrsdrLkj5gTznjv2qwba7W1ubYzxzM0DCOQsd6nHyknJJxxk59eKpafK1trsdrIsUQeQLAiEYMIRACQDwCxIHrj2qkNPqOs0it7SOONULADJ7D0I/wA9as6PbQtqE2rXaubWzBjVTyHmIHHPZVP47qpaxK0E8867fOKhAAThufTp1J/T0FbviB5bfSrO2lKo0camVVXALEDJx65pzbdl3Kabsu5yniDWGBaVh5VlHJvkbPUDoBj3xXN+KrvSr64xPeTxNYJHKwiXInEgU/LyOgI61o+JDNAlpPFbm4jW4USITkbCcHI6fieKp+JfD4ttNNwJE1DUxNstUwHJtwB8rL3wD+A6Vq9FoVPRqKMO0vzAw1GDToRdyXDzwPGGYs6sAc/NwPmPTuK7/RZdYudMvJb6wt7eYuVtljTEgAJBdlyflBxzjvXDTaEbO7nsJxNBdm3lNgiMSspPYHPBxkY75Ga6TwvcpdLZ6ob17S4jspNNmMhIZZECsGHbG3rnHSpXZESbO0sZJbb7OZNgmlQM6AcKxHIH0NXp3hcjYGwDzjgqenFZWot5ev8AkbmeRbaCV3x8rFgxyvtjHP8AWpEkMayysxIiQsVHUnGce9ZuKepSV0pHR2FykFjI07jcFJYE8Y9qyfEEUMelmZJpYCSzvJF8zKoU5IXv1x3rJm1doLa3+0Hy/NkEfmykKgLZwCTx2z+FdLFZpcaXa3hCTTFSQYnDxsueqkH+XpWfL7N8zM2rMimb7EI7uWUJp0gVbdEViqgr0bqBn14rVYQzW7NYhnnZS3knoeOMfjWYNTDWokttxjWTyyrdT7Gs7X7yay8iHTLiCFnZS5lYiRk/iCgEc0/ZuT8w5W9BLQSWEV9Y/YbW2YkxWymTYtwCM7ywycgZHcjbWL4ig1QaMlvpV00Mq4PmM2WIGAVJxkjjg+9bM0yS26rI0cpjbeDKPnXrgjuMjPTrVlZ2JEkRSSJVyxkAAz6YrVXiaKOt2cxaabbnQ3t9RhZzKoM9xGfLLnPXgVgQ63bfYxZeF7SbzJLwJb7W2+YUXcxbnoMgnPB449PQ9Rms5LGd7naLZIS8pK8KvOQQK870nQ7aC9t9XstQs10WyuDNJM5YsgbBWNAPvEgY2EZyDx63zu17BJoz7xNfe9S3Nsbc7gAltMFMx3fdDjp6n/8AVXcT2Zs7q0a50/fFNGxkjglXeoERyBkqDzuPBycjqai1q5hlmF5oOkYvISBFLqRkiXHO5xHkZIwOSDzjHSqvie01W71OykM7eSZ/MYIFKRxgDaTnBLZyTnI6Yq1NvcUrzKujaZpdtFDNA2oWrZZPLVmRsuCNxBIPT+Ltin+C9Suriymmmt7l727glha9B/1axkbvqzKck+3et5odLltzHfNbNtGPM3LGy8+owPypFuNDs2ayt9WnE3lkGHegypwSTgcHp6E8daUt7JESRmaJZx2FjbW0MlvbMeIo2zm5mCkuc4x0A6nnIqiZpdI8W6jC+lXhvFhUORiSN1A++B24I6H9aba/8JFrF7HevZ2scCRFYraQqCpycP22sf72e3Nbk13qA0tVs9SsY5CD5UjFbiLYM/3uV/8ArVLb6fcD5rjNFuru6mnubiEWkU43rE+fOP8AtN2X6DmtGe5dbdYI5BNbEHOeTGCeGU5zn+lZ51iHTorVriK2fegN3c/N5ecdQc9M4wBV9nttY0QNoV+9nNMQYXeEOp56YPY468US03RLS6o04YBJG7AMzcAsx/OqWtQx3lpeWbGSLzl24Q7DwOx9+f1osHkht3t76RSyqI/kXacgHPfp0pYYnlAZ5FkYfc2HOR06jvWfLrccZWdpGbo32vR4WgeXMMC4inkcsHPOQwPIAGBxxiu1GpXFjo0slvp5kuGK/Lbc59wPTrXJ62hOnXQkt2mkSNiEwcuccKOefzpfhfqb22kWem3Ussk0qmYM6sMcAlST6Z/H3qakfaK9rsJx5EnbQ3df1FdLtotOtnjuboIBOW5CAjoPQ98e9c5qOp6jOtov+oith0iG1euckfl7cU+O8N/qB1K/ttrSsskkKNkDA6Z46YxXRapdG+kWS3hEkmQkKsMMB0H1/wDrUl+7srfMSShZNanN22lwR215ew2jWc17ue4bJOJGOSygnoc9B+VR6tY3Us1zISDa2sQ8i3TrnhndvU4XAHPHTqa3LbUI5r+705VlZ4wI/tAAKOH5DDB5AKnmobqFBa3FrPKHJIjlkUngHI27u3UfSqjJphe6KkLJdSQ3sZkjEgVtrjBU7R37+vp3HWq9zdwaVrFjFcSQ2emGYvMTA5YXAHDs68Afd6+h/CtDrEVhczT30bW2kQ5eOWTIO3eUCBcZOdpbPoy/gtnpFyl/Lq91qM1ybwsLezjXaFjY7gSM85GO2c0SSegWNXUM2vkyxGK4W4R5YpYzhWZTgrzyD8ymqAg8/wAc2wVUUJAN4HRUQFhj3JI/XirWl/bVS4i1aOONvtH+iRo2XSMDkt9cf54qtps8U9/rr2mJLmC2eSPDDDbQWC4/CqS0ZUdU7mXqBTWtXtrIpdR4vI13bNgY7+zd+ua6TxvPEmozkyLGXfHLYAJ7CsrwT5t9rmgzXQ3yjbPISMEP5fOR25zxWL8V7uC1mkS4DyGSXCbGA2kc55/Km0vaa9EaLSS8kYPiSS2jvJf7Wumk02SMD7NE371ZByGHbHXJPY/SunttOtfEeraBqEd4be32C2ih2852OQSe3YY74rhoNPtdV0oXE92ss9l+9ZAu13gOWKnnqCTg+/0qO11g26aTNoYnjm0+58wLIwbczkEeg6qRz61bvd/gRK71W50/xE1H+xdd0K5W3iuGtRIGBY4LDA7Vgajq0U2matYJbrDsujd29zEGxJu+V1bPUkMD2xjFU72/ivdduLa7Tz4rm+eVlBwyO5wwB+v4GtzxFdjUNX/sBoVa8CiAOx2qCMEDP4dam275hpaanWa1qFnZaNoWrpMCW0KGOaAAlnEbhd6t0OC5UjOenoabZAaqiSWshNtcbC3VWyDkfgc4PtXH30D6Z4aa2w87Wl3NAI3Odiyldy+/3AQemcmuy8CSpJotnCzsXgc25Y8btuf6UoqUI2ZdO8VY3dY0yK9shHfKs0ZkXduHykA108Qtb7wpJFBCYIkiEccaqFCjtj2rn5LqS+ae32MYg21W28ZFa2h3c1rJFGsoSN45HZcdhtwfXOWrGcXbzRlPZMoX2nCy0W3gt44luHm3qcnBPuc9KxNYtItbSSK9ihkuhKojcMUK9N2GAzjPbvXQa7PJPc28UzhyjbgR/BisiGHSdHtLvUbSxvEDyhzFFl8EEHIXnAOTnFaQbtd7lp6Xe5VubZNPkhsJpAjuFT7+7gDjn1rZitWh064f5WDDIDHoM8/yrh4fsLahLPplpunkbGZFY/e543V0R0/UBqUTT6iyW8MWxLSPKg5XOZM9T7D0rWa2TZpK9kPcwtbi11YxLBIxV97GMCNjxljjHBGTnviuH8PmdfG14PIM1ktw3lgIHVdgI8wN91VUA/oOua6jxbpP9pWUkr35tbdEDXI2lkcKd3HowOcEc8kc9Kb4WurDQfBbajYQ3X2i4jPEsWWbYDjC57lt3XktSd9LGUmW9S8Sx3BN06xpNNGiWUU/y5X+KdgeQpyAvHOCa57X9KtLWA6vqdzK99NKR9okJKIMcKADxwDj39K5jwWH1bxjHPdBd3mBp2uOQ8m7ccj/AIDjA6Y+tev61YebLu3zrMuTBtQGJXOdsjDqzDdwM4H15oUlFKyBaaGJpMMl006yackVnbhIgzSq7SsfTbwB3x71j+PPC8SajFey2klxA+I3NopZsgfLkDnaADnHtWxqd1Lba5okMGqWc08Mfl3dvLOQ8owNvyhSMg7m/wCBVu2mq2cpk+z3yvc+Ycwt2yB09Rj0zg0ScpapApvqcpZlvDmiw3esXF2wXe4kMDGSXIyFx/AAB1OO/wBKt6HoFzZ6ZAWkM0X2bkxAbJQcngYOfTH+Na5srUw3UiQsBO7SS71OWY43Zz64/Cp/D9tBpttZ2Fv532aFco0jZJGc4zUym90Duloed6odW1GGCCayNpavcN5iyYDeSMBVI7E89PWtfXoLXTdD0i60+V/tdqzxfZs7E+9kyEd1CZOM8E5NdJ4gWyluZGkdoCjb9xYBF+vpXIX8kizRQ20sxkilkdJgPnTzVwGiGfmx3HcZ7jNaJ80eZbhNXSN651ez/tXS/sollk1JfPRy23bGVBwfeo4L3T7PUoTfmVNVMUk1vZRKXWR2ONobpngAD1yfSq/hm0uXt9P+3RwpNpivAuF/1qc7ZVJ5AIJHI5xUjaZq0v8AaElxc+fG75t4o8xgY+6HP8QHFG6Sehko3VjpLWFtWkTyba4tpJUJMN5HsYe3596bPZT+dLZwRC1uvlO+4U7GxnJxxn2I9a5fR4dR025kW+NrJbphxLbEqVbr0P8AQ9q721uhrCrqKQytLDD5JVTyw3Dn9KyqJ0/eT0Lu17sjjrkQWmp2U95LJHaQpJlY1LGRtucHHOOCOnJIAqnpnie6m+ISwQWkjREK8KTAxlAkTO4CH+MswGfRcYrZ1C9S2sbhTEzxJGZJEByzKo3bQBz2/M1Vs2/4SW50vVtLuYYXtgyzxTRZklikVchD2OMipqNtGTd9WaWjWk2l6bDAvmLLFEFXHfp29as3iQx2+6e/jt0DAybnUbmzwpJ4AJPt29ajRLwI8QhkeXK7txKjj/8AXTr21tgkkjRpMTuiIYBsIWxtOeCCTyKV9Rkb2WnXryWt8tu+FJaGQq5jx90lDz346dabrDiytmuYJZGm2KIhEm8yE4UAYIxye/SrjWMJ8yeFLdZw4tmfy13OQPlUnqTgcZ9PpToGNvfW8iqpKne4bHKA85Prjp+FJS1uO9zlpIpk1iCzgvbGO+A3P9qnyULDjCjqeevJ9q5rwal1o2s6ZBbWaT30sqRXgi3YSPP3z6EDqen17+gXHhPSBrsuqR348qY/JFFbpmEtksxc/Ng+2MZqxofhrTNJ1ubU7G8lu5LwTRffbbECq5XBJyCQOac611pv6Fc8VF+Y6wddM0+W7syzySSNCjygblQnccY75OM15f44nhuNVtpri4jltYJQl5GwyY2IJUkd8gHgeleja0zxM9nDjFqfL25A+bnJP1rzi7h0yL7FfalbSxC+vR9qSQfIrgMvOcfKQzHI5FXFe65dy4qyuYf7m+l8QalabUitrcRhIRtEkbYQHB9sE1k6ZZxx6aL+4eSSzMvlTRIhJC4yGPI74/GtK/kstIOq6abGS3my8KTxyl1fng5PBUgdRng5qfUp7az8OSWSkpPGvkyqMYkkG05GO2D1/wBn3oSUvedtExlDwnZQ3mtWM42Q2ttPG93JM4K43decdegHqfxp897fav4lNwoCvFcPLE5AQhQ+4rk9ccn86ZosMh02BpI52t7+f7DIA2FPKkN05IJ4/wB2t2C1S/tL61hvDFJDJ5Cu3IyCAfwOP1qaUOZKz8/UpJM09fsru48f/YbW68gzRLfZmGUkZVZxnHXILAH3qx4S1GyRLwW0M8cqiK5ljlIwN6gnZ3wCTx9Kgm1b7D4g0K/vrlZF03T1tmYAF2ySv4gbj7jFdV4102+kt5LCxtg0JcWhmUchhLGwcn02kj2wa2TadpE8zi0maOnaml0yukolhuF/d7eDnHX9KoXWqRLfSLHiW5s45AyAAs8ZClsd+uOnTGama3S2uoo0YAIxVXAxhcdPxwPzqKCyiiuZbhl8ubI3S5OSoJ4J9ORmkkrltLcoaDeOdTttPs474319G8iwXFyZwqqOu89MjPrj+fa37xaFGjtIBJGVSUNnB6A4/wAa4HQtc3anbozvExHmoWIVXAbGFzjJPXHXBrYufEdldX9zaarp1xNHAPMmuLrasLYXIxuPzZI4HtSnFuXkZzVn5Fq0vfM1P7bALURs4iilCgl2JOFB56f0JPFZcWkajqd0uoX+rSQJMCwhdcyIcsAemAF3E985I4FO13xFY6X/AGNc6np8rA75ILcMIjbDy8lhGOC3OPXOQDWDK2peMLeW7tNUt9IRCJLWKaXZNJsJ3MAoyQQcgZPK0Xtsg5r7Eem3N1pImtIUvLi4aZ44rqeFgis0u0FlJwWK7n47HuOak8cm8m8RLBoss9zPbpG4WFcrABhQXx1zwMdvetzwfrFxe6bPc3kc8aW/lpLdS5HmEAKxVAOBk8fU+lOmmudM0jWo7/VZIrp3lvVewIWVYlwFUPgZ6Ec+uM9qpze6Jbszm9E0t9Q16eC4SO31Ozs5bpfs/wByeQELnPfk5Jrs7y71LWtGt7S2ku7W5jnWASRsEcsmDv3Y4QjPPPT3rnvh1cQ/8JreanFNbJBJbMyqFVHDEBzkAnOBncRx7Cug0vSdYn0S9t7HVYTdlv8ARbiTDIkeQQvQ54yKU5d+gSfM9Sq1pa6lLenUZIrkXrFG8mNYmRQckFgA75IGeQOnGKrx6R4W/tiHS4LMw6jZr5yKhcEIe+7PPJBwT3rT0G/XV4551W6W5t3W3niuV8kblHULzjJ6n9KzI5tf1C8t5x9k06SF/KmspCHJhByXD8segAA4z+NLS+had1oX9aguLHRnfT5IoZIGMmbhmMYHckDqMZ4PGfpWQPGC3elpc2NxDD9nO648+Ji208KFUcEt2yal1e/vb3Qrm5tjKPtCDZF5QkbeCcjjPBz36Cq91Zail7ptvdXDalC0YDD/AJZxSx/8temD97AH16AVdukhNdTZeO18Ta1IBYXEc1jcqXLMfJkYjg7M84OeuKg1ywWzuZbm5u5hfRXC3iNGQ/klewT0wSD7kVLYaXY6Xb6vqD3sksVzMZiVbhW3HCqAeTk4wfyrA1y5hmuBqNuwvjalUmsoWJJcn5d2OSA2Dt4GRz0pQXbYW5p2EWn3F/PrcNpLBe3g/wCWznCrwASuOCRg4q5PdXccsWy0Wa1LbHmUlpQCMZ24wQCe3NSWzySKokRi/BYOec45z9K1LaHKOUyHBBDZ/lRJqGiK9mranHeLbJYoY4brTp9TspGMnnWTsArdMHoc/X9a7r4WmTkxPMViHkYmA3Hao4YAnkE459Kktd8dzFGJGIyc44BPbP61s+Co4IJpkt4/LjWSQ7W7sSST15znOfesa1W9OSZlVehwd/AbnWdNmtvJaS3l8+4Vi3zQOCpUcYOTnvwRT59L3RTJa74ZpseWYSFKMGByCfUAiqtve3sht43tnwvySeWflBB+8D12kc88jnPvrDy5ZU8xgqk/ebkLTbcSLNaEdtJqumanZxzS3F5ZSZWWSe4G6Pg7Rt6kE46E/Sr8lzFHqNxA63Fs0QJw0JKynAIZW6Ee2c8U9ohOTFOEZiMqwc8gjjBHtUNjbJDDDaw3ISOOJlSaf995ZA+Un+9jpjINZ3W7E1clMEd5plsl5GdzTLcAEYJZT8jHH4ECp7ZWYojR+azqDvQgZQn7wPcY59DS28c3lJPcbJbkogkZWJViVB4z26YptqEgiWKwdFtogQPL5CEclc9uv61L1GvIZOI4GZpIfNjBAUqxUMSR0989qfpzIuorFCsUYeNwqrjkgqSB6nAzj2qO4laRBG6iaPeHK7e4wTu+tQaxpyy3Vrc2bSILWRblLfGCX44bIzxyMcZB+lPfRl7qwzXtOW18S394Mlb0I7HPBwPT6k/nXB3kEVxq+pQ6hfs9hbosk1jNnbEjEAFSf4csBkYKnHYmvWt1vr1tJZqrQ3MMbSQEsG3KD0+o4H5GvNNf05Jr2G9kmhR0V4ZIXXPnRkfMh5HTBI9MZ7VrRk5R5eq/r8io6q3VHn+gpvv9SsI7A3MLYWK1nbO1t4xhuMHGemM1o6xavFq5bU9OMNmbhJTMwyucAFefXgEe2ap6veNL/bLbYri3+SPCriSEDgN68ED8z61sW0t7qNp/Zt9MZ4Zlhube8kXndwBuzxWsEvh/rqaGhql7ZeSujb0W4LSwouMKsoJAyexDAfz715sqXNtbLlykQkyxQ5KMOOcd8ZNeleNHs7KNJLjTG/tm/wBPi1GRyB5cMh+8ydyc5yO2O+KxfCWmWupan9m1aNYo5FS7uQDgeX97PtwM/Q1M7VbOL1Qou6uyLRvD9pYSR3fiG9QWbCOSEDJ8xSA/I/EjHqD+Pqn9qv4qtdRhtr57eyl8me2kAG4heXUgcjJArzTVbqTxHc26xQRraTXLC3eUBIrW1j4OcYG3BIz/ALPc4rsvBen28Dzz2EAhhlmkKuT9+HPyKo7Dbg89fWjlil6f8OS1zWNnULMSXBSB5FiPAbuvPr3qhrdpL50900oW3udPFjBs++p3HcTxjJ/kcdq2NZn/ALOskZEVrmZvKt43OFZzzzjsACfwqreA6lpZUvDHIUJieNjtG4dVx1HOQfeiDbs+hUney7GINH02GZria2nU+SjQxSNlEKjAk56NgAf0qC7bSNT0uOeSJdUS3JkFtBMIwCB825ieBjr1PpWn4cvdMuLZtOhuJIbrRlZZRcZwqD7zZHUZ9fT0rP8AD6WAtVd7O2s9NurowGM5BkUEAOcjABzyPSqXVCvzaI53UYNT1nSb7UGmSX7eBOkYyCgxgomcgcDn2FO8F3V3d+TBeWpmSw+RL9JFzblFBCDHUZzyPX0rRv8Aw9BpmqWcOoSz3RvbvMhk+SIOoIWPb0PXgcfd9K0ZNL1a4knk0q8ttFSOcKI5kzvXHLjAIIJ/lz7q+vNcNEtC5JdX889wkCMs0cPzXTMXKuxOP3f8TbVYgew9RnT1iPRLvwxavqJe1jurTa89xJ5M/uCAeoPOOR04rJW/hMNzq9z5ZgtkKQ3ByEYhdjyLHnAJbI3c8cDgZrYj0uw1m4ttc1W3a4MaKsEEsZwhxkZDAcZOeRzRMh73MjS10rSruwvp2SOFITFBNfSCJnB5yScbic56dMV0FlctLcX9nd218Yjl/tTCMQMpIwi7Tk4B64+tMjtLS4lW1vWGp3EwaULchZmOCN20EYAHHCgAcVqJIsjlkJ8sgdB1+n6VE3cbV2cxDcyf8JNc2Us1kJABMscO4SyqcLufPBIAGSDz9Ko6ZoEemajcatquofbNQm+TzXXyook4HGWPJOPYdqvX9zpelave3EVgP7YkhEX2kyMFbcPkBTOCTgDOO3rzWlqFtDrejQR6tb3FtBdqsrwxPtaIkA8bh1B45H+NF27Noppx0Zzt5JHJ4uRY9WFrZMrxBBchIZLgjGeDk84BHcg8iqGhXcOvi+sLy1uCtq+071MXmScg5VSOmM7Tn3qC806wur+50WKC4tjYf6T9tUB3Vichfm+7nIIYHqar2A1HUtSlsNFuo9Pto52kkkUfMELcsuO/AALHLHPOOmib6bILW1Os1bS4rjS7PS9NMljBDIGjmQ8x7RuLYzlmYk49znty+zsoNPtYrXTYxsUDkr87H1Y4+Zj6/wAulak1xDAhYuUh+UB52G7oBuY4wT3P1rz7VvG1zFdXU9hGhsYsxwTEE+c3zDcPbIHH50oJsa9072Oza1s31DUpo7a0GCXk5yTjAAHJJNaUxSARJFlTIBs3ghmOM5I7fSvLX8TJdWen2usfbLy4sJUuZ4Y0GHbk7T6AZGfyrWPia6Hi+NLrdILkrHZQIcIinBeR/ccgD1B/Fum92yJSk3dnbhsFzxvUEdeKm0i/l0mwMos7y9uI32vBFtLkHOGGSOKqrc2sxnFvJHK0TbZAP4PY1bsbmKGaF8B0ZTuL8444H05rGUXazQStKNjho7u60yNjqtnc6aqHapugH3A8A/LnPUZ4xk8VJpeuW95di03hpk++Iw2F578DH0NdZ470qa6sI7/TRfNq1pjyls5vLkdCw3KMgg8ZPIrz3wla28t3rH2iKZRLOyMk7gswHBBK498nFKFRTjcypz51dmrpWuFvETWcyTNp7xG6aaSNUECYOBnHIbAIJPeuqsngnjFzbvGYJ4wN8Q3N7MPUev8A9auL8cWOoSadI+nxve25AE1pFxlR3wPmOOMY7E1mxeJ9U0G70iDyh/ZrrGi4wzjjG3HqPSqkluiuTmWjPWLopNDGsc7IqKFMo5yBwP8ACqFid8RW02lcujYYEh1Yq3A4zxVTUdf0ax1BbS7vra3uG2yCLYxKk9jgHAP9auzW9noz3twI4LRbo+bIVBGZM8MevP0rJK2hmnYbO0cUnkTck/MCBxx/SrNv/q4pLV2lUgKG2sCCOO/p/SsXxDYS6nod1Hoc08d4XR5FQ4doRjIQjnB6kZyD7cVi+EfED2mpXOmOJzeSwO1vBIG2GRRwr8ErkEjdx0q5Jct+prGLcXJdDrry1fTtQ03UXvnQRXZMhCgKyMAhVgPqDmub8VaYlx5rXZlieKXzleJdzxsDnIH8XcYPUVs7tQuY7SO+b+zLgweY8lviRhOGGY9rZDoV9D1B5wau61BG0a3EaFBN8sibeFbqMfUUU3yy1CLd7M8U1A2mnz2WoPEJ4r1WhmuFBWPGccxnODgDI+uM4zRdQsmqHTfKlFleBfLlUZ8twACV9jtGR7V13ivTHQWbaHDa/YZCzXkdyqssMmc+ZzyAeenTn1rl73+0rGaAPdzG2kiNy00TF1RwDkA9xwo59RXXFJmilc6mxuIvEPh+8bWHlW60ALAnmYzNbycc8e2fxrK060efQpheeXHdPEEeW2kBaROiqcdBgkH2rHN1da0LUwP9nhu4DFO2MKsisQpOOcY2/TmtrVbqKKNLTw1Mp/s+PyJPMUBWcDaZGz1+8SBRHTYW2iIPFEKWPga2jtIXSC4uvLk8vphcnZnnrtz+PtXZeC5Q3h+yn2hN8Ywq84HTp6Vwt9Fe6TZ2EN+XMd3qMd8FJ+ZFQGNDtH8T/Nx6KK6nwK97b2K2+opgh22A8EKDxnH4msmr3ZcXudVf26XiwJIeGbYJO67vlOPcgkfjVCfR9L0i7Om6XO0zW0Mas8t0HZF5wpHbPPGB1q1fR+b9jk2s6wXAkb0K4IwfYEq2P9mrOsWFrZTPe2yws9xEp37cM+BgZYDt0/Gs1KzRNveRysNndweJmvbm6RbC5ia3ntoow7MhVkViWHOPlPXtisfUdF159MgsfsC3B066R0QTJ/pECH/WHkHk+/c+ldTaW8i2ai6nM05cyPM64DA9FBznA4/H60eYYZEZphFD833nG1um4dxWjjzXsO3Yt6lZyXjwvdRJK8c/nxh15Qg5zk55znBGPSob+yfXPCt6L0nSm3tGfM2tgKQd4OcYI7549eKrm6/sua2Fzqd5qH26bMCRwoHA6kLtxuAzkscYAFbEtx/aGlpDdWvliWMmS1lVZMc9G6j3qHfSwuxgWL6ZqNzp9rotxKdO02EGZ1iAS4Y8bMNglcDO4A811t0fKs98UYOI9wU5G7jJz71RtBDZWyQRBI1XG2ONcKntjFVtX8QW+malZwzL5gfMsqKfmWJQWLY98YHrkCizdkCVtWc14Amu9Q8StcXbqt1ZGfyTEQUaOdCV55z90kdfvDPSrfg6/nhlOmPB5cdvJLEXZyfmUg9/94n8q4zQbvUtPvLIWlyGMssDvbxqeI5NxCn1A3cfWr1vrtzqDasluHtr5Xl1FJYiCXjV9rRlcddoPfnFbciS16kr4rnZa5okF3qkOqugllt4igQxgkn+Ek+2TijTo9SupI3udjdCguASiNz2GM4Hb1qLw/4ssb1vIvJkhm8uORC3Cyq44OezZ4x/Oui3oJ2iZlyORn6Z/wAKz1jobKSs1YyoY7iLUtQkDK0M1v5RgZUUSuMbSW65HTFQaDHZ/ZJ7yGPY1zK0kxbrlSUUfQBeB23Gl1qzu7m8iWKYPZ3BEVzHIu4BQGOV5GCflGevemXMlxHpV/LOogkWGQhkHcA/MMdORn8aqysTFanKXmspqniC3S6Zm01fMiEZyo85RyXPoBjjPeoZbnSgRaW0NksAbfdRTZAjUYIYE5yef1qpqEZvvD0GozyBJrrUl+2QKAFj2qFZh/vnk/Sst2e78RyhrB0HmyIwkBwIW4Un8O9bJpaCTckXG8RS22s6g8WxLYhoHKAYlAHyMWHr65qxf2tk+j6LfK0VoZbYxRBWJYsWII3E9skknsai0exFgl9bEC6s7hcC3KnLMD0BHJOPStceB7saHPrmqwS28UaKNOs5HDBASMllJzjH8PU55obcbc1hS91jvDVhPpIe8vmvY0Sfy2tTJiKYbR+9Zj0B9Oc9K7ezuhcEvHGY7dfvZA+XP3fp0OPx9K5O48JXslo2qa7ffabmSQzjTYW3vjbhE2jjPsOBio9BvLWHxHqUMZkiluo4/NXljHMMs0Yx1wAeaStNWe5ndL3ke2FACcDj24rwHxnpTaX8RWikkmsrO+b7QZYpiqGID5nfqS2VYnp7DpX0GRz39a81+OGneb4dttViXM1nKqt6MrEYVh6bgPpn3rx6L96xyUZWkZXhVXtdJW4l1EyIVEhnlOxEHXgnkAep5rmNNnn8Va7CLMN5cl+2ZZMfJEGDFsE9cEcfWuo8LXNprGgNZsUhjCm0kychTjbk+xH865/QtKn8Ga3au+6S3nuDZum3zHd8EARrgH7xHPsPXFd0m+53xk4uVuxveKpNPt/GdzLcadZXVzeRAxyMjDy41IBB+bBbI4IA49elWdY1jXp4rRRb2UemXMJ8zVmlC/ZjuYbjzjgAEKRk5x1rV8O6dDa6depNPLqs0t09u8d+dyHYdpKA5AAHy7hgkgjjAwkOn6Vd38MkCRO1gxRLeCbbHEVznMQPOCeSR6VDS+z0Mbx5Uramteat4aurOPTrDUhdXlugRCY2BmIAyC+0KWY+hHJqno1vPeXDNfLeWCSHZFDMp8w46ny+cA+5z7U06Vaw6rLf3Jf7Sy4SNOUIPU598fzq7BcODc+YWXz4WwysQVYDjaf8alR5Y2ix2svdZbvvDlpEUmZ/nXkSTMAF7g/XimzrAbAWpfeY3JMgbO4Yxn16nvXN6ZaW+m2ccG/z5gxaWabl5JDklj+fA7VJdw3E09vJHdPEkDF2VRkSKVIKH88g84wKrkdrtjUX1ZSnjURz280rLFK3k5wCQD0/HvXJXK29hFrlhdXgvLC3kCk8o0Zb+H8/5HpW54suJylrY6bcwx6m8gZhJgcHoBkHnGD+Nc3qdvFpkGsSTOXkv5EVmZAFDDOT6AZJrtjzWRd03cuaBpflaT4lvYo4LiOS0ijtbWQ5IkOCAAO4Ukn9azIbKS/0bVon22rKqZjgwSwUguxHU8gDjpTLnT5rC50W2iuWiSaRZSNx35OM5x37U/Vzdi5vJItkN9KnkwwRNjy1Zic5HfGe+eRRyrUB1vbXWrWs9/zGYIo44DJJuMYPyFj7gliPTtW54d1ebGoXl4yfYY3VYZJGA2qBgnJ7EbePX61V8PR2qXM8U8ryXd7IsTKi5VQME57D/wCsaradYT3GsX1vM6votxEIo0V/kYZBXb/tYQk05LoGzPR9IvrS/RXgnWaB1J34JDdv8adrlgt7p1nMHdY7C7BCp/y0ypGCf7oyeK4Lw3BdWniaVFjSGB4HWG3U8HAAzj+6Mnk4yR9a9Lt5EfR7uC4LRtvEibRnc2BweK5akOVpoL63ON8RWeo3NzZm0vpbGGB8yCLkyDqOe/pg0kllJfaabW8hi3SHzRKrYIJ/3cc5raE6Q7YW+Y7d5LDk1KZEZVljCBMZyfyrVNo1KWl6ZFp9ykipukMaxNI5JJAyQPTHP48ZrRv7yOK1mlY4SJWdzGM4AGScdziuZu/EemywanbyC4SeyQSGVXALnkMij2xnPqPxrh/Dmqza01/4f1W6ka0uy06XZBLxyRKXX8CAQR/tZ7VE3Zq+7M3LqdLe3Wr+IPDNreeHJ54iLmSGVBN5blCAVfOexyDg1l+ILaTWtQ1e4mTy7qw8iOYpnNxEH2bic9TgHI9vSqmpxXd1bRnw1PNHZvdg20KOQcuuD37Fen+1W09jqFlN4o0ezu1OpxXIlMivh/L3cgN6gk8ZrZfFytE2tqUYdVSJ5W06z819LiiRJD951XeqlsdTgjp/Su00WJdfskuLO0WK5nSUOkKAvGBglTxkZJziucgu9PtNU1iDTG/fSMZDubpKVyyp/sg+vriqfgnxXqOirb6xIpkhhu5WmhV8G4QoFckdTtypHuac20tN9bA72uhk9hLqlldWsYW28ny7m0k6H5UwYj9GGRnvn1qr4X8S37SXF5eyGS0t4FZxwW3+Yq8dxncfb8q6Eapa6/fXWmwtPYalexNPBnG1Jf8AWKh/3sY/H3rmNYV76cxvAlnd3jw6eIYl/dxumGJJ92I4HqTUz3uv6/rYq/Y9Vu7qCCy+2TSlLcLu3MMDH+SK4nWfEoupmtbVPOieEifOdsEb4G8nsfm/CuM0yyvl1WLT5mkuxMoYxRuxBG7BOexAB59aNe094r5xYxrAjRr+4WXcAEH3mJ69M+5yfapV7cyXqXd7Gt4ontmt75bDf5SKjzKo+RGL4TH4A/nU8eoibUrWONjIkQiKyS9J1IHPsPas77XBN5OipCyvMyi5l28SbUIBz1wDz+FdZ4P0PzNStLWSVRFbvvZgoUFFJYYPTnBzmt4yabk3ohbXZ315/ZHhnS7XVNTjt45BukWJWAyzDouOv6AV5j4i1+18Wa1Fealqr29tDkR26McIOwz6+/eum+MN0mrXtvBZ2s9zDaW/Eafxs3I7dAMHjnmvP9VsLddLsFSNNMvXDNNBuLkr2ZuOPpWNKLa55LUyglZN7s2tOW/021a6jjn1GaWQlXDFdicY56kn24q9qscOn3tpf3UdhaiQGWVZHO95WHPTg4zzVGHUNYtNGgtrbZJMNric52IPQqR3GOaRbE65qa6vbEX8EQMbC4UrCX2gEIMfj19K6JNpjfmfQzKP/rUw2kdzbSQXCLNDKGV1kAIYHOQR6c9KnVQQB14xUyD6V8y2cCR4P48gh8F+INPstLZWVw100UoCYiYgY8zIBOUPUV1q3M1zYpf6eltdXtsu638/7qFvlMhPUbRu4HJ4Hqa7nxJ4e0vxHYfY9YtVnhyCpztZfow5Feb3Pg7WfBsl9N4fFzrOkuuY7IAGaJs9PdQP7vJ4yO9d1OsqitJ6nSpqSs9zZwYLeBJHXesXzybAm9jy7EDgEnJOPU1Rmu7WG727kE0kRk3L/Eo65PftXDeK9e8R2EtjdX1hPpVnHIrRo2VlnKjng87ckA/XFaEXgnX9U0DwtbxRGPfZTzyyqo481iY1ZiR0UqcHpniuhOEWky9jprPX7CecWsN0JJHXzPL5zt6EgVL9vtTDujlDQuBtZRkGvPJ7SbRfFL2NlpVzf6vaWhgnhtVZzyAvO0EYIPJ/rVmbwp4j0XV9P0jRbS5LS6e0wM4DASlcyAMBt+UkD8j/ABCqk6cZWKVlua2v6rNa6zHpkUcWLmNpoZGU5DZOM8jjgj8av+Ib9tP0y5fUZEgEnzRtbrl0PVl6+oIBrm/GmgXPhyy0ebV7mOCW6he2ON0hicnMrBhxj5uBnvXN28+3UbBLqKSW2kYwKblfmlUHAbHUEDg49xzW0ZRlqmSlfU17m5i1fWtPuEuJ4rm5hBhkkQH5kyoP5qfxFa1pe6ifEFzLDGraZB+5uWkZdhZQck55znpjtirGr6dHa6Jp8UbxwTQRzxwq5+aEkscKc5AOf51wq3t9b6S0cyh3uJGDEHL5ULtJ9c5P1xWt1bUaV0dhrMFq7w63KXkuDmC2jUZDMDyQOx5PNcbNe3mlzTSOEmuLzMobdu2LuwDj17V3Gg2UWpaBZfbldrguWKoxDAtxhR1OcVX+G2mLe6zNLr6N9hsGnSJJDgb2I2qT/d647ZNRN2Wg78pgSW8lgiQySqbmcs7PGxJSNwQCR65B/D61dvrm2t9N0W7a4P2S3tpTFbouC0m5gS31IAz9K5nUby+VZYZGkX7MxSBj0wWwOe+Oa6OLV7W2nsLsWkc2ntbyom6PqQcMoHTB5/Onzp6dimjobRpB4la+eM/Yre3BjbGBMssZwSf9nce3GKffeOtKt9OkaORppw3lrGikbm+p7e9c/qurprUkQku5LSGezJFmoI9emOONvHGeKg8DA6vq1nplnZJMryYX92qt5ScszN1HpmolbdsIqyuzsbCxv9b0e31cxvbTWl/5yw7v+PhI1UlCemCx6+grmrLU54Nd16CC8EumXMsi2+Du8pnDMo9sZwfoa9Y+IWlSTeFbW3WaS1gjfM8MLbfP4+4WB6dTx1rx9tO8P2GqadaG3mE81wrYklO3A4GcYx1P1qKUuf3/ADFF812RG4srbTLO01C3cz2EM7yxpjbK0mchmHPAxj6Cq/hXS5J9SgvrCWIPK7q9tyVMTIVx9cE/j3qe1kF/c6rY3sKRSYNt9oKAPEueVI6HGPrjvUl0q6bfaPb+HwZbyBHZ5FTLMQAC3f8A/VmtnGLadtP1KtYn0iS20nxP4e0VBLJF9tjaRpRg8uMc/lSeN7n/AIRzxXNewxStJfyymdZW4IDDhccjnn/9Vcv/AGjLaeJYptTRvNiuvNkbuBkA4+mDiuo+LOhyxeLr/Urd4riwkVLlTv5jDLgLt+vPFZym7+7v+WwP4rEF/dnQtU1a9uYkWaaNVjt0P98ZY5x2wR710uj+HZILy2urho8zQlTbO2doJVg3AwAeQcnniqd3aQahHG93ZxzsY0IbBG8gHlsHPGeldnJHea15lzpQAkeJV2BtrDCgHaPXI9q3m3H0E20c7faRYWXjv7ZMEfzIYo03gMiSsAoHTg5I57Vi39lDD4/v9MhJuBDfLK4JH/LOEyOw9CNhGe9dnPE8GmXN5hZ54EIjWQZPmAZGc9CCP0ryzR9Si0mC51aUm7lkj+xM7H5meXLTMPXCfLnP8QrCTcUmhJs0/A7Wts1tezSOTJCykDlwgYsyjHHNZ+s6otzPrOoXFuitKi+SADt37xhQR2AB474plrcjTLq5MQaVriye1sA45QyMBkjt8pIH0FaF34ZuNN8GQLOo+3S3L3ilMEKsa7VUnvk5wParbeyWpd7OxmWc0d1rluVYwyWjssrI+Y2j6nacZHOevrXpvwrto9W125mVsJbqpIwD5inOAT2rlfCmhXWuWMdvZQGO+uJBcSDd+7iUkBmx2GOcfSvdtH0rTvCeisiyiO0gUtJNIQM+pNZYiuqcOX7TM6srR5erPJfHMN9ceLtVS2ZYIlkVPMYcIoUDjsDWHrumyX9gWht5HmjTy492fmOBlj6twSK6/W/EF1rMtz/ZSwf2cXMhcxr5gPU4Y+vtg9q4LVLfUdSvGubGaWGzjjKj903zHHIIPXOOgB4rop8yppNFJ9yx4RsWk026e+1NBZBdiqkmW3f7S9uPerurWtnrF9o2iWSTWWk2cDuQlwsbsTj94w55PA5GeawtTu7u2tUS2SGG3JLETjBlkOMkIpO1QOxOf5V1Phbw7bw3/wDaU9uI7mVScrIz5JHLYOOuTxRKz1fQlo9yT7oHapBuIwMA9jTByB2+tOUrggEEDgivmmcSHZ5zwBQOBn+dIDkjHPsKAQeSPxoGJNHHNE0U8UU0bAgpKgdSMYwQcinqFG0KAoAwFUYAA6YFNPXJpf4s0DuBRBK8ixp5jqFZ8AMwHQE9ccnFJJEHlicMB5eR90ElT1Ge3QflTwMntinjnHOT1ovYe5maxo9hrVp9n1W0huoAdwWRcgHBGfrz1rLvfBGgXv8AZCz2YSPSQRbRxOVUAnPzd25569Sc5rpSvGexqPOG2t19aqNSS2YXaPnDx1p/iiPxnqkot7x41ci3cQO8bLxgghSOnOaztL0nxHd/6OdOu5prhxlxaOgxnI+cqFHOeeK+otpLdsjkGobyeK2gee4kCovOT1z6D3rsjjJp6LU1VZpJWPMJvAmuWlzYz6S1ozQxxFklcgCQZznsR7g1y+t+GfF1paG3h0+5nllPVPnBGeQdvTp0PavQdT+JulWOo21otnfytMxTeyCNAR05bgk47VPefE7wvaTvFd3k0MyNyklu/TH3gcYI/WtViMQt4lKc0tUcloXgDVdQeL/hIbWG3sIVRY7dmAZsEkn5CcdT1OST6VyuqWNpp2q6jZSWUkFrDLIsBYMu1gxwwH0PbrkV7fL4lsINOt7y4d1huY1mhRELuUYZDEDpkdu3Sp9St9N13STFdtHcWM3CnfjDDnKnsR1/nRDF1Iu9RaMSqWd2tD5jM1xqOn2t/CXe8t3+zGVhkbD0IA54yR+NeifCDT7GT4g32oWtzJLNbROXTC7cv8rL0HAJ4Irc1b4UgvAdG1ma1Ebb2W4iD7j9V2/litHwd4asPCF5B/Yccuq3Golkur0SqI4UUgnA54zjjJOR1qqleM4Wjq2VOpFqyO113T01XSbi0P3nU7CezdjXgPiLwnfR6rbx6zp120URJaaFcrs7/N0x/KvfdRvbi0mtxBp891DI4R3iYZiBP3ip5I+laMkSzRvFKoaOQFGXPBU8EflXNRxEqMbNXTJhUcFsfM+qWtubOwtNPLSXV40xuJnIJ+RCASR0Ixzms/wv9psPDGp6pbuf7TMkVtGM8+WzLux6dAPoa6bX9KHhTxI6SxlbZHkkhkK584OhAUn1Hyk/Q+tXfAfhma9023m02Epb/amEoaQkNHhTkeuDxXqtxa576G72u9jB1/TLPULi7kvUkiltLvyyVIyY2GeevIOfzrQns9S1iQapeqtrb2Vu1nMjgguyqQjIMYIyV5z2NHjC5Q310sIOTOfvL2Bxz78Vb024uUgsNHYzNNPGcI6cgctg5HYCtdLXQ2noy/AZL/QZmjaBEsYg0kjkKqqR6nqa9Q+HmjCx0OAXKvFLNhpMEZKkDH6Vk/DLw7PpEd5PcxptvNpMbDLADPXPBBz0xxXbX0tymnXMlkqm8WFzAr9N+Dtz7ZxXk43EczdKGxlOV/dWx4Ferq2sf21ZapJFa3M88mEiI/dheowM5yAMtz+NecQ6QsRWe6uImtrZwDHGS6u+5ePoRgE10Fjo0tlrbw6zem2u/s7KYnHzB2Byc8+p/Oud022uLjUHj0+KWeCCF3ZthXIX52Ptwvf0r0bRUUmv67mtkjZ1LzLy5g1WRVt1gmaYAjkkcouMeoGR2zWvp2uSah4W0eIyA3UIMbhhktknH4nIrmr65u20HT0t0a7WZJb2UFDujUylcEg9Mr19+1d98N9Eju/EdpMypHb2q+bDEQTkAgA578nH4H0oU1rN9CZSUfeZ6b4A8ORaPpwu5kK31yu6QZwEHUKB6CuC+NPiy4k+0abpwZ7S1VTcbWADOTkZ9VHHA7/SvQfHviJdC0narKt5cgpEzsAqnuTn09O5rwC/1zTZGcXlv9ughPm7wGHmvjkMTjnJ9646Efat16jt2/ryIppt87K2g6fJqenxy3lrJfymQuAGZBFH1OCMKXbGACfzrptJjvLxWs9s1rIifuYIIwVtFY9HZiMsQDnAJz7VLpSa3/wi8Os2EdlpemW5eayhnO8u5JBKoOwGcEjJ4qX4c395eX1/NdQXpnnkE0k00SqjDBGV4GPoARzXYqiWi7DvrdFrw94GtdF8y7n827eQgbFUZ69wOMd63v7ZsRfSWdu+6aBN0nloWWMZwFLdAeelbUccjWuCpwzEDzDtwMcY4z61x2o/aNJh+ztcXVzNfzt5ENkohZVUbvvAEnAByTycj3qIy5nb7iL31Z7Iew9aUnqAKRT8o4xx0I6UuRjtz2rwzlEPXmkGDml/mPSk4Y88Giwrj8jP6cUmfm9aTvz60ZwefpQO5Ip45PHtUmTjjioRjBIpwbA5ApNDTHk89KRwScnmkyCOMDvn1p4wxPpnvStYZGoIGD0rN8SXEcGnsLlHNvK2yRlH3RWxt+ZeAPrXE+ILu5vL1bXzFS0Z2UqyZ3c8ZB7VvQp80vQcFdmXq3h6z1LRSVa3vrNMLKUx5qnPqD+vX61jppEDp5dxDHdxQpuRZoRIygHHUjmtu0uYIJotQgVYiD5bg/L9p9fXGRirV19n3G7sGeFTiU84ZCeoGK9FSlH3Xqjo5mkc1p99Hq0ZuGBjdl8yOGXiVlDbd2D26dqrT6PFda5pl7e6rLZwW0ufKzujkYnGFUgjcQSOnPtir19a3E2sW2tiSAQxwPZ3Uch24ib5xJwP7wA/Kk1GPUFt9ml3kVjcxkE3DJu8tB97YMH5scD+nWtLtphdtWO91W71FZEng+zw2K5MpaMyyueoVEBGSfTr6VzM+q6Tqf2S28K6jDZw2Vwq3Ef2N0GG5x820oc9WI6/jXC2Q8R6/Fd2viC6uLuK4urYRQ7trWyiTJn+6BtVQQTgZyK17bQ9Kng33FhauZ2Ls0qBizHnJJ5JPXNc9Og1vpYlU9bHfanfavpMy3lzqWlJo4CrI08LAjJxkOGxk+mMc11SOHRHXkOAQR0rzG30+WGys9Ghi06TSDJi7srrKpNE2PutklWU8jGMmvQtM05NMN2IZp3imkMgSV9yxcABU9FGOlc1eCjp1M2rFtxGxG+JGOQfmUHBHQ81DbW9vZF1tbeOLzXMj+WMbmPU49asnnkAjFAx8vTg9a5ru1hGXqmhWGp30F3dwq80PKkgcU610HTobiOX7LD5kT743K5KtjbkH1wcVp9Vyf16il4P/wBcVXtJ25b6Dux5brx+VG7nIH0zQPoB649aB14PesrAcT460S2Zxf22lG7vWDK0mWbYCOpUHBri9N0rVp4m0+z0yODTvKe2dR8qsj/eBbBP5c+9e04BUqR8vcGmxIiqFRAg64Arsp4yUIcjV/U0VSyOA0T4cWNu/mXreZG9sLdoVyqhQenHOBxjvnmup0PQ7fSI5mRYk3EAKoIWONQAqjPoB19a2OhwfWuf8YamLO28kSLHLOrbCzBdzAZwP/rVPtateXK3uRdyZ478V9Sh167uJrzyTZ2bFbeIE7mIJHzYIzk9hXG+CtPm8SXp0+4CWekWh+1XcqqB5KDsN3G4k4G7P44re1HXJLjW44JVE+o3Mqxj92CW3dMY5PXr/Otzxm+m6D4Fv9M0tU+1GUJczRxgJPMOSqH+Lyw3J7EivTlFU4pR/A6J6WitzduLnUNWVrCzMMXhmNPsm2Z3ee9QDBYupXHbp6elaOi6bbaZamKyhcJGNqouSFHpyc1l+Emurfw5ayarKFcxKzbhhY1A4yT3xySe+a1xfwLaNfSNNPYqfmNqvml/90LknqPpUtKN0jN6IuarfF9KFtaRpHeyjCvNyI/U7R1PXg8evvwPiXV9R0zUZ5blYLq2jYNaBU8uRM5DLGRlmbHLHpgcDmuw0e/uryJpH0cWUm87IN7S5THDMeNp9qknQSOShaGXu6jBJ9s9KcbQexKstDt8+34UueOKYSAen4UZ574ryGjmHjkgdBS59cDIqPr1p2cYyeaQDz0/TpSYyBxk+9NJOcnp2OaTIzhgCCMfWmBIvBINL2AIApgZd2e/rS7+evzdaLDuSA4FJLKsEEkkmdkaljjk4HJ/lTc9zS5DZVvunIP0pNAmSuyxIzYPygk4Gen8646/Ey21ncMVj+0M2Y9pDjnoTzjjt64rq4CyQxo7bnRQpbpkgdax/EunT3dpbmynWJ4JhI2Yg++PBDJ7Z45HpW1CSjKzKi9TGt4I7tXmkEMrKNkbB3kJQDoQVAU5zwCfrVcEpJBtthKFBzECQZBjqD2PsPSpJP8ARL14GV44952uDnAxkFc9PXHvVu4tIy0b2k6SIgK4QndH746//rruukzVMqG3tmDAqtzbMhSVH/iiIIZG79Mj2NVotJWOyYJOgtTII4DcSbJYxwFjYscMfTnkY6GpVMf2supDIyMGIJ+YHPOR7jtnP51Bq1hZ6vo9xYPdRu7RrvglPl7nU5WRWOBu7f4VVmtmO9tSn8una5FYXFwsd8Iy6xOyq5UggkKCcjqPzpmsX9jo1ik94zKhlWOIIAzEk7cAfSq2r3WuR39q48P6bPewRlBeXbL5i8Nj5h8xHPQEjmn63p0Ws+E9FN1aQ6fqMk/nG0jAAa4Ctux9QN2OuR3q7vRP/gFOTurml5URhki3JNCfkGAGXHTb/OsC88d6j4Uju7SdpdV1HULuT7JGHz9kUbQi4OSc54HTpycnHRR2xhhs8Wvkttcvjo5z1+vf8TXNaTpsWn6/c6hqjrLf31wVtUcF9gJJwuBkYAGT2x2pygpqzHG0lqbuleNPEMNhp0d3p0d7O0LyXMshEDRsGbEflqGzwByOu7nGCK2/DGtjxnYWt1pGuPay2cpe8tY41lyGztRi6ggYBwQPXuOMW2meTVbiGaxMVuiKY7ncCJCc5UL1GPesrw1YaXoHjtdUk1BbK0mD+YnnCKIyN8qhiSAR8rsFxkE9hjOE8OuW8FqiJJJHsijaArNuI6nAGafz17V5Jr/xCvbHxbc6bpAbWGEbW6QxRBFgmDcuzH73HGMgcVShPjSNjd3Hie6nnVt62scKLGR6MBken+ea5lhJyehKptntQPcnJoJIPOcdK4LwR4t1S9u4dL1vS/JZIfm1F7mMec4P/PMdCeOld307g1hUpOm7SJd07Mcw45H4mkyM47GgkY54JHemRukigoysp7qc1nYVxWLYxgH6cVgeKtHk1Kwma2H+lmJlX5Qd3BwBkgLz3zW+pwefpVTU5JorNjaLuc/7WNo7ke9aU3KMk4hF6nhNr4JvNF1CbXdQjlS9lYW1jEij5biRdolLZ5VeTx3+la/xS8PR2nh/wjodhKIzultIzn7zOikk+pLKP++vpXdC4lj0M391C0lvaobhvtcmWGAf4m6H3rhbzV7Xx74y8M3GnSu1rpRe+uYvLOI1DIEGcclmH5Gu+Tblt11sauTcud9Bnhu4upLQ6R4m+xzalDGqy2saZMSEAASg/KTjBO3jBrpobWGGMLCscceMIqKFVR9BxXmWt3ktt4uv7yPW4ysly0t3HFGyyMO0bPtx0AAGfU471e07x0LmC6m/s+e3tYcAOPmGewznqfrit4wdkupfKd3d2iyanZ30s8qraKwSENiMueN5HQkDI59auRTwtLtUIRjuep78/lXEa14oew08NdxRteTjdDaxb8onbexGC3XOB9K1NJfUL2CCbENvE6hkznzHyDklWAKqOAPXrVeyutSWkf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endobronchial biopsy taken from a six-year-old girl with severe, steroid-dependent asthma. The airway epithelium is heaped up in places, alternating with areas of squamous metaplasia. There is marked thickness of the basement membrane, and the underlying smooth muscle is hyperplastic with some fibrosis. There is little submucosal inflammation evident in this biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan Brugman, MD and Leland Fan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21137=[""].join("\n");
var outline_f20_41_21137=null;
var title_f20_41_21138="Robot-assisted rad hyst 3";
var content_f20_41_21138=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/53583/Closure_vaginal_cuff_conv.mp4?title=Robot-assisted+rad+hyst+3\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Closure of the vaginal cuff",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Colleen M Feltmate, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21138=[""].join("\n");
var outline_f20_41_21138=null;
var title_f20_41_21139="Crohns disease fistula US";
var content_f20_41_21139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn's disease fistula on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    B-mode transabdominal ultrasound in a patient with Crohn's disease of the right colon showing a hypoechoic bowel wall thickening and transmural inflammatory reaction and blind ending fistula (mes) in direction to the abdominal wall (abd wall). The lumen (Lu) is not seen due to mucosal swelling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christoph F Dietrich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21139=[""].join("\n");
var outline_f20_41_21139=null;
var title_f20_41_21140="Weaning from mechanical ventilation: The rapid shallow breathing index";
var content_f20_41_21140=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Weaning from mechanical ventilation: The rapid shallow breathing index",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21140/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21140/contributors\">",
"     Scott K Epstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21140/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21140/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21140/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21140/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/41/21140/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuing mechanical ventilation is a two step process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Readiness testing &mdash; Readiness testing refers to the evaluation of objective clinical criteria in order to decide whether a patient is ready to begin the process of discontinuing mechanical ventilation. Some clinicians also use physiological tests, known as weaning predictors, to predict whether a patient is ready because they are hesitant to begin weaning on the basis of clinical criteria alone. The rapid shallow breathing index (RSBI) is one of the best studied and most commonly used weaning predictors.",
"     </li>",
"     <li>",
"      Weaning &mdash; Weaning is the process of decreasing ventilator support and allowing patients to assume a greater proportion of their ventilation. It may involve either an immediate shift from full ventilatory support to a period of breathing without assistance from the ventilator (ie, a spontaneous breathing trial [SBT]) or a gradual reduction in the amount of ventilator support [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. Regardless of which approach is chosen, extubation is considered once the patient demonstrates the ability to breathe without the ventilator.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definition, accuracy, effect on clinical outcomes, and measurement of the RSBI are reviewed here. The role of the RSBI in readiness testing is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=see_link&amp;anchor=H18#H18\">",
"     \"Weaning from mechanical ventilation: Readiness testing\", section on 'Approach to readiness testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General aspects of readiness testing, methods of weaning, and extubation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=see_link\">",
"     \"Weaning from mechanical ventilation: Readiness testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=see_link\">",
"     \"Methods of weaning from mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=see_link\">",
"     \"Extubation management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid shallow breathing index (RSBI) is the ratio of respiratory frequency to tidal volume",
"    <span class=\"nowrap\">",
"     (f/VT).",
"    </span>",
"    As an example, a patient who has a respiratory rate of 25",
"    <span class=\"nowrap\">",
"     breaths/min",
"    </span>",
"    and a tidal volume of 250",
"    <span class=\"nowrap\">",
"     mL/breath",
"    </span>",
"    has an RSBI of (25",
"    <span class=\"nowrap\">",
"     breaths/min)/(.25",
"    </span>",
"    L) = 100",
"    <span class=\"nowrap\">",
"     breaths/min/L.",
"    </span>",
"   </p>",
"   <p>",
"    Patients",
"    who cannot tolerate independent breathing tend to breathe rapidly (high frequency) and shallowly (low tidal volume). Thus, they generally have a high RSBI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACCURACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RSBI was originally described in a prospective cohort study that evaluated a population of mechanically ventilated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/3\">",
"     3",
"    </a>",
"    ]. The study found that an RSBI &gt;105",
"    <span class=\"nowrap\">",
"     breaths/min/L",
"    </span>",
"    was associated with weaning failure, while an RSBI &lt;105",
"    <span class=\"nowrap\">",
"     breaths/min/L",
"    </span>",
"    predicted weaning success with a sensitivity, specificity, positive predictive value, and negative predictive value of 97, 64, 78, and 95 percent, respectively. The pretest probability of weaning success in the study population was approximately 60 percent.",
"   </p>",
"   <p>",
"    The sensitivity is the probability that a patient who successfully weans will have an RSBI &lt;105",
"    <span class=\"nowrap\">",
"     breaths/min/L",
"    </span>",
"    and the specificity is the probability that a patient who fails weaning will have an RSBI &ge;105",
"    <span class=\"nowrap\">",
"     breaths/min/L.",
"    </span>",
"    The positive predictive value is the probability of successfully weaning when the RSBI is &lt;105",
"    <span class=\"nowrap\">",
"     breaths/min/L",
"    </span>",
"    and the negative predictive value is the probability of failing weaning when the RSBI is &gt;105",
"    <span class=\"nowrap\">",
"     breaths/min/L.",
"    </span>",
"   </p>",
"   <p>",
"    Positive and negative predictive values are not optimal measures for assessing the quality of a weaning predictor, since they vary according to the pretest probability (ie, prevalence) of weaning success in the population studied. Likelihood ratios are better measures because they are independent of the pretest probability. The likelihood ratio positive (LR+) and likelihood ratio negative (LR-) are calculated as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef72793 \" href=\"UTD.htm?5/40/5771\">",
"     table 1",
"    </a>",
"    ). The greater the deviation of the LR+ from 1, the more powerful a positive test is as a predictor of a positive outcome. The greater the deviation of the LR- from 1, the more powerful a negative test is as a predictor of a negative outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=see_link\">",
"     \"Evaluating diagnostic tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When data from the original prospective cohort study were used to calculate likelihood ratios, the LR+ was 2.7 and the LR- was 0.05. This indicated that there was only a small increase in the probability of weaning success among patients with a positive RSBI (&lt;105",
"    <span class=\"nowrap\">",
"     breaths/min/L).",
"    </span>",
"    In contrast, there was a large increase in the probability of weaning failure among patients with a negative RSBI (&ge;105",
"    <span class=\"nowrap\">",
"     breaths/min/L).",
"    </span>",
"   </p>",
"   <p>",
"    These findings were supported by a systematic review of 20 RSBI studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/4\">",
"     4",
"    </a>",
"    ]. Pooled results of predictors of success in trials of unassisted breathing found an LR+ of 1.66 to 2.1 and an LR- of 0.11, indicating that there is only a small increase in the probability of weaning success among patients with a positive RSBI, but a moderate increase in the probability of weaning failure among patients with a negative RSBI. A Bayesian analysis of the same studies found similar LR+ and LR- values, supporting the conclusions from the systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taken together, the evidence suggests that a negative RSBI is better at identifying patients who will fail weaning than a positive RSBI is at identifying patients who can be successfully weaned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of the RSBI on clinical outcomes was demonstrated by a trial that enrolled 304 mechanically ventilated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition to having their RSBI measured daily, all of the patients underwent daily screening. This consisted of assessment of their ratio of arterial oxygen tension to fraction of inspired oxygen",
"    <span class=\"nowrap\">",
"     (PaO2/FiO2),",
"    </span>",
"    positive end-expiratory pressure (PEEP), hemodynamic stability, mental status, and cough. Patients randomized to RSBI-dependent weaning underwent an SBT if they passed all components of the screening and had an RSBI &lt;105",
"    <span class=\"nowrap\">",
"     breaths/min/L.",
"    </span>",
"    In contrast, patients randomized to RSBI-independent weaning underwent an SBT if they passed all components of the screening, regardless of their RSBI.",
"   </p>",
"   <p>",
"    The group that underwent RSBI-dependent weaning took one day longer to discontinue mechanical ventilation. There was no difference in the total duration of mechanical ventilation, length of stay, or reintubation rate.",
"   </p>",
"   <p>",
"    A limitation of the trial was that it used a single RSBI threshold; many clinicians with expertise in discontinuing mechanical ventilation believe the optimal threshold varies from patient to patient. The trial was otherwise rigorously conducted. There did not appear to be any selection bias, since the trial's RSBI-independent weaning group had a nearly identical rate of weaning success (59 percent) compared to that seen in the original prospective cohort study described above [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the prospective cohort study that originally described the RSBI, the respiratory frequency (f) and tidal volume (VT) were measured using a hand-held spirometer attached to the endotracheal tube while a patient breathed room air for one minute without any ventilator assistance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are many variables that may influence measurement of the RSBI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventilator support &mdash; If the RSBI is measured on ventilatory support, the values will be lower than if measured during independent breathing [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. This was demonstrated by a study of 36 patients that measured the RSBI during pressure support ventilation, continuous positive airway pressure (CPAP), and independent breathing through a T-piece in each patient [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/7\">",
"       7",
"      </a>",
"      ]. The RSBI was &lt;105",
"      <span class=\"nowrap\">",
"       breaths/min/L",
"      </span>",
"      during PSV and CPAP in all patients, but increased to &gt;105",
"      <span class=\"nowrap\">",
"       breaths/min/L",
"      </span>",
"      during independent breathing through the T-piece in 13 of the 36 patients (36 percent). To avoid this confounding influence, we set the ventilator to a pressure support level of 0 cmH2O and a positive end-expiratory pressure (PEEP) of 0 cmH2O if we plan to measure the RSBI while the patient is connected to the ventilator.",
"     </li>",
"     <li>",
"      Method of measuring the respiratory frequency &mdash; If the RSBI is determined while the patient is breathing through the ventilator, one must be cautious about using the respiratory rate measured by the ventilator because it may be underestimated if the patient makes inspiratory efforts that are not sensed by the ventilator (untriggered breaths). Such unmeasured inspiratory efforts falsely lower the RSBI. This is most likely to occur in patients who have chronic obstructive lung disease with dynamic hyperinflation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other &mdash; A number of other factors have been shown to increase the RSBI, including a narrow endotracheal tube, female gender, sepsis, fever, supine position, anxiety, suctioning, and chronic restrictive lung disease. In one study, women and those with a narrow endotracheal tube were more likely than others to have an RSBI &gt;100",
"      <span class=\"nowrap\">",
"       breaths/min/L,",
"      </span>",
"      independent of the weaning outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/10\">",
"       10",
"      </a>",
"      ]. In another study, endotracheal suctioning increased the RSBI for up to five minutes, often rising to &gt;100",
"      <span class=\"nowrap\">",
"       breaths/min/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21140/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discontinuing mechanical ventilation is a two step process that consists of readiness testing and weaning. During readiness testing, objective clinical criteria are used to determine whether a patient is ready to begin weaning. Some clinicians also use physiological tests, known as weaning predictors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rapid shallow breathing index (RSBI) is a popular weaning predictor. It is the ratio of respiratory frequency to tidal volume",
"      <span class=\"nowrap\">",
"       (f/VT).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is only a small increase in the probability of weaning success among patients with an RSBI &lt;105",
"      <span class=\"nowrap\">",
"       breaths/min/L,",
"      </span>",
"      but a moderate increase in the probability of weaning failure among patients with an RSBI &ge;105",
"      <span class=\"nowrap\">",
"       breaths/min/L.",
"      </span>",
"      In other words, an RSBI &ge;105",
"      <span class=\"nowrap\">",
"       breaths/min/L",
"      </span>",
"      is better at identifying patients who will fail weaning than an RSBI &lt;105",
"      <span class=\"nowrap\">",
"       breaths/min/L",
"      </span>",
"      is at identifying patients who can be successfully weaned. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Accuracy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence that RSBI-dependent weaning improves clinical outcomes, such as duration of weaning, duration of mechanical ventilation, length of stay, or reintubation rate. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The RSBI was originally measured using a hand-held spirometer attached to the endotracheal tube while a patient breathed room air for one minute without any ventilator assistance. There are many factors that may influence the measurement of the RSBI. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of the RSBI in readiness testing is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=see_link&amp;anchor=H18#H18\">",
"       \"Weaning from mechanical ventilation: Readiness testing\", section on 'Approach to readiness testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21140/abstract/1\">",
"      Esteban A, Frutos F, Tobin MJ, et al. A comparison of four methods of weaning patients from mechanical ventilation. Spanish Lung Failure Collaborative Group. N Engl J Med 1995; 332:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21140/abstract/2\">",
"      Brochard L, Rauss A, Benito S, et al. Comparison of three methods of gradual withdrawal from ventilatory support during weaning from mechanical ventilation. Am J Respir Crit Care Med 1994; 150:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21140/abstract/3\">",
"      Yang KL, Tobin MJ. A prospective study of indexes predicting the outcome of trials of weaning from mechanical ventilation. N Engl J Med 1991; 324:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21140/abstract/4\">",
"      Meade M, Guyatt G, Cook D, et al. Predicting success in weaning from mechanical ventilation. Chest 2001; 120:400S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21140/abstract/5\">",
"      Tobin MJ, Jubran A. Variable performance of weaning-predictor tests: role of Bayes' theorem and spectrum and test-referral bias. Intensive Care Med 2006; 32:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21140/abstract/6\">",
"      Tanios MA, Nevins ML, Hendra KP, et al. A randomized, controlled trial of the role of weaning predictors in clinical decision making. Crit Care Med 2006; 34:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21140/abstract/7\">",
"      El-Khatib MF, Zeineldine SM, Jamaleddine GW. Effect of pressure support ventilation and positive end expiratory pressure on the rapid shallow breathing index in intensive care unit patients. Intensive Care Med 2008; 34:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21140/abstract/8\">",
"      Patel KN, Ganatra KD, Bates JH, Young MP. Variation in the rapid shallow breathing index associated with common measurement techniques and conditions. Respir Care 2009; 54:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21140/abstract/9\">",
"      Purro A, Appendini L, De Gaetano A, et al. Physiologic determinants of ventilator dependence in long-term mechanically ventilated patients. Am J Respir Crit Care Med 2000; 161:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21140/abstract/10\">",
"      Epstein SK, Ciubotaru RL. Influence of gender and endotracheal tube size on preextubation breathing pattern. Am J Respir Crit Care Med 1996; 154:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21140/abstract/11\">",
"      Seymour CW, Cross BJ, Cooke CR, et al. Physiologic impact of closed-system endotracheal suctioning in spontaneously breathing patients receiving mechanical ventilation. Respir Care 2009; 54:367.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1614 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21140=[""].join("\n");
var outline_f20_41_21140=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACCURACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1614\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1614|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/40/5771\" title=\"table 1\">",
"      Likelihood ratios",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=related_link\">",
"      Evaluating diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=related_link\">",
"      Extubation management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14423?source=related_link\">",
"      Methods of weaning from mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=related_link\">",
"      Weaning from mechanical ventilation: Readiness testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_41_21141="Chlorpheniramine and phenylephrine: Patient drug information";
var content_f20_41_21141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine and phenylephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/773?source=see_link\">",
"     see \"Chlorpheniramine and phenylephrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ed ChlorPed D [OTC];",
"     </li>",
"     <li>",
"      Ed-A-Hist&trade; [OTC];",
"     </li>",
"     <li>",
"      LoHist [OTC];",
"     </li>",
"     <li>",
"      Maxichlor PEH [OTC];",
"     </li>",
"     <li>",
"      nasohist&trade; [OTC];",
"     </li>",
"     <li>",
"      NoHist LQ [OTC];",
"     </li>",
"     <li>",
"      NoHist [OTC] [DSC];",
"     </li>",
"     <li>",
"      Sudafed PE&reg; Sinus + Allergy [OTC];",
"     </li>",
"     <li>",
"      Triaminic&reg; Children's Cold &amp; Allergy [OTC];",
"     </li>",
"     <li>",
"      Virdec [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chlorpheniramine, phenylephrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703293",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, glaucoma, very bad heart disease, trouble passing urine, ulcer disease, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12027 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21141=[""].join("\n");
var outline_f20_41_21141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150108\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011426\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011428\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011427\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011432\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011433\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011435\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011430\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011431\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011436\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011437\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/48/773?source=related_link\">",
"      Chlorpheniramine and phenylephrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_41_21142="Colonic ischemia on computed tomography";
var content_f20_41_21142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Colonic ischemia on computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan of the abdomen is from a 72-year-old female who presented with acute abdominal pain. Image A is an axial projection through the cecum and image B&nbsp;shows the cecum and ascending colon reformatted in the coronal plane. The images show an accumulation of air within the wall of the cecum (orange, large arrows), a finding that is characteristic of pneumatosis coli. Associated radiolologic findings include: the lack of formed stool in the colon reflecting loss of mucosal function, thickening of the peritoneum and lateral conal fascia (blue, arrowhead), and ascites (white, small arrow).&nbsp;No portal venous air was evident.&nbsp;In the appropriate clinical setting, the findings are highly suggestive of acute ischemia of the large bowel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21142=[""].join("\n");
var outline_f20_41_21142=null;
var title_f20_41_21143="Treatment of Graves' hyperthyroidism";
var content_f20_41_21143=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Graves' hyperthyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21143/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21143/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21143/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21143/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21143/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21143/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/41/21143/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graves' disease, an autoimmune disease characterized by antibodies against the thyrotropin (TSH) receptor (also called thyroid-stimulating immunoglobulins), is the most common cause of hyperthyroidism. This topic will provide an overview of treatment options for Graves' hyperthyroidism, while specific therapies are reviewed in separate topic reviews. The causes of hyperthyroidism and the pathogenesis of Graves' hyperthyroidism are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link\">",
"     \"Pathogenesis of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic approach to Graves' hyperthyroidism consists of both rapid amelioration of symptoms with a beta-blocker and measures aimed at decreasing thyroid hormone synthesis: the administration of a thionamide, radioiodine ablation, or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/1\">",
"     1",
"    </a>",
"    ]. In the only randomized prospective trial comparing these three therapies, each was equally effective in normalizing serum thyroid hormone concentrations within six weeks; after treatment, 95 percent or more of the patients were satisfied with their therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, most patients reported that they would recommend the therapy to a friend without reservation (medical: 68 percent; surgical: 74 percent; radioiodine: 84 percent). The risk of relapse was 37, 21, and 6 percent in the thionamide, radioiodine, and surgery groups, respectively.",
"   </p>",
"   <p>",
"    Because all three treatment modalities are effective, the choice of therapy should involve active discussion between clinician and patient (",
"    <a class=\"graphic graphic_table graphicRef67833 \" href=\"UTD.htm?33/40/34443\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/3\">",
"     3",
"    </a>",
"    ]. Individual patient factors may influence choice of therapy. As an example, in a patient with mild hyperthyroidism and minimal thyroid enlargement, thionamides or radioiodine are good options. In a patient with severe hyperthyroidism and a large goiter who requires rapid control of hyperthyroidism, surgery might be the best option.",
"   </p>",
"   <p>",
"    Whatever treatment is used, initial monitoring should consist of periodic clinical assessment and measurements of serum T4 and sometimes T3 levels. Serum TSH concentration may remain low for several weeks after the patient becomes euthyroid. In addition, since hyperthyroidism results in a negative calcium balance, reduced bone density, and increased fracture risk, patients (with the exception of those with hypercalcemia) should be advised to ingest 1200 to 1500 mg elemental calcium daily through diet or supplements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"     \"Laboratory assessment of thyroid function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=see_link\">",
"     \"Bone disease with hyperthyroidism and thyroid hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach outlined below is consistent with Hyperthyroidism Management Guidelines from the American Thyroid Association and the American Association of Clinical Endocrinologists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers ameliorate the symptoms of hyperthyroidism that are caused by increased beta-adrenergic tone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/5\">",
"     5",
"    </a>",
"    ]. These include palpitations, tachycardia, tremulousness, anxiety, and heat intolerance. Thus, a beta-blocker should be started (assuming there are no contraindications to its use) in most patients as soon as the diagnosis of hyperthyroidism is made, even before obtaining a 24-hour radioiodine uptake. We usually give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    (25 to 50",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    which has the advantages of single daily dosing and beta-1 selectivity; however, all beta-adrenergic blocking drugs effectively diminish hyperthyroid symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"     \"Beta blockers in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Thionamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thionamides",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    (PTU) are the primary drugs used to treat Graves' hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/6\">",
"     6",
"    </a>",
"    ]. Methimazole is preferred because of its longer duration of action, allowing for once daily dosing, more rapid efficacy, and lower incidence of side effects (",
"    <a class=\"graphic graphic_figure graphicRef54732 \" href=\"UTD.htm?28/35/29245\">",
"     figure 1",
"    </a>",
"    ). PTU is preferred during the first trimester of pregnancy because of the potential teratogenic effects of methimazole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=see_link\">",
"     \"Pharmacology and toxicity of thionamides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of thionamide therapy in Graves' hyperthyroidism is to attain a euthyroid state within three to eight weeks. This can be followed by ablative therapy with radioiodine or surgery or by continuation of the drug for a prolonged period (usually one to two years) with the hope of attaining a permanent remission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"     \"Thionamides in the treatment of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to initiating thionamides, we obtain baseline blood tests, including a complete blood count (white count with differential) and a liver profile (bilirubin and transaminases) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/4\">",
"     4",
"    </a>",
"    ]. We do not use thionamides in patients with a baseline absolute neutrophil count &lt;500 mm3 or elevated liver transaminases (more than fivefold the upper limit of normal) except in selected patients after careful assessment of alternatives and risks.",
"   </p>",
"   <p>",
"    The starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    varies according to the severity of the hyperthyroidism. Patients with small goiters and mild hyperthyroidism can be started on 10 mg once daily; this regimen is as effective as larger doses in most cases (",
"    <a class=\"graphic graphic_figure graphicRef82645 \" href=\"UTD.htm?37/17/38173\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with larger goiters and more severe hyperthyroidism should be started on 20 to 30 mg daily. We administer initial therapy in divided doses in these patients to minimize gastrointestinal side effects, and then change to single daily dosing. If long-term medical therapy is chosen, the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    is then tapered to a maintenance dose with the goal of maintaining a euthyroid state.",
"   </p>",
"   <p>",
"    In countries where",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    is unavailable, carbimazole can be used. It is metabolized to methimazole, and the dose required to yield a similar dose of methimazole is approximately 40 percent higher. For example, a 10 or 20 mg dose of carbimazole yields roughly 6 and 15 mg of methimazole, respectively.",
"   </p>",
"   <p>",
"    Patients should have their thyroid function assessed at four to six week intervals until stabilized on maintenance thionamide therapy. Patients with persistently low serum TSH concentrations after more than six months of therapy with a thionamide are unlikely to have a remission when the drug is stopped, and the thionamide should not be discontinued unless a decision has been made to proceed to destructive therapy.",
"   </p>",
"   <p>",
"    There are several other issues related to thionamide therapy, including management of complications, the prevalence of permanent remission after cessation of therapy (about 20 to 30 percent), the time course of relapse, and their negative effect on subsequent radioactive iodine therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacology and toxicity of thionamides\", section on 'Toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"     \"Thionamides in the treatment of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Iodinated contrast agents and iodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have severe hyperthyroidism or are allergic to thionamides may benefit from alternative medical therapies. The oral radiocontrast agents sodium ipodate and iopanoic acid are potent inhibitors of the peripheral conversion of T4 to T3. They are not used as primary therapy because of possible induction of resistant hyperthyroidism. However, when given in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    (at doses of 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    they can rapidly ameliorate severe hyperthyroidism and can also be used to prepare a hyperthyroid patient for early surgery. However, these drugs are not currently available in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=see_link\">",
"     \"Iodinated radiocontrast agents in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iodine elixirs, such as 10 drops of saturated solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    (SSKI) daily, can be used to ameliorate very mild hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=see_link\">",
"     \"Iodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other medications have been used in the management of hyperthyroidism, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids inhibit peripheral T4 to T3 conversion and, in patients with Graves' hyperthyroidism, reduce thyroid secretion. They have been used in patients with severe hyperthyroidism and thyroid storm, although their efficacy is not well demonstrated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42632?source=see_link\">",
"       \"Drug interactions with thyroid hormones\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      blocks thyroid hormone release, but its use has been limited by its toxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42453?source=see_link\">",
"       \"Lithium and the thyroid\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       Cholestyramine",
"      </a>",
"      , given in a dose of 4 g four times daily with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      , lowers serum T4 and T3 concentrations more rapidly than methimazole alone [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/7\">",
"       7",
"      </a>",
"      ], and may be useful adjunctive therapy in selected patients who require rapid amelioration of hyperthyroid symptoms.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      is a naturally occurring peripheral antagonist of thyroid hormone action that has been shown to ameliorate hyperthyroid symptoms and may prove to be useful clinically [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      , a monoclonal antibody that causes peripheral B cell depletion, may induce a sustained remission in patients with Graves' disease and low TRAb levels, but its cost and side effects limit its utility [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In China and many other countries, Chinese herbal medicines are used alone or in combination with antithyroid drugs to treat hyperthyroidism. These herbs are claimed to weaken the biological effects of thyroxine and inhibit the transformation of T4 to T3. Some are said to be able to modulate the function of sympathetic nerves or the immune system. In a systematic review and meta-analysis of 13 trials of 1770 participants, the addition of Chinese herbal medicines to antithyroid drugs was beneficial in some patients for reducing relapse rates, improving symptoms, and reducing adverse effects such as agranulocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/10\">",
"       10",
"      </a>",
"      ]. However, the methodological quality of the trials was poor, and the authors concluded that there are currently no well-designed trials to provide strong evidence for Chinese traditional herbal medicine in the treatment of hyperthyroidism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radioiodine ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioiodine is widely used for the treatment of Graves' hyperthyroidism. It has been the therapy of choice in the United States, being selected by 60 percent of thyroid specialists who responded to a survey in 2011, but only 13 percent of European thyroid specialists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We usually recommend radioiodine therapy. Although a thionamide provides control of hyperthyroidism as long as the drug is taken, the persistent remission rate when the drug is discontinued one to two years later averages only about 30 percent. However, there are patients in whom it may be reasonable to delay radioiodine (or surgery). Included in this group are patients with mild hyperthyroidism and patients with small goiters or with goiters that shrink during thionamide therapy. If radioiodine is chosen, the patient must be comfortable with the decision to ablate the thyroid and be aware that prolonged thionamide therapy lasting even decades is an acceptable alternative as long as the drug is tolerated and the hyperthyroidism is controlled.",
"   </p>",
"   <p>",
"    Clinicians and patients must also be aware that radioiodine therapy may be associated with an increased risk of the development or worsening of Graves' ophthalmopathy. However, ophthalmopathy did not progress in a study of patients with minimal ophthalmopathy who were carefully monitored to avoid hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link&amp;anchor=H30632428#H30632428\">",
"     \"Radioiodine in the treatment of hyperthyroidism\", section on 'Radioiodine and ophthalmopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35239?source=see_link\">",
"     \"Treatment of Graves' orbitopathy (ophthalmopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radioiodine may be given as primary therapy to patients with mild, well-tolerated hyperthyroidism. In comparison, patients who are not tolerating hyperthyroidism well, are elderly, or have underlying heart disease are usually pretreated with a thionamide to ameliorate the hyperthyroidism before radioiodine treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link&amp;anchor=H30632329#H30632329\">",
"     \"Radioiodine in the treatment of hyperthyroidism\", section on 'Pretreatment with thionamides'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radioiodine is administered as a capsule or, less commonly, an oral solution of sodium 131I, which is rapidly absorbed from the GI tract and concentrated in thyroid tissue. It induces extensive tissue damage, resulting in ablation of the thyroid within 6 to 18 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/12\">",
"     12",
"    </a>",
"    ]. A discussion on dosing and side effects and particularly late hypothyroidism can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link\">",
"     \"Radioiodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of radioiodine therapy is destruction of the gland, with the early development of hypothyroidism. This eliminates the risk of recurrent hyperthyroidism. On the other hand, some clinicians prefer lower doses of radioiodine with the aim of achieving a euthyroid state while lowering the risk of early hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/13\">",
"     13",
"    </a>",
"    ]. However, many of these patients have persistent subclinical or overt hyperthyroidism. Furthermore, there is a risk both of recurrent overt hyperthyroidism and of the insidious onset of late hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link\">",
"     \"Radioiodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 10 to 20 percent of patients fail the first radioiodine treatment and require a second or subsequent dose. These patients usually have more severe hyperthyroidism or larger goiters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is an unpopular therapy for Graves' hyperthyroidism, being selected by only 1 percent of thyroid specialists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/11\">",
"     11",
"    </a>",
"    ]. It is primarily indicated in patients who have an obstructive goiter or a very large goiter, in patients with active ophthalmopathy who desire definitive therapy for their hyperthyroidism, in pregnant women who are allergic to antithyroid drugs, and in patients who have allergies or poor compliance on antithyroid drugs but refuse radioiodine. Surgery would also be indicated if there was a coexisting suspicious or malignant thyroid nodule or primary hyperparathyroidism. However, most thyroid nodules associated with Graves' disease are benign, in which case surgery would not be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who want rapid restoration of euthyroidism, fear radioactivity, or have had an adverse effect with thionamide drugs may also prefer surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=see_link\">",
"     \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thyroidectomy during pregnancy may be necessary in women who cannot tolerate thionamides because of allergy or agranulocytosis. The indications for surgery are similar to those in nonpregnant women and men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss is a common feature of hyperthyroidism, and many patients gain considerable weight after treatment of their hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. In the largest study of 162 hyperthyroid patients followed for up to 24 months after treatment (radioiodine, a thionamide, or surgery), mean (&plusmn;SE) weight gain was 5.4 &plusmn; 0.5 kg and increase in body mass index (BMI) was 8 &plusmn; 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the same report, preexisting obesity, a diagnosis of Graves' disease, and prior weight loss independently predicted weight gain. Patients who developed hypothyroidism, even transiently, gained the most weight in spite of T4 replacement (8.06 &plusmn; 1.42 kg). This phenomenon does not appear to be simple regaining of previously lost weight since the percentage of overweight (BMI &gt;25",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    and obese (BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    patients increased from 38 and 10 percent just before the treatment to 56 and 19 percent at the end of the follow-up period.",
"   </p>",
"   <p>",
"    Proposed mechanisms for the excessive weight gain include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subnormal energy expenditure after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/16\">",
"       16",
"      </a>",
"      ], without concomitant reduction in appetite or food intake [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inadequate thyroid hormone replacement [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients should be advised about the likelihood of weight gain, that may in part be prevented by dietary advice [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21143/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table summarizes the advantages and disadvantages of the three major treatments for hyperthyroidism: a prolonged course of antithyroid drug, radioiodine, or surgery (",
"    <a class=\"graphic graphic_table graphicRef67833 \" href=\"UTD.htm?33/40/34443\">",
"     table 1",
"    </a>",
"    ). The choice of therapy should involve active discussion between clinician and patient; it is also determined by the severity of the patient's hyperthyroidism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assuming there are no contraindications to its use, we recommend using a beta blocker for patients with moderate-to-severe hyperadrenergic symptoms until euthyroidism is achieved by thionamides, radioiodine or surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Beta blockers'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"       \"Beta blockers in the treatment of hyperthyroidism\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We typically start with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      25 to 50 mg daily, and increase the dose as needed (up to 200 mg daily) to reduce pulse to under 90 beats per minute if blood pressure allows.",
"     </li>",
"     <li>",
"      For patients with significant symptoms of hyperthyroidism, we suggest starting a thionamide (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      ) to achieve euthyroidism quickly (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Thionamides'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"       \"Thionamides in the treatment of Graves' disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once patients are euthyroid on a thionamide, we suggest radioiodine therapy as our first choice for definitive therapy of the hyperthyroidism, given its lower cost and lower complication rate than surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Primary antithyroid drug therapy is an alternative option for patients with mild disease and small goiters.",
"     </li>",
"     <li>",
"      For patients who are less symptomatic, there is no need to pretreat with a thionamide, and radioiodine can be given soon after the diagnosis is made.",
"     </li>",
"     <li>",
"      For patients with hyperthyroidism due to a very large or obstructive goiter, we suggest surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=see_link\">",
"       \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We advise women desiring to become pregnant in the near future to consider radioiodine or surgery six months in advance of a planned pregnancy to avoid the need for a thionamide during the pregnancy. However, if radioiodine or surgery is not desired, PTU therapy would be the preferred drug during the first trimester of pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link\">",
"       \"Hyperthyroidism during pregnancy: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several concerns of the patient also may influence the choice of therapy. As an example, the recommendation to avoid close contact with young children for several days after radioiodine administration may make this treatment temporarily unattractive if alternative childcare is unavailable. Patient fears regarding radiation exposure or agranulocytosis from thionamides should also be considered.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/1\">",
"      Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 1995; 273:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/2\">",
"      T&ouml;rring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996; 81:2986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/3\">",
"      Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med 2011; 364:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/4\">",
"      Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/5\">",
"      Geffner DL, Hershman JM. Beta-adrenergic blockade for the treatment of hyperthyroidism. Am J Med 1992; 93:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/6\">",
"      Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/7\">",
"      Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, Espinoza-de los Monteros AL. Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. J Clin Endocrinol Metab 1996; 81:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/8\">",
"      Benvenga S, Ruggeri RM, Russo A, et al. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2001; 86:3579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/9\">",
"      El Fassi D, Nielsen CH, Bonnema SJ, et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 2007; 92:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/10\">",
"      Zen XX, Yuan Y, Liu Y, et al. Chinese herbal medicines for hyperthyroidism. Cochrane Database Syst Rev 2007; :CD005450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/11\">",
"      Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab 2012; 97:4549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/12\">",
"      Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994; 330:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/13\">",
"      Goolden AW, Stewart JS. Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 1986; 24:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/14\">",
"      Cantalamessa L, Baldini M, Orsatti A, et al. Thyroid nodules in Graves disease and the risk of thyroid carcinoma. Arch Intern Med 1999; 159:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/15\">",
"      Dale J, Daykin J, Holder R, et al. Weight gain following treatment of hyperthyroidism. Clin Endocrinol (Oxf) 2001; 55:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/16\">",
"      Jacobsen R, Lundsgaard C, Lorenzen J, et al. Subnormal energy expenditure: a putative causal factor in the weight gain induced by treatment of hyperthyroidism. Diabetes Obes Metab 2006; 8:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/17\">",
"      Watts MR, Moore A, Alexander WD. Weight gain and treatment for thyrotoxicosis. QJM 2002; 95:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/18\">",
"      Obermayer-Pietsch BM, Fr&uuml;hauf GE, Lipp RW, et al. Dissociation of leptin and body weight in hyperthyroid patients after radioiodine treatment. Int J Obes Relat Metab Disord 2001; 25:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/19\">",
"      Tigas S, Idiculla J, Beckett G, Toft A. Is excessive weight gain after ablative treatment of hyperthyroidism due to inadequate thyroid hormone therapy? Thyroid 2000; 10:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21143/abstract/20\">",
"      Alton S, O'Malley BP. Dietary intake in thyrotoxicosis before and after adequate carbimazole therapy; the impact of dietary advice. Clin Endocrinol (Oxf) 1985; 23:517.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7872 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21143=[""].join("\n");
var outline_f20_41_21143=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Thionamides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Iodinated contrast agents and iodine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radioiodine ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Weight gain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7872\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7872|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/35/29245\" title=\"figure 1\">",
"      Methimazole versus PTU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/17/38173\" title=\"figure 2\">",
"      Methimazole dose response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7872|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/40/34443\" title=\"table 1\">",
"      Treatment Graves",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=related_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=related_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42632?source=related_link\">",
"      Drug interactions with thyroid hormones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=related_link\">",
"      Hyperthyroidism during pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=related_link\">",
"      Iodinated radiocontrast agents in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=related_link\">",
"      Iodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42453?source=related_link\">",
"      Lithium and the thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=related_link\">",
"      Pathogenesis of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=related_link\">",
"      Pharmacology and toxicity of thionamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=related_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=related_link\">",
"      Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=related_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35239?source=related_link\">",
"      Treatment of Graves' orbitopathy (ophthalmopathy)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_41_21144="Role of physical activity and exercise in obese adults";
var content_f20_41_21144=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of physical activity and exercise in obese adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21144/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21144/contributors\">",
"     George A Bray, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21144/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21144/contributors\">",
"     F Xavier Pi-Sunyer, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21144/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21144/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/41/21144/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical activity is a component of energy balance that is particularly important in the pathogenesis of obesity and in its treatment. The components of energy expenditure are resting (basal)-energy expenditure (REE) (eg, heat production for maintenance of body temperature, maintenance of ionic gradients across cells, and resting cardiac and respiratory function), diet-induced thermogenesis, and physical activity (",
"    <a class=\"graphic graphic_figure graphicRef80202 \" href=\"UTD.htm?24/56/25486\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal management of overweight and obesity starts with a combination of diet, exercise, and behavioral modification. In addition, some patients eventually require pharmacologic therapy or bariatric surgery. Physical exercise and activity are also important for maintaining long-term weight loss and can be beneficial in preserving lean body mass while dieting. A dose-response relationship has been demonstrated in overweight adult women between the amount of exercise and long-term weight loss maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This role of physical activity in the prevention and treatment of obesity will be reviewed here. Basal metabolic activities, thermogenesis, and other interventions in the management of obesity are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=see_link\">",
"     \"Pathogenesis of obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"     \"Behavioral strategies in the treatment of obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link\">",
"     \"Dietary therapy for obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obesity in children and adolescents is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18378?source=see_link\">",
"     \"Management of childhood obesity in the primary care setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF PHYSICAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate measurement of total daily energy expenditure (TEE) is possible using the doubly-labeled water technique [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/1\">",
"     1",
"    </a>",
"    ]. By subtracting energy expenditure (determined by measurement of resting energy expenditure [REE] and adding diet-induced thermogenesis, which accounts for 10 to 15 percent of the total) from TEE measured by doubly-labeled water technique, an estimate of energy expenditure as physical activity can be made. The physical activity level (PAL) can also be expressed as the ratio of total energy expenditure (TEE from doubly-labeled water) to resting energy expenditure (REE).",
"   </p>",
"   <p>",
"    Alternative approaches to measuring physical activity include the use of triaxial accelerometers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/3\">",
"     3",
"    </a>",
"    ], pedometers, questionnaires that estimate physical activity, and physical activity scores. Compared with calculations using TEE and REE, questionnaires that estimate physical activity and physical activity scores are relatively unreliable. Pedometers, which provide a single dimensional measurement of activity, are useful in providing feedback to patients and may help increase walking activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In spite of the limitations of these methods, estimates of activity correlate well with health risks associated with inactivity. Unfortunately, these estimates suggest that Americans become less active as they age. In the Surgeon General's Report on Physical Activity, for example, the percent of time Americans spent in physical activity decreased as their age increased (",
"    <a class=\"graphic graphic_figure graphicRef64352 \" href=\"UTD.htm?15/28/15822\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVENTION OF WEIGHT GAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is important for the primary prevention of obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/6\">",
"     6",
"    </a>",
"    ]. Low levels of physical activity and recreation are related to weight gain in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/7\">",
"     7",
"    </a>",
"    ]. In young adults transitioning to middle age, higher compared with lower levels of physical activity over 20 years were associated with smaller gains in weight [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/8\">",
"     8",
"    </a>",
"    ]. In this young (mean age 25 years) normal weight population, 150 minutes of moderate activity per week was adequate to prevent weight gain.",
"   </p>",
"   <p>",
"    In older or obese adults, however, higher activity levels may be necessary for prevention of weight gain. In a cohort of over 34,000 women (mean age 54.2 years) who were consuming a usual diet and were followed for a mean of 13 years, there was a mean weight gain of 2.6 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/9\">",
"     9",
"    </a>",
"    ]. Compared with women who engaged in &gt;420",
"    <span class=\"nowrap\">",
"     min/week",
"    </span>",
"    of exercise, women who engaged in &lt;150 and 150 to &lt;420",
"    <span class=\"nowrap\">",
"     min/week",
"    </span>",
"    gained significantly more weight (0.12 and 0.11 kg, respectively). Physical activity was inversely related to weight gain only among normal weight (BMI &lt;25",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    women. Thus, in order to maintain normal body weight in the mid-life, high levels of physical activity (approximately 60",
"    <span class=\"nowrap\">",
"     minutes/day)",
"    </span>",
"    were necessary. Once overweight, physical activity in the absence of controlling caloric intake did not prevent weight gain. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Exercise as a single treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a 12-month randomized trial, men and women (mean age 55 years, mean BMI 29",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    who were randomly assigned to a moderate to vigorous exercise intervention (60 minute session six",
"    <span class=\"nowrap\">",
"     days/week)",
"    </span>",
"    were better able to maintain their weight than controls (-1.4 versus +0.7 kg for women, -1.8 versus -0.1 kg for men) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/10\">",
"     10",
"    </a>",
"    ]. Exercisers also had significant decreases in waist and hip circumferences, fat mass, and percentage body fat. After 12 months, those in the intervention group were exercising a mean of 298",
"    <span class=\"nowrap\">",
"     min/week",
"    </span>",
"    compared with 68",
"    <span class=\"nowrap\">",
"     min/week",
"    </span>",
"    in the control group. These results suggest that in older individuals (particularly women), more than 68 min per week, and perhaps at least 300 min of",
"    <span class=\"nowrap\">",
"     exercise/week",
"    </span>",
"    may, be necessary to prevent long-term weight gain.",
"   </p>",
"   <p>",
"    The contribution of physical activity interacts with genetic factors in the prevention of obesity. In a study of 970 healthy female twins, total body and central abdominal fat were 5.6 and 0.6 kg lower, respectively, in women who reported vigorous weight-bearing activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/11\">",
"     11",
"    </a>",
"    ]. Even in women who had an overweight twin, higher levels of physical activity resulted in significantly lower total body and abdominal fat (4.0 and 0.5 kg, respectively). In addition, a meta-analysis of 45 studies in adults evaluating the interaction between physical activity and genetic risk for obesity showed that the risk of obesity in patients with FTO variants (associated with higher BMI and waist circumference) was attenuated by physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/12\">",
"     12",
"    </a>",
"    ]. These findings suggest that physical activity is likely to protect against obesity regardless of an individual's genetic predisposition to it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT FOR OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise has been evaluated as a single treatment for obesity, in combination with diet, and for maintaining weight loss after successful completion of a weight loss program. In most studies, exercise only modestly improves weight loss. The reasons for this finding are uncertain but may be due, in part, to difficulty in adhering to sufficiently vigorous exercise regimens. In addition, for patients who are adherent with exercise training, increases in muscle mass may offset loss of adipose tissue, resulting in less net weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exercise as a single treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated the effect of exercise alone in inducing weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Weight losses were in general quite small (approximately 0.1",
"    <span class=\"nowrap\">",
"     kg/week),",
"    </span>",
"    except in military recruits (1.8",
"    <span class=\"nowrap\">",
"     kg/week)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/15\">",
"     15",
"    </a>",
"    ], whose exercise program was more rigorous. In meta-analyses of trials examining the effects of exercise on weight loss, exercise resulted in modest reductions in weight compared with no treatment (weighted mean difference -1.6 kg) and with high versus low intensity exercise (mean difference -1.5 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In addition, exercise modestly decreased waist circumference and blood pressure.",
"   </p>",
"   <p>",
"    While it may be difficult to lose weight with exercise alone, exercise appears to have a beneficial effect on body fat. In a 12-week study of diet-induced versus exercise-induced weight loss (of approximately 7.5 kg) on body composition and insulin sensitivity in 52 obese men [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/18\">",
"     18",
"    </a>",
"    ], the main findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A greater reduction in total body fat in the exercise-induced weight loss group",
"     </li>",
"     <li>",
"      Similar reductions in abdominal obesity, visceral fat, and insulin resistance in the two treatment groups",
"     </li>",
"     <li>",
"      In a third treatment group assigned to exercise without weight loss (increased caloric intake to match energy expenditure), abdominal and visceral fat was decreased, but to a lesser degree than in the other treatment groups",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exercise also has beneficial effects on body composition in premenopausal and postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In a randomized trial of moderate-intensity exercise (most commonly brisk walking, on average three hours per week), versus a stretching program (control group) for 12 months, postmenopausal women in the exercise group lost more weight (mean difference -1.4 kg), and had greater decreases in body fat, intra-abdominal fat, and subcutaneous fat [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Exercise plus diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise programs added to diets with moderate to severe caloric restriction have little additional effect upon weight loss. As an example, a systematic review of 17 randomized trials in overweight and obese patients (BMI 25 to 37",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    showed that compared with weight loss by diet alone, adding exercise to diet produced slightly greater weight loss than diet alone (mean increase in weight loss approximately 1.5 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/21\">",
"     21",
"    </a>",
"    ]. However the results were statistically significant in only two of the trials. The exercise interventions ranged from 60 to 240",
"    <span class=\"nowrap\">",
"     minutes/week.",
"    </span>",
"    Similar findings were subsequently reported in obese elderly adults (mean age 70 years) who were randomly assigned to diet or exercise alone, diet plus exercise, or control [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/22\">",
"     22",
"    </a>",
"    ]. Body weight decreased similarly in the diet alone and the diet plus exercise group (10 and 9 percent, respectively), but did not decrease in the exercise alone or control groups. However, physical functioning improved significantly in all groups compared with controls, and the improvement was greatest in the combined diet plus exercise group (increase from baseline of 21 versus 12 and 15 percent for diet and exercise alone, respectively).",
"   </p>",
"   <p>",
"    The frequency and intensity of exercise may explain why exercise does not improve weight loss above that achieved with calorie restriction. If a patient utilizes 100 calories during exercise each day (700 calories per week), it would take five weeks to utilize the energy in one pound of fat. Thus, it takes a considerable amount of time and effort to expend calories, more than most people perform. In trials that were designed to assess higher intensity or longer duration (up to 300",
"    <span class=\"nowrap\">",
"     min/week)",
"    </span>",
"    of exercise, the following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 12-month trial of 184 overweight, sedentary women (mean BMI 32.6",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      who were randomly assigned to one of four exercise programs in addition to caloric restriction, weight loss was the same in all groups, regardless of exercise intensity or duration [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/23\">",
"       23",
"      </a>",
"      ]. The mean achieved duration of exercise in the highest duration groups was approximately 200",
"      <span class=\"nowrap\">",
"       min/week.",
"      </span>",
"     </li>",
"     <li>",
"      In a 12-month trial of 130 severely obese adults (mean BMI 43.6",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      who were randomly assigned to immediate or delayed physical activity in addition to caloric restriction, the initial activity group lost significantly more weight in the first six months than the delayed-activity group (10.9 versus 8.2 kg) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/24\">",
"       24",
"      </a>",
"      ]. After 12 months, at which time both groups were participating in an exercise program, the magnitude of weight loss did not significantly differ between the two groups (12.1 versus 9.9 kg). The addition of physical activity resulted in greater reductions in waist circumference and hepatic fat content.",
"      <br/>",
"      <br/>",
"      This trial was limited by high attrition rates (20 to 25 percent) and difficulty in achieving the desired exercise intensity (300",
"      <span class=\"nowrap\">",
"       min/week).",
"      </span>",
"      The mean achieved duration of vigorous physical activity was 71",
"      <span class=\"nowrap\">",
"       min/week.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adding exercise to diet may have important benefits independent of weight loss. Physical activity attenuates the diet-induced loss of muscle mass, which increases physical functioning and insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. Physical activity may offset the decrease in total energy expenditure that occurs with weight loss, such that the calorie restriction required to match energy expenditure is achievable [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4594783\">",
"     'Benefits'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Maintenance of weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;In observational studies, exercise consistently stands out as an important factor in maintaining weight loss after any weight reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/2,6,30-32\">",
"     2,6,30-32",
"    </a>",
"    ]. In a meta-analysis of 493 studies (observational studies and randomized trials) involving aerobic exercise for short durations (average 15.6 weeks), diet, or a combination of both in moderately overweight subjects (average BMI 33.4",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    with an average weight of 92.7 kg), the diet and exercise group maintained 8.6 kg of weight loss after one year compared with 6.6 kg in the diet-only group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/14\">",
"     14",
"    </a>",
"    ]. In a subsequent report, the maintenance of weight loss had a graded relation to the amount of exercise that individuals continued after their initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, in a prospective study of weight maintenance in over 4500 premenopausal women, women who maintained &ge;30",
"    <span class=\"nowrap\">",
"     minutes/day",
"    </span>",
"    of activity were less likely to regain than women who remained sedentary (OR 0.7, 95% CI 0.5-0.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, results from randomized trials are mixed, but the majority (8 of 12) show no significant difference in weight regain for diet only versus diet plus exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/21\">",
"     21",
"    </a>",
"    ]. The reason for this is unclear since epidemiologic, cross-sectional, and prospective correlational studies repeatedly suggest an essential role for physical activity in weight loss maintenance. In many of the randomized trials, participants had difficulty adhering to the exercise regimens, a limitation which may explain, in part, the difference in the findings. Other limitations include variability in the amount and duration of exercise prescribed. In one systematic review of observational and randomized trial data, weight regain was reduced by participation in high levels of physical activity (eg, at least 60",
"    <span class=\"nowrap\">",
"     minutes/day",
"    </span>",
"    brisk walking), a level not achieved by most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/6\">",
"     6",
"    </a>",
"    ]. Post-hoc analysis of randomized trials shows a clear dose-response relationship between physical activity and weight loss maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4594776\">",
"    <span class=\"h1\">",
"     OVERALL HEALTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical activity is important for overall good health [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/34\">",
"     34",
"    </a>",
"    ]. A sedentary lifestyle in adults may also be associated with increased mortality. In a prospective study of 17,013 Canadian adults, there was a progressively higher risk of all cause and cardiovascular mortality across higher levels of sitting time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits and risks of exercise, independent of its effects on weight, are reviewed briefly below and in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4594783\">",
"    <span class=\"h2\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise and physical activity have several benefits for overweight subjects, even in the absence of significant weight loss (",
"    <a class=\"graphic graphic_table graphicRef51565 \" href=\"UTD.htm?10/2/10283\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise can improve glycemic control and insulin sensitivity, and may prevent the development of type 2 diabetes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"       \"Effects of exercise in diabetes mellitus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aerobic training has beneficial effects on serum lipoprotein concentrations, body composition, and aerobic capacity, and improves hemostatic factors associated with thrombosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17015?source=see_link\">",
"       \"Effects of exercise on lipoproteins and hemostatic factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long-term aerobic exercise regimens have in most studies had a beneficial effect upon the systemic blood pressure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/2998?source=see_link\">",
"       \"Exercise in the treatment and prevention of hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long-term exercise programs cause a greater decrease in abdominal fat than lower body fat and help maintain it [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/36\">",
"       36",
"      </a>",
"      ]. This is important because subjects with abdominal obesity are at increased cardiovascular risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link\">",
"       \"Screening for and clinical evaluation of obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several studies have found a strong inverse relationship between habitual exercise and fitness and the risk of coronary disease and death [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"       \"Exercise and fitness in the prevention of cardiovascular disease\"",
"      </a>",
"      .) The value of exercise for reducing cardiovascular risk can be illustrated by the findings from a meta-analysis of 33 cohort studies evaluating the association between cardiorespiratory fitness and all-cause mortality or coronary heart disease (CHD) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/38\">",
"       38",
"      </a>",
"      ]. Compared with patients with a high or an intermediate level of cardiorespiratory fitness, those with a low level had a higher risk for all-cause mortality (RR 1.7, 95% CI 1.5-1.9, low versus high) and for CHD events (RR 1.6, 95% CI 1.4-1.8, low versus high).",
"      <br/>",
"      <br/>",
"      Similarly, in a systematic review of 36 studies, the risk for all-cause and cardiovascular mortality was higher in individuals with normal BMI and poor fitness than in those with high BMI and good aerobic fitness, even after adjustment for other cardiovascular risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, adiposity and fitness level are important prognostic factors in obese individuals. In the Lipids Research Clinics and the Nurses' Health Studies, both physical fitness and adiposity were independent predictors of mortality; higher levels of fitness did not completely negate the association between adiposity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4594790\">",
"    <span class=\"h2\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise has been associated with an increased risk of musculoskeletal injuries, cardiac arrhythmia, acute myocardial infarction, and bronchospasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     A PROGRAM FOR PHYSICAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing the level of physical activity would be beneficial to all ages and all groups, particularly for the prevention of obesity. For those who are able, walking 150 to 250 minutes per week (&ge;30",
"    <span class=\"nowrap\">",
"     min/day,",
"    </span>",
"    five to seven days per week) would be beneficial in preventing weight gain and in improving cardiovascular health [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/6,34\">",
"     6,34",
"    </a>",
"    ]. This will increase energy expenditure by 1000 to 1200 calories per week, or slightly more than 150 calories per day. The amount of energy expended depends upon the duration and intensity of the exercise, and the subject's initial weight (",
"    <a class=\"graphic graphic_table graphicRef66344 \" href=\"UTD.htm?36/56/37774\">",
"     table 2",
"    </a>",
"    ). As an example, a 120-pound person walking three miles per hour expends slightly less than 2 calories per minute more than standing still. At 160 pounds, the difference is 2.4 calories per minute, and at 200 pounds it is 3 calories per minute. Thus a 30-minute walk at three miles per hour for a person weighing 200 pounds would dissipate an extra 90 calories as compared with 60 calories for a person weighing 120 pounds.",
"   </p>",
"   <p>",
"    There appears to be a dose effect for physical activity and weight loss, with very high levels being required in the absence of a diet to produce significant weight loss. The optimal strategy to lose weight is to combine a calorically-reduced diet with gradually increasing amounts of physical activity. Although exercise is not required for weight loss, increasing amounts physical activity during weight loss is important so that patients will be able to sustain adequate amounts of exercise to maintain the weight loss. In addition, physical activity during weight loss may prevent loss of lean body mass. In the weight loss maintenance period, most people require &gt;60 minutes per day of moderate intensity activity to successfully maintain the loss.",
"   </p>",
"   <p>",
"    Any exercise program should be designed to fit into the health and physical conditions of the subject. Subjects who are about to begin an exercise program, even those whose only exercise will be walking, should be advised of the possibility of musculoskeletal stresses and strains and joint injury. Existing medical conditions, age, and preferences for types of exercise should all be considered in the decisions. Medical evaluation prior to initiation of an exercise program is typically not necessary for asymptomatic patients at low risk for coronary heart disease. However, there may be certain groups in which evaluation is warranted. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the benefits and risks of exercise\", section on 'Medical evaluation prior to exercise'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for coronary heart disease\", section on 'High-risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal combination of aerobic and resistance exercise is uncertain. In one trial, 136 obese men and women were randomly assigned to one of four groups (resistance, aerobic, combined, or sedentary control) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/43\">",
"     43",
"    </a>",
"    ]. After six months, body weight decreased by 0.64, 2.77, and 2.3 kg, respectively, and increased by 0.28 kg in the control group. Compared with the control group, cardiorespiratory fitness increased in the aerobic and combined exercise groups. Abdominal and visceral fat decreased and endurance increased in the aerobic and combined groups, whereas skeletal mass and muscle strength increased in the resistance and combined exercise groups. Insulin sensitivity improved in the aerobic and combined groups. In addition, progressive resistance training has been shown to improve physical functioning in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/44\">",
"     44",
"    </a>",
"    ]. Thus, a multicomponent program that includes aerobic and resistance training is typically preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/45\">",
"     45",
"    </a>",
"    ]. As an example, a program that includes balance training (15 minutes) and flexibility (15 minutes) (particularly for the elderly), aerobic exercise (30 minutes), and high-intensity resistance training (30 minutes) may be effective. However any type of physical activity is better than none and combining activities the patient is willing and able to do may be the most important factor to consider when designing a program for your patients.",
"   </p>",
"   <p>",
"    Finding appropriate places to exercise can facilitate any program of exercise. Health clubs or local YMCA or community centers may be helpful, but for most people walking is the most appropriate form of exercise. In one study of obese women, the combination of diet plus advice to increase physical activity by incorporating short periods of activity into daily schedules (eg, walking instead of driving short distances, taking stairs instead of elevators) was as effective for inducing weight loss as diet plus structured aerobic activity (aerobics classes) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21144/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       \"Patient information: Exercise (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"       \"Patient information: Exercise (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10852622\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of overweight and obesity should include a combination of diet, exercise, and behavioral modification. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low levels of physical activity and recreation are related to weight gain and increased risk of cardiovascular disease in both men and women. Increasing the level of physical activity would be beneficial to all ages and all groups, particularly for the prevention of obesity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevention of weight gain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In moderately overweight adults, exercise programs added to diets with moderate to severe caloric restriction have only a modest effect upon weight loss. However, adding exercise to diet may have other important benefits independent of weight loss. Physical activity attenuates the diet-induced loss of muscle mass, improves physical functioning, and may offset the decrease in total energy expenditure that occurs with weight loss, such that the calorie restriction required to match energy expenditure is more easily achieved. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Exercise plus diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical exercise and activity are important for preventing weight regain after successful weight loss. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Maintenance of weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical activity should be performed for approximately 30 minutes, five to seven days a week, to prevent weight gain and to improve cardiovascular health. There appears to be a dose effect for physical activity and weight loss, and much greater amounts of exercise are necessary to produce significant weight loss in the absence of a calorically-restricted diet. Therefore, when weight loss is the desired goal, a diet should be combined with physical activity and the activity gradually increased over time as tolerated by the patient. For many individuals, &gt;60 minutes per day of activity may be required to prevent weight regain following a significant weight loss. Any exercise program should be designed to fit into the health and physical conditions of the subject. Existing medical conditions, age, and preferences for types of exercise should all be considered in the decisions. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'A program for physical activity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/1\">",
"      Westerterp KR. Assessment of physical activity: a critical appraisal. Eur J Appl Physiol 2009; 105:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/2\">",
"      Jakicic JM, Marcus BH, Lang W, Janney C. Effect of exercise on 24-month weight loss maintenance in overweight women. Arch Intern Med 2008; 168:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/3\">",
"      Bonomi AG, Goris AH, Yin B, Westerterp KR. Detection of type, duration, and intensity of physical activity using an accelerometer. Med Sci Sports Exerc 2009; 41:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/4\">",
"      Bravata DM, Smith-Spangler C, Sundaram V, et al. Using pedometers to increase physical activity and improve health: a systematic review. JAMA 2007; 298:2296.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/6\">",
"      Donnelly JE, Blair SN, Jakicic JM, et al. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2009; 41:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/7\">",
"      Bauman AE, Reis RS, Sallis JF, et al. Correlates of physical activity: why are some people physically active and others not? Lancet 2012; 380:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/8\">",
"      Hankinson AL, Daviglus ML, Bouchard C, et al. Maintaining a high physical activity level over 20 years and weight gain. JAMA 2010; 304:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/9\">",
"      Lee IM, Djouss&eacute; L, Sesso HD, et al. Physical activity and weight gain prevention. JAMA 2010; 303:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/10\">",
"      McTiernan A, Sorensen B, Irwin ML, et al. Exercise effect on weight and body fat in men and women. Obesity (Silver Spring) 2007; 15:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/11\">",
"      Samaras K, Kelly PJ, Chiano MN, et al. Genetic and environmental influences on total-body and central abdominal fat: the effect of physical activity in female twins. Ann Intern Med 1999; 130:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/12\">",
"      Kilpel&auml;inen TO, Qi L, Brage S, et al. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med 2011; 8:e1001116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/13\">",
"      Slentz CA, Duscha BD, Johnson JL, et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE--a randomized controlled study. Arch Intern Med 2004; 164:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/14\">",
"      Miller WC, Koceja DM, Hamilton EJ. A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes Relat Metab Disord 1997; 21:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/15\">",
"      Lee L, Kumar S, Leong LC. The impact of five-month basic military training on the body weight and body fat of 197 moderately to severely obese Singaporean males aged 17 to 19 years. Int J Obes Relat Metab Disord 1994; 18:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/16\">",
"      Thorogood A, Mottillo S, Shimony A, et al. Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am J Med 2011; 124:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/17\">",
"      Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev 2006; :CD003817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/18\">",
"      Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000; 133:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/19\">",
"      Irwin ML, Yasui Y, Ulrich CM, et al. Effect of exercise on total and intra-abdominal body fat in postmenopausal women: a randomized controlled trial. JAMA 2003; 289:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/20\">",
"      Ross R, Janssen I, Dawson J, et al. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. Obes Res 2004; 12:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/21\">",
"      Catenacci VA, Wyatt HR. The role of physical activity in producing and maintaining weight loss. Nat Clin Pract Endocrinol Metab 2007; 3:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/22\">",
"      Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011; 364:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/23\">",
"      Jakicic JM, Marcus BH, Gallagher KI, et al. Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial. JAMA 2003; 290:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/24\">",
"      Goodpaster BH, Delany JP, Otto AD, et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA 2010; 304:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/25\">",
"      Chomentowski P, Dub&eacute; JJ, Amati F, et al. Moderate exercise attenuates the loss of skeletal muscle mass that occurs with intentional caloric restriction-induced weight loss in older, overweight to obese adults. J Gerontol A Biol Sci Med Sci 2009; 64:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/26\">",
"      Shah K, Stufflebam A, Hilton TN, et al. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 2009; 17:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/27\">",
"      Weinheimer EM, Sands LP, Campbell WW. A systematic review of the separate and combined effects of energy restriction and exercise on fat-free mass in middle-aged and older adults: implications for sarcopenic obesity. Nutr Rev 2010; 68:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/28\">",
"      Iba&ntilde;ez J, Izquierdo M, Arg&uuml;elles I, et al. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 2005; 28:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/29\">",
"      DiPietro L, Dziura J, Yeckel CW, Neufer PD. Exercise and improved insulin sensitivity in older women: evidence of the enduring benefits of higher intensity training. J Appl Physiol 2006; 100:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/30\">",
"      Avenell A, Brown TJ, McGee MA, et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet 2004; 17:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/31\">",
"      Turk MW, Yang K, Hravnak M, et al. Randomized clinical trials of weight loss maintenance: a review. J Cardiovasc Nurs 2009; 24:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/32\">",
"      Mekary RA, Feskanich D, Hu FB, et al. Physical activity in relation to long-term weight maintenance after intentional weight loss in premenopausal women. Obesity (Silver Spring) 2010; 18:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/33\">",
"      Schoeller DA, Shay K, Kushner RF. How much physical activity is needed to minimize weight gain in previously obese women? Am J Clin Nutr 1997; 66:551.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Global Recommendations on Physical Activity for Health, 2010. file://whqlibdoc.who.int/publications/2010/9789241599979_eng.pdf (Accessed on February 08, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/35\">",
"      Katzmarzyk PT, Church TS, Craig CL, Bouchard C. Sitting time and mortality from all causes, cardiovascular disease, and cancer. Med Sci Sports Exerc 2009; 41:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/36\">",
"      Hunter GR, Brock DW, Byrne NM, et al. Exercise training prevents regain of visceral fat for 1 year following weight loss. Obesity (Silver Spring) 2010; 18:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/37\">",
"      Sui X, LaMonte MJ, Laditka JN, et al. Cardiorespiratory fitness and adiposity as mortality predictors in older adults. JAMA 2007; 298:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/38\">",
"      Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 2009; 301:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/39\">",
"      Fogelholm M. Physical activity, fitness and fatness: relations to mortality, morbidity and disease risk factors. A systematic review. Obes Rev 2010; 11:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/40\">",
"      Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am J Epidemiol 2002; 156:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/41\">",
"      Hu FB, Willett WC, Li T, et al. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004; 351:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/42\">",
"      Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation 2012; 125:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/43\">",
"      Davidson LE, Hudson R, Kilpatrick K, et al. Effects of exercise modality on insulin resistance and functional limitation in older adults: a randomized controlled trial. Arch Intern Med 2009; 169:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/44\">",
"      Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev 2009; :CD002759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/45\">",
"      Mathus-Vliegen EM, Obesity Management Task Force of the European Association for the Study of Obesity. Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. Obes Facts 2012; 5:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21144/abstract/46\">",
"      Andersen RE, Wadden TA, Bartlett SJ, et al. Effects of lifestyle activity vs structured aerobic exercise in obese women: a randomized trial. JAMA 1999; 281:335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5379 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21144=[""].join("\n");
var outline_f20_41_21144=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10852622\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEASUREMENT OF PHYSICAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVENTION OF WEIGHT GAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT FOR OBESITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exercise as a single treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Exercise plus diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Maintenance of weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4594776\">",
"      OVERALL HEALTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4594783\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4594790\">",
"      Risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      A PROGRAM FOR PHYSICAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10852622\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/5379\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5379|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/56/25486\" title=\"figure 1\">",
"      Components energy expenditure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/28/15822\" title=\"figure 2\">",
"      Physical activity with age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5379|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/2/10283\" title=\"table 1\">",
"      Benefits physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/56/37774\" title=\"table 2\">",
"      Energy spent with activity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=related_link\">",
"      Behavioral strategies in the treatment of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17015?source=related_link\">",
"      Effects of exercise on lipoproteins and hemostatic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/2998?source=related_link\">",
"      Exercise in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18378?source=related_link\">",
"      Management of childhood obesity in the primary care setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_41_21145="Medical consultation for electroconvulsive therapy";
var content_f20_41_21145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical consultation for electroconvulsive therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21145/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21145/contributors\">",
"     Anjala Tess, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21145/contributors\">",
"     Gerald W Smetana, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21145/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21145/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21145/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21145/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/41/21145/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroconvulsive therapy (ECT) is a commonly performed procedure in the United States. Use of ECT is rising, and psychiatrists often request medical evaluation before ECT since many eligible patients are elderly with multiple medical comorbidities. This topic review will discuss the use, indications, anesthetic technique, procedure, and morbidity of ECT, as well as risk assessment and strategies to reduce the risk of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary indication for ECT is for the treatment of major depression that is refractory to antidepressant medications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/1\">",
"     1",
"    </a>",
"    ]. Indications listed in the American Psychiatric Association",
"    <a class=\"external\" href=\"file://psychiatryonline.org/content.aspx?bookid=28&amp;sectionid=1667485\">",
"     guidelines",
"    </a>",
"    for the treatment of patients with major depressive disorder include depression with psychotic features, catatonia, persistent suicidal intent, food refusal leading to nutritional compromise or dehydration, and pregnancy and other situations where a rapid antidepressant response is required (",
"    <a class=\"graphic graphic_table graphicRef55438 \" href=\"UTD.htm?15/8/15499\">",
"     table 1",
"    </a>",
"    )&nbsp;. The report also recommends ECT for patients who have previously shown a positive response to it and for those who have medical conditions that prevent the use of antidepressant medications. The Canadian Psychiatric Association clinical guidelines for the treatment of depressive disorders suggest similar indications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=see_link\">",
"     \"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other psychiatric conditions for which ECT is effective include bipolar depression and mania [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNIQUE AND ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECT is usually administered two or three times per week for a total of 6 to 12 treatments. The treatment typically causes a 30 to 60 second generalized tonic clonic seizure, an effect that is essential to the success of ECT. The patient is preoxygenated with supplemental oxygen (2",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    via nasal cannula while the procedure is being set up. Prophylactic beta blockers may be administered immediately before or during ECT to blunt the hypertensive, tachycardic response to the seizure. The anesthesia of choice is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"     methohexital",
"    </a>",
"    . Other induction agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    . Skeletal muscle relaxation is used during ECT to minimize the motor seizure and prevent musculoskeletal injury. The standard agent is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    via intravenous infusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13128?source=see_link\">",
"     \"Technique for performing electroconvulsive therapy (ECT) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should be aware of certain potential side effects or complications of ECT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Psychiatric Association lists the following conditions as associated with increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unstable or severe cardiovascular disease",
"     </li>",
"     <li>",
"      Space-occupying intracranial lesion with evidence of elevated intracranial pressure",
"     </li>",
"     <li>",
"      Recent cerebral hemorrhage or stroke",
"     </li>",
"     <li>",
"      Bleeding or otherwise unstable vascular aneurysm",
"     </li>",
"     <li>",
"      Severe pulmonary condition",
"     </li>",
"     <li>",
"      ASA (American Society of Anesthesiologists) Class 4 or 5 (",
"      <a class=\"graphic graphic_table graphicRef56098 \" href=\"UTD.htm?8/33/8733\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECT is one of the safest procedures performed under general anesthesia. With modern anesthetic technique, the rate is sufficiently low and the potential life saving benefit is compelling enough that absolute contraindications to treatment no longer exist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiovascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 15- to 20-second parasympathetic discharge occurs during the procedure as the patient enters the tonic phase of seizure. This can lead to arrhythmias including bradycardia with or without hypotension, atrial arrhythmias, premature atrial and ventricular contractions, atrioventricular block, and asystole. Asystole can occur with the first treatment or at any time later in a patient's course [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/5\">",
"     5",
"    </a>",
"    ]; patients are at higher risk with longer periods of subconvulsive seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/6\">",
"     6",
"    </a>",
"    ]. In one study of older adult patients, 66 percent had asystole lasting greater than 5 seconds with no lasting complications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/7\">",
"     7",
"    </a>",
"    ]. A history of hypertension or evidence of ischemia on electrocardiogram (ECG) did not predict asystole, nor did current use of calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , angiotensin converting enzyme (ACE) inhibitors, diuretics, or psychiatric medications (beta blockers were not included). Interestingly, patients with heart block",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rhythm abnormalities were less likely to develop asystole (54 versus 16 percent).",
"   </p>",
"   <p>",
"    The clonic phase of the seizure then leads to a catecholamine surge that causes tachycardia and hypertension. The duration of tachycardia usually correlates with the length of the seizure itself [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/8\">",
"     8",
"    </a>",
"    ]. These hemodynamic responses continue into the postictal period and usually resolve within 10 to 20 minutes of the seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/9\">",
"     9",
"    </a>",
"    ]. Occasionally patients have persistent hypertension that requires treatment. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Postprocedure hemodynamic changes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All patients are followed with ECG during the procedure; even healthy patients can have transient ECG changes. However, these changes are rarely significant, as illustrated by a study of 29 patients comprising a total of 80 treatments, in which no one had persistent T wave inversion, pathologic Q waves, or a demonstrable rise in cardiac enzymes at four and six hours (although some had a mild increase in creatine kinase [CPK], presumably from skeletal muscle) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ECT can also cause a transient depression in the ejection fraction of healthy patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/11\">",
"     11",
"    </a>",
"    ]. A study in 53 adults undergoing ECT found that seven developed new global left ventricular (LV) systolic dysfunction and eight developed regional wall motion abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/12\">",
"     12",
"    </a>",
"    ]. Among the 14 patients who developed global or regional abnormalities after the first ECT treatment, 13 had resolution of these abnormalities after the fourth ECT treatment (generally about one week later), and there were no short-term adverse events in any of the patients with LV dysfunction.",
"   </p>",
"   <p>",
"    Several studies have investigated the incidence of serious cardiac complications from ECT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 42 patients who had undergone ECT, 12 of the 17 patients with underlying cardiac disease had cardiac complications [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/13\">",
"       13",
"      </a>",
"      ]. Most of these were benign and self-limited, including atrial and ventricular ectopy and nonsustained ventricular tachycardia. There was evidence of ischemia in two patients and one cardiac arrest of unknown etiology. Seventy percent of all complications, self-limited or not, occurred in patients with cardiovascular disease identified on the history, physical examination, or ECG, and all occurred in patients greater than 50 years of age. This study did not, however, systematically document the degree of preexisting cardiac disease.",
"     </li>",
"     <li>",
"      A prospective study of 40 patients with cardiac disease found that 55 percent had at least one complication with ECT [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/14\">",
"       14",
"      </a>",
"      ]. These included minor complications, such as transient arrhythmias or ST segment changes, and major complications, such as persistent ECG changes accompanied by chest pain, asystole, or persistent arrhythmias. Only 7.5 percent in the control group without cardiac disease had a cardiac complication, and all were transient and minor.",
"     </li>",
"     <li>",
"      A case-control study of 80 patients over the age of 50 found that the risk of major complications was 11.5 percent in patients at high risk for cardiovascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/15\">",
"       15",
"      </a>",
"      ]. The patients were able to complete their course of therapy once the complications were treated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that the incidence of important cardiac complications are relatively rare and almost always occur in older patients and those with underlying cardiovascular disease. Furthermore, even patients at high risk for cardiac complications tolerate ECT well and, if complications occur and are treated, the vast majority can complete the treatment course. As an example, one study treated 80 patients, one-half of whom had preexisting cardiac disease (depressed ejection fraction, conduction disease, or frequent premature ventricular contractions) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/14\">",
"     14",
"    </a>",
"    ]. Among those with cardiac disease, eight had major complications including chest pain, arrhythmia, ischemia, and one myocardial infarction. Anesthesiologists and cardiologists treated the complications as they occurred and 36 of 38 patients went on to complete treatment, including the patient with the myocardial infarction. Similarly, a second study treated 53 patients and, of the 27 patients at risk, 31 percent required changes in medication or pretreatment with subsequent treatments because of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/15\">",
"     15",
"    </a>",
"    ]. Twenty-five out of 27 patients completed the course of ECT; there were no deaths. Despite these successful outcomes, it is not known how many of the patients in these studies were on beta blockers or other antihypertensive medication prior to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Central nervous system and other effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cerebral effects occur with ECT, including increases in cerebral blood flow and intracranial pressure. Memory loss, disorientation, and delirium are the primary clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ROLE OF THE MEDICAL CONSULTANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preprocedure evaluation of patients before ECT is similar to the approach to a patient undergoing any procedure that requires general anesthesia: to identify medical issues that place the patient at risk, to propose strategies to reduce risk, and to treat complications after the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Preprocedure evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete history and physical examination will help to identify pertinent risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/16\">",
"     16",
"    </a>",
"    ]. We agree with the recommendation from the American Psychiatric Association that no specific laboratory tests are required in the pre-ECT evaluation. We recommend measurement of serum electrolytes only for patients taking diuretics or other medications that increase the likelihood of an abnormality and for patients with established renal disease or congestive heart failure. We suggest an electrocardiogram in patients over the age of 50 years, since most cardiac complications occur in older patients. There are no indications for other routine laboratory studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The history should include a review of previous difficulties with anesthesia or ECT. As mentioned above, there are no absolute contraindications to ECT and most patients can have the procedure without serious complication, but clinicians should seek risk factors that may require intervention or management. Important considerations include risk factors for cardiac ischemia or arrhythmia, heart failure, and the presence of brain tumors or other neurosurgical issues. A history of skull fractures should be determined, as this may affect electrode placement.",
"   </p>",
"   <p>",
"    The history should also include a medication history, to specifically inquire about use of herbal medications. In one study, 54 percent of outpatients with psychiatric conditions used alternative medication in addition to routine pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/17\">",
"     17",
"    </a>",
"    ]. Common alternative medications, including Ginkgo biloba, ginseng, St. John's wort, valerian, and kava kava, have CNS effects which might interfere with ECT. The treating psychiatrist should be made aware of a patient's herbal supplement use, to determine if the herbal products should be tapered prior to initiating ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    has been reported to cause status epilepticus after ECT and so should be tapered prior to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/19\">",
"     19",
"    </a>",
"    ]. The treating psychiatrist may also choose to taper or discontinue antidepressants",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other psychotropics prior to treatment.",
"   </p>",
"   <p>",
"    A summary of management strategies for preexisting medical conditions is shown in a table (",
"    <a class=\"graphic graphic_table graphicRef55652 \" href=\"UTD.htm?33/11/33981\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Strategies to reduce the risk of cardiac complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 American Heart Association",
"    <span class=\"nowrap\">",
"     /American",
"    </span>",
"    College of Cardiology (AHA-ACC) guideline update for noncardiac surgery assigns procedure-related risk to several types of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/20\">",
"     20",
"    </a>",
"    ]. Though not explicitly mentioned in the AHA-ACC guidelines, ECT can be treated like a low-risk procedure because it is usually well tolerated even in those at risk, the duration of hemodynamic changes is brief, and the mortality rate is low [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/14,15,21\">",
"     14,15,21",
"    </a>",
"    ]. As a result, it is difficult to prove a beneficial effect of any intervention to reduce cardiovascular risk. Nevertheless, a cardiac risk assessment is warranted preoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Barring major clinical predictors of coronary risk (unstable angina, decompensated heart failure, severe valvular disease, malignant arrhythmias), most patients can undergo ECT with appropriate medical management [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/22\">",
"     22",
"    </a>",
"    ]. Some have suggested that sedentary patients with intermediate risk factors should undergo further noninvasive risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/23\">",
"     23",
"    </a>",
"    ]. However, we feel that this population can proceed without further evaluation given the low morbidity of ECT and the potential use of prophylactic beta blockers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Postprocedure hemodynamic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short acting beta blockers are used to quickly treat persistent or severe tachycardia and hypertension after ECT. Other agents that have been useful for the treatment of postprocedure hypertension are intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/24\">",
"     24",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/25\">",
"     25",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/9,22\">",
"     9,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prophylactic beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short acting beta blockers, such as intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    , can be used to prevent transient and persistent hypertension and tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/24-30\">",
"     24-30",
"    </a>",
"    ];",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    is administered to prevent bradycardia in these individuals. Several authors have raised concern regarding widespread use of beta blockers because these drugs have been implicated in cases of prolonged asystole [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/6,31,32\">",
"     6,31,32",
"    </a>",
"    ]. However, in these reported cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    was not used and in some cases patients had subconvulsive treatments that can also cause bradycardia.",
"   </p>",
"   <p>",
"    While it is clear that treatment of postprocedure hemodynamic changes is indicated, use of prophylactic beta blockers to reduce risk for patients undergoing ECT is controversial. The overall risk of cardiovascular complications due to ECT is low and no studies have documented reduced cardiac complications with the use of short acting beta blockers before ECT.",
"   </p>",
"   <p>",
"    The 2001 American Psychiatric Association guidelines list three considerations for the use of prophylactic short acting beta blockers, that also are relevant in patients taking long acting beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers may increase the risk of asystole (though this appears to be less of a risk if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      is used [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/7\">",
"       7",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      The absolute rise in the heart rate and blood pressure with ECT is no greater in those with baseline elevated blood pressure or heart rate [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a theoretical risk that excessive blunting of the hemodynamic response with beta blockers may reduce the necessary supply of oxygen to the brain to protect against decreased seizure length and cognitive side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there is some evidence that beta blockers might result in a decrease in seizure length and potentially decrease the efficacy of ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/30,35\">",
"     30,35",
"    </a>",
"    ], although this is not found in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Psychiatric Association chose not to make a specific recommendation with regard to using prophylactic beta blockers but does recommend that patients with unstable hypertension be stabilized prior to starting ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/4\">",
"     4",
"    </a>",
"    ]. We do not recommend routine use of beta blocker in low risk patients, given the theoretical risks and unclear benefit. We suggest the use of prophylactic short-acting intravenous beta blockers for patients at very high risk of complications from transient hypertension (eg, intracranial aneurysm, unstable angina or recent myocardial infarction) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/16\">",
"     16",
"    </a>",
"    ]. Collaboration with the treating psychiatrist, anesthesiologist, and cardiology consultation is beneficial in such patients.",
"   </p>",
"   <p>",
"    Typical bolus doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    are 5 to 20 mg IV, and for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    , 10 to 50 mg IV. The most authoritative study of the use of beta blockers during ECT found that labetalol produced dose-dependent reduction in HR and rate pressure product (RPP) using 5 and 10 mg doses, compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/38\">",
"     38",
"    </a>",
"    ]. It is not necessary to prevent the transient hypertension and tachycardia associated with the seizure in most patients; the main goal of the use of these agents is to reduce the risk of myocardial ischemia (a possible result of the increased oxygen demand associated with tachycardia) in patients with coronary artery disease. Other agents, such as calcium channel blockers or nitroglycerine, are sometimes given during ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other prophylactic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications other than beta blockers have been used to try to prevent postprocedure hemodynamic changes. As an example, a small randomized trial found that prophylactic intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    was effective in a dose-dependent fashion at minimizing the acute hemodynamic response to ECT without shortening the duration of seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Coexisting cardiac disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should receive their routine antihypertensive (other than diuretics) with a small sip of water approximately two hours before ECT. Diuretics should not be given, because it is better for the bladder to be empty during the procedure to prevent the patient from soiling himself as a result of the seizure. Patients on long-standing diuretics should have electrolytes checked before proceeding to ensure potassium and magnesium are replete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antianginals such as nitrates and beta blockers should be continued in patients with documented coronary heart disease who are already taking them. Patients taking long acting beta blockers may receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    with induction given the potential increase in the risk of bradycardia and a small study that showed that atropine should be protective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/7\">",
"     7",
"    </a>",
"    ]. This should be discussed with the anesthesiologist.",
"   </p>",
"   <p>",
"    If ECG changes or chest pain occur during the treatment period, treatments should be postponed until the patient is evaluated and treated for potential ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/22,41\">",
"     22,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Heart failure and valvular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECT should be delayed in patients with decompensated heart failure or significant valvular disease, pending cardiology consultation and completion of a thorough evaluation and optimization of cardiac status. One report of ten patients who completed ECT (total of 144 ECT sessions) with severe aortic stenosis (valve area 0.7 to 1.0 cm2) noted good control of blood pressure and heart rate with continuation of chronic antihypertensive medications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    addition of a short-acting beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/42\">",
"     42",
"    </a>",
"    ]. All patients were asymptomatic and tolerated ECT. There were no deaths attributable to ECT or aortic stenosis. Two patients had drops in blood pressure requiring intervention, and seven patients required intravenous medication to control systolic blood pressure &gt;180 mmHg. In patients with severe aortic stenosis, a cardiologist should be consulted, and clinicians should strive for tight control of blood pressure and heart rate with attention to avoiding excessive preload or afterload reduction. Little data are available for management of patients with less severe valvular disease, though ECT can be performed safely, with appropriate precautions, in most patients with underlying cardiac conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study examined the safety of ECT in patients with compensated heart failure with reduced ejection fraction (range of 15 to 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/44\">",
"     44",
"    </a>",
"    ]. In 35 patients receiving a total of 513 treatments, all patients tolerated the procedure well and with no cardiac complications after treatment. Consistent with other studies looking at cardiac complications, three patients suffered non life-threatening transient arrhythmias. Eighty percent of treated patients did receive prophylactic beta-blockers if they had experienced prolonged hypertension or tachycardia with prior treatments.",
"   </p>",
"   <p>",
"    In patients with a remote history of heart failure or compensated disease, we recommend a baseline echocardiogram, if not recently performed, to assist with periprocedure management. In those with compensated systolic dysfunction, one may simply continue diuretics and vasodilator therapy and minimize volume overload. In patients with diastolic dysfunction, control of blood pressure should limit the occurrence of flash pulmonary edema. This group will benefit from prompt treatment of post-seizure hypertension if it develops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Pacemakers and implantable defibrillators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pacemakers and automatic implantable cardiac defibrillators (AICDs) can safely undergo ECT. As an example, in a case series of ECT in 26 patients with pacemakers and three patients with AICDs there was only one serious cardiac event, an episode of supraventricular tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical team should be prepared to deactivate pacemakers with a magnet if any aberrant signals occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/22\">",
"     22",
"    </a>",
"    ]. A cardiologist should deactivate AICDs before induction and reactivate the device after the seizure is complete to avoid excessive charge. The patient should have continuous ECG monitoring while the defibrillator is deactivated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/46\">",
"     46",
"    </a>",
"    ], and the team should be prepared to defibrillate should the patient develop an unstable rhythm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Coexisting neurologic and neurosurgical disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Brain tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early recommendations considered brain tumors and other space occupying lesions to be absolute contraindications to ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/47\">",
"     47",
"    </a>",
"    ]. This concern was based upon the observation that ECT raises cerebral blood flow, which in the presence of a brain tumor could translate into an increase in intracranial pressure (ICP) and neurologic deterioration.",
"   </p>",
"   <p>",
"    These concerns were illustrated in a review of 35 patients with brain tumors undergoing ECT, 74 percent of whom had major adverse neurologic and cognitive side effects, with a one-month mortality of 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/48\">",
"     48",
"    </a>",
"    ]. Notable characteristics of patients who suffered neurologic deterioration included the presence of a depressive illness, no previous psychiatric illness or ECT, headache, and the presence of even soft neurologic findings on exam. However, this study may have had a selection bias given that only one patient was known to have a tumor before treatment.",
"   </p>",
"   <p>",
"    Subsequently, one group reviewed 10 cases of successful treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Eight patients had meningiomas in differing locations, and two patients had metastatic breast cancer. No one had abnormal neurologic examinations or evidence of increased ICP at baseline, and four had normal spinal fluid measurements. There were no adverse events other than a prolonged seizure after one treatment. Most recently a case report described successful treatment of a patient with primary brain cancer and documented elevated ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/53\">",
"     53",
"    </a>",
"    ]. He was treated with steroids and short acting beta blockers to minimize edema and elevations in blood pressure during the clonic phase of seizure.",
"   </p>",
"   <p>",
"    Based on this information, ECT is probably safe in patients with brain tumors as long as there is no evidence of elevated ICP. Given that the available safety data are in the form of case series or reports, we agree with the American Psychiatric Association that the decision should be made on a case by case basis with the involvement of neurologic and possibly neurosurgical consultants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/4\">",
"     4",
"    </a>",
"    ]. Evaluation should consist of a detailed history and physical examination to seek evidence suggestive of elevated ICP, such as headache, papilledema, or abnormal neurologic examination. Any such evidence should prompt further investigation such as head CT or MRI. Although data are limited, providers have successfully used steroids to minimize edema [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], and neurologic consultants may consider using them in patients in whom elevated ICP cannot be ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have suffered a stroke have a high rate of depression. In a study of 14 patients with completed strokes undergoing ECT one month or more after the event, none had deleterious neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/56\">",
"     56",
"    </a>",
"    ]. Similarly, a second study of 24 patients with a history of stroke found no difference in the efficacy or cardiac complication rate compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/57\">",
"     57",
"    </a>",
"    ]. Rates of delirium were similar in both groups, although within the study group all patients with delirium had their strokes within the preceding year. Adequate blood pressure control is important for such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports exist of successful ECT in depressed patients with dementia and organic brain disease, with efficacy rates similar to that of nondemented patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In a review of 135 patients with organic and depressive dementia, 21 percent developed delirium or cognitive and memory deficits; all but one had cleared by time of discharge from the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of delirium correlates with the degree of underlying dementia or organic brain syndrome, but is transient and does not interfere with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/59\">",
"     59",
"    </a>",
"    ]. The clinical staff should be aware that delirium is a potential side effect in demented patients. These patients can often be managed with reassurance and alterations in level of supervision [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Neuromuscular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with neuromuscular disease, particularly post-polio syndrome, depolarizing muscle relaxants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    may lead to severe hyperkalemia and circulatory collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Thus, depolarizing muscle relaxants should be avoided. Patients with neuromuscular disease may receive short-acting, non-depolarizing agents for neuromuscular blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178071413\">",
"    <span class=\"h3\">",
"     Epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of ECT and anticonvulsants in patients with epilepsy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\", section on 'Psychotropic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear evidence of an effect of ECT on blood sugar control in diabetic patients. In a small study of 19 patients with insulin-requiring type II DM, ECT itself did not lead to significant acute changes in blood sugar [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/64\">",
"     64",
"    </a>",
"    ]. Individual patients who developed hyperglycemia or hypoglycemia after ECT were found to have changed their behaviors (eating or activity) in response to resolving depression, and these behavioral changes were thought to be responsible for the change in blood sugar control.",
"   </p>",
"   <p>",
"    Patients generally do not take anything by mouth on the morning of ECT. As a general rule, we recommend holding oral hypoglycemic agents on the morning of the procedure. For insulin-requiring diabetics, on the morning of the procedure we recommend giving half of the usual total morning insulin dose (both intermediate and short-acting) as intermediate-acting insulin and withholding short-acting insulin. If the ECT will happen in the early morning, where breakfast is likely only delayed, then patients may delay taking their usual morning insulin until after ECT and before eating. A more detailed discussion of these issues can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=see_link\">",
"     \"Perioperative management of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of ECT in patients who are anticoagulated is controversial because of concerns about a possible increase in the risk of intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/65\">",
"     65",
"    </a>",
"    ]. In a case series of 35 patients receiving long-term anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    who underwent 284 ECT treatments, no major adverse effects occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/66\">",
"     66",
"    </a>",
"    ]. The INR on the day of ECT was below subtherapeutic (below 2.0) 36 percent of the time and supratherapeutic (above 3.5) only 3 percent of the time. These data suggest that if there is an increased risk of intracerebral hemorrhage with ECT in patients appropriately anticoagulated with warfarin, that risk is small.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of psychiatric conditions in pregnancy poses challenges, as psychotropic medications may have significant side effects in both mother and fetus. However, ECT is generally thought be safe in pregnant patients by the American Psychiatric Association and the American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21145/abstract/4,67\">",
"     4,67",
"    </a>",
"    ]. The safety of ECT and modifications in technique for treating pregnant patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4362?source=see_link&amp;anchor=H4605992#H4605992\">",
"     \"Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes\", section on 'Electroconvulsive therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=see_link&amp;anchor=H1561541#H1561541\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\", section on 'Electroconvulsive therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13128?source=see_link&amp;anchor=H13734882#H13734882\">",
"     \"Technique for performing electroconvulsive therapy (ECT) in adults\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a pregnant patient considers ECT, the informed consent and evaluation should be performed with an obstetrician and an anesthesiologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/50/37664?source=see_link\">",
"       \"Patient information: Electroconvulsive therapy (ECT) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform a history and physical examination and obtain an ECG in all patients before planned ECT. Identify risk factors for cardiac complications of the procedure using one of the published cardiac risk indices or guidelines. Risk factors include coronary heart disease, valvular disease, and heart failure, as well as diabetes mellitus, hypertension, hypercholesterolemia, and advanced age. Suggestion for management of preexisting conditions is shown in a table (",
"      <a class=\"graphic graphic_table graphicRef55652 \" href=\"UTD.htm?33/11/33981\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Preprocedure evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delay ECT for patients with unstable angina, decompensated heart failure, or severe symptomatic valvular disease until these conditions are stabilized. Cardiology consultation is recommended in these patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Coexisting cardiac disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest routine use of prophylactic beta blockers, which might decrease the seizure duration and increase risk of asystole. However, short-acting intravenous beta blockers should be considered for patients at very high risk of complications from transient hypertension (eg, significant aortic stenosis, intracranial aneurysm, unstable angina, or recent myocardial infarction). Cardiology consultation is useful in patients at very high risk.",
"      <br/>",
"      <br/>",
"      Continue nitrates, beta blockers, and other antihypertensive drugs in patients with preexisting cardiac conditions. If a patient is on a beta blocker, use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      with induction to reduce the risk of asystole.",
"     </li>",
"     <li>",
"      Although ECT is likely safe for patients with high-risk neurosurgical lesions including recent stroke and brain tumor, neurosurgical consultation is recommended, as ECT is never an emergent procedure. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Coexisting neurologic and neurosurgical disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetic patients should generally hold oral hypoglycemics and short-acting insulin the morning of ECT. For early morning ECT, where breakfast is likely only delayed, patients may delay taking their usual morning insulin until after ECT and before eating. If breakfast and lunch are likely to be missed, then we recommend giving half of the usual total morning insulin dose (both intermediate&ndash; and short-acting) as intermediate-acting insulin. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Diabetes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      therapy can be continued in patients receiving ECT who have an INR below 3.5 and a strong indication for anticoagulation. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/1\">",
"      Fink M, Taylor MA. Electroconvulsive therapy: evidence and challenges. JAMA 2007; 298:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/2\">",
"      Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments (CANMAT). Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001; 46 Suppl 1:5S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/3\">",
"      Fink M. Indications for the use of ECT. Psychopharmacol Bull 1994; 30:269.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association, Weiner RD, Coffey CE. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, 2nd ed., American Psychiatric Association, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/5\">",
"      McCall WV. Asystole in electroconvulsive therapy: Report of four cases. J Clin Psychiatry 1996; 57:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/6\">",
"      Kaufman KR. Asystole with electroconvulsive therapy. J Intern Med 1994; 235:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/7\">",
"      Burd J, Kettl P. Incidence of asystole in electroconvulsive therapy in elderly patients. Am J Geriatr Psychiatry 1998; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/8\">",
"      Larson G, Swartz C, Abrams R. Duration of ECT-induced tachycardia as a measure of seizure length. Am J Psychiatry 1984; 141:1269.",
"     </a>",
"    </li>",
"    <li>",
"     Abrams R. Electroconvulsive Therapy, 2nd ed., Oxford University Press, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/10\">",
"      Dec GW Jr, Stern TA, Welch C. The effects of electroconvulsive therapy on serial electrocardiograms and serum cardiac enzyme values. A prospective study of depressed hospitalized inpatients. JAMA 1985; 253:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/11\">",
"      Fuenmayor AJ, el Fakih Y, Moreno J, Fuenmayor AM. Effects of electroconvulsive therapy on cardiac function in patients without heart disease. Cardiology 1997; 88:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/12\">",
"      McCully RB, Karon BL, Rummans TA, et al. Frequency of left ventricular dysfunction after electroconvulsive therapy. Am J Cardiol 2003; 91:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/13\">",
"      Gerring JP, Shields HM. The identification and management of patients with a high risk for cardiac arrhythmias during modified ECT. J Clin Psychiatry 1982; 43:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/14\">",
"      Zielinski RJ, Roose SP, Devanand DP, et al. Cardiovascular complications of ECT in depressed patients with cardiac disease. Am J Psychiatry 1993; 150:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/15\">",
"      Rice EH, Sombrotto LB, Markowitz JC, Leon AC. Cardiovascular morbidity in high-risk patients during ECT. Am J Psychiatry 1994; 151:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/16\">",
"      Tess AV, Smetana GW. Medical evaluation of patients undergoing electroconvulsive therapy. N Engl J Med 2009; 360:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/17\">",
"      Knaudt PR, Connor KM, Weisler RH, et al. Alternative therapy use by psychiatric outpatients. J Nerv Ment Dis 1999; 187:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/18\">",
"      Patra KK, Coffey CE. Implications of herbal alternative medicine for electroconvulsive therapy. J ECT 2004; 20:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/19\">",
"      Devanand DP, Decina P, Sackeim HA, Prudic J. Status epilepticus following ECT in a patient receiving theophylline. J Clin Psychopharmacol 1988; 8:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/20\">",
"      Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009; 120:e169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/21\">",
"      Abrams R. The mortality rate with ECT. Convuls Ther 1997; 13:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/22\">",
"      Dolinski SY, Zvara DA. Anesthetic considerations of cardiovascular risk during electroconvulsive therapy. Convuls Ther 1997; 13:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/23\">",
"      Applegate RJ. Diagnosis and management of ischemic heart disease in the patient scheduled to undergo electroconvulsive therapy. Convuls Ther 1997; 13:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/24\">",
"      Nurenberg JR. Intravenous nitroglycerine in the management of posttreatment hypertension during electroconvulsive therapy. J Nerv Ment Dis 1991; 179:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/25\">",
"      Avramov MN, Stool LA, White PF, Husain MM. Effects of nicardipine and labetalol on the acute hemodynamic response to electroconvulsive therapy. J Clin Anesth 1998; 10:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/26\">",
"      Castelli I, Steiner LA, Kaufmann MA, et al. Comparative effects of esmolol and labetalol to attenuate hyperdynamic states after electroconvulsive therapy. Anesth Analg 1995; 80:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/27\">",
"      Kovac AL, Goto H, Arakawa K, Pardo MP. Esmolol bolus and infusion attenuates increases in blood pressure and heart rate during electroconvulsive therapy. Can J Anaesth 1990; 37:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/28\">",
"      Mayur PM, Shree RS, Gangadhar BN, et al. Atropine premedication and the cardiovascular response to electroconvulsive therapy. Br J Anaesth 1998; 81:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/29\">",
"      Stoudemire A, Knos G, Gladson M, et al. Labetalol in the control of cardiovascular responses to electroconvulsive therapy in high-risk depressed medical patients. J Clin Psychiatry 1990; 51:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/30\">",
"      van den Broek WW, Leentjens AF, Mulder PG, et al. Low-dose esmolol bolus reduces seizure duration during electroconvulsive therapy: a double-blind, placebo-controlled study. Br J Anaesth 1999; 83:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/31\">",
"      Decina P, Malitz S, Sackeim HA, et al. Cardiac arrest during ECT modified by beta-adrenergic blockade. Am J Psychiatry 1984; 141:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/32\">",
"      Wulfson HD, Askanazi J, Finck AD. Propranolol prior to ECT associated with asystole. Anesthesiology 1984; 60:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/33\">",
"      Webb MC, Coffey CE, Saunders WR, et al. Cardiovascular response to unilateral electroconvulsive therapy. Biol Psychiatry 1990; 28:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/34\">",
"      Prudic J, Sackeim HA, Decina P, et al. Acute effects of ECT on cardiovascular functioning: relations to patient and treatment variables. Acta Psychiatr Scand 1987; 75:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/35\">",
"      Howie MB, Black HA, Zvara D, et al. Esmolol reduces autonomic hypersensitivity and length of seizures induced by electroconvulsive therapy. Anesth Analg 1990; 71:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/36\">",
"      Howie MB, Hiestand DC, Zvara DA, et al. Defining the dose range for esmolol used in electroconvulsive therapy hemodynamic attenuation. Anesth Analg 1992; 75:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/37\">",
"      Dannon PN, Iancu I, Hirschmann S, et al. Labetalol does not lengthen asystole during electroconvulsive therapy. J ECT 1998; 14:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/38\">",
"      McCall WV, Shelp FE, Weiner RD, et al. Effects of Labetalol on Hemodynamics and Seizure Duration During ECT. Convuls Ther 1991; 7:5.",
"     </a>",
"    </li>",
"    <li>",
"     Kellner CH, Pritchett JT, Beale MD, Coffey CE. Handbook of ECT, American Psychiatric Press Inc, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/40\">",
"      Zhang Y, White PF, Thornton L, et al. The use of nicardipine for electroconvulsive therapy: a dose-ranging study. Anesth Analg 2005; 100:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/41\">",
"      de Silva RA, Bachman WR. Cardiac consultation in patients with neuropsychiatric problems. Cardiol Clin 1995; 13:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/42\">",
"      Mueller PS, Barnes RD, Varghese R, et al. The safety of electroconvulsive therapy in patients with severe aortic stenosis. Mayo Clin Proc 2007; 82:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/43\">",
"      Rayburn BK. Electroconvulsive therapy in patients with heart failure or valvular heart disease. Convuls Ther 1997; 13:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/44\">",
"      Rivera FA, Lapid MI, Sampson S, Mueller PS. Safety of electroconvulsive therapy in patients with a history of heart failure and decreased left ventricular systolic heart function. J ECT 2011; 27:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/45\">",
"      Dolenc TJ, Barnes RD, Hayes DL, Rasmussen KG. Electroconvulsive therapy in patients with cardiac pacemakers and implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2004; 27:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/46\">",
"      Pinski SL, Trohman RG. Implantable cardioverter-defibrillators: implications for the nonelectrophysiologist. Ann Intern Med 1995; 122:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/47\">",
"      Smith LH, Hughes DJ, Hastings DW, Alpers J. Electroshock treatment in the psychoses. Am J Psychiatry 1942; 98:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/48\">",
"      Maltbie AA, Wingfield MS, Volow MR, et al. Electroconvulsive therapy in the presence of brain tumor. Case reports and an evaluation of risk. J Nerv Ment Dis 1980; 168:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/49\">",
"      Dressler DM, Folk J. The treatment of depression with ECT in the presence of brain tumor. Am J Psychiatry 1975; 132:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/50\">",
"      Mattingly G, Figiel GS, Jarvis MR, Zorumski CF. Prospective uses of ECT in the presence of intracranial tumors. J Neuropsychiatry Clin Neurosci 1991; 3:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/51\">",
"      Fried D, Mann JJ. Electroconvulsive treatment of a patient with known intracranial tumor. Biol Psychiatry 1988; 23:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/52\">",
"      Zwil AS, Bowring MA, Price TR, et al. Prospective Electroconvulsive Therapy in the Presence of Intracranial Tumor. Convuls Ther 1990; 6:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/53\">",
"      Patkar AA, Hill KP, Weinstein SP, Schwartz SL. ECT in the presence of brain tumor and increased intracranial pressure: evaluation and reduction of risk. J ECT 2000; 16:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/54\">",
"      Zwil AS, Pelchat RJ. ECT in the treatment of patients with neurological and somatic disease. Int J Psychiatry Med 1994; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/55\">",
"      Hsiao JK, Messenheimer JA, Evans DL. ECT and Neurological Disorders. Convuls Ther 1987; 3:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/56\">",
"      Murray GB, Shea V, Conn DK. Electroconvulsive therapy for poststroke depression. J Clin Psychiatry 1986; 47:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/57\">",
"      Martin M, Figiel G, Mattingly G, et al. ECT-induced interictal delirium in patients with a history of a CVA. J Geriatr Psychiatry Neurol 1992; 5:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/58\">",
"      Price TR, McAllister TW. Safety and Efficacy of ECT in Depressed Patients with Dementia: A Review of Clinical Experience. Convuls Ther 1989; 5:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/59\">",
"      Nelson JP, Rosenberg DR. ECT Treatment of Demented Elderly Patients with Major Depression: A Retrospective Study of Efficacy and Safety. Convuls Ther 1991; 7:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/60\">",
"      Durr AL, Golden RN. Cognitive effects of electroconvulsive therapy: a clinical review for nurses. Convuls Ther 1995; 11:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/61\">",
"      Beach TP, Stone WA, Hamelberg W. Circulatory collapse following succinylcholine: report of a patient with diffuse lower motor neuron disease. Anesth Analg 1971; 50:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/62\">",
"      Liu S, Modell JH. Anesthetic management for patients with postpolio syndrome receiving electroconvulsive therapy. Anesthesiology 2001; 95:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/63\">",
"      Gyermek L. Increased potency of nondepolarizing relaxants after poliomyelitis. J Clin Pharmacol 1990; 30:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/64\">",
"      Netzel PJ, Mueller PS, Rummans TA, et al. Safety, efficacy, and effects on glycemic control of electroconvulsive therapy in insulin-requiring type 2 diabetic patients. J ECT 2002; 18:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/65\">",
"      Bleich S, Degner D, Scheschonka A, et al. Electroconvulsive therapy and anticoagulation. Can J Psychiatry 2000; 45:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/66\">",
"      Mehta V, Mueller PS, Gonzalez-Arriaza HL, et al. Safety of electroconvulsive therapy in patients receiving long-term warfarin therapy. Mayo Clin Proc 2004; 79:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21145/abstract/67\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009; 114:703.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4817 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21145=[""].join("\n");
var outline_f20_41_21145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR ECT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNIQUE AND ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Central nervous system and other effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ROLE OF THE MEDICAL CONSULTANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Preprocedure evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Strategies to reduce the risk of cardiac complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Postprocedure hemodynamic changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prophylactic beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other prophylactic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Coexisting cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Heart failure and valvular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Pacemakers and implantable defibrillators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Coexisting neurologic and neurosurgical disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Brain tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Dementia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Neuromuscular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H178071413\">",
"      - Epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4817\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4817|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/8/15499\" title=\"table 1\">",
"      Indications for ECT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/33/8733\" title=\"table 2\">",
"      American Society of Anesthesiologists physical status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/11/33981\" title=\"table 3\">",
"      Mgmt pre-exist conditions in ECT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4362?source=related_link\">",
"      Bipolar disorder in pregnant women: Treatment of mania, hypomania, and mixed episodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/50/37664?source=related_link\">",
"      Patient information: Electroconvulsive therapy (ECT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=related_link\">",
"      Perioperative management of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13128?source=related_link\">",
"      Technique for performing electroconvulsive therapy (ECT) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=related_link\">",
"      Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_41_21146="Overview of cancer pain syndromes";
var content_f20_41_21146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of cancer pain syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21146/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21146/contributors\">",
"     Russell K Portenoy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21146/contributors\">",
"     Lara K Dhingra, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21146/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21146/contributors\">",
"     Janet Abrahm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/41/21146/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21146/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/41/21146/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is a complex symptom that affects most aspects of life, including physical functioning, daily activity, psychological and emotional status, and social life. Among patients with cancer, there is substantial heterogeneity in how pain is experienced and in how it appears.",
"   </p>",
"   <p>",
"    In many cases, the constellation of symptoms and signs can suggest a specific cancer pain syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/1\">",
"     1",
"    </a>",
"    ]. The identification of such a syndrome may help to elucidate the etiology of the pain, direct the diagnostic evaluation, clarify the prognosis for the pain or the disease itself, and guide therapeutic intervention.",
"   </p>",
"   <p>",
"    Cancer pain syndromes can be broadly divided into those that are acute and those that are chronic. Acute pain syndromes usually accompany diagnostic or therapeutic interventions, whereas chronic pain syndromes usually are directly related to the neoplasm itself or to an antineoplastic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will provide an overview of acute and chronic cancer pain syndromes. Cancer pain assessment is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE PAIN SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most acute cancer pain syndromes are iatrogenic, ie, related to a diagnostic test or treatment (",
"    <a class=\"graphic graphic_table graphicRef79852 \" href=\"UTD.htm?31/44/32459\">",
"     table 1",
"    </a>",
"    ). However, some are disease-related, such as pain due to acute hemorrhage into a tumor, bone pain from a pathologic fracture, and visceral pain from acute obstruction or perforation of a hollow structure (",
"    <a class=\"graphic graphic_table graphicRef71104 \" href=\"UTD.htm?6/47/6907\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Directly related to cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pain syndromes that are directly related to the tumor may necessitate urgent treatment of the underlying lesion, in addition to aggressive pain control.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhage into a tumor &mdash; The prototype for this type of pain is bleeding into a site of hepatocellular carcinoma (HCC). This is typically accompanied by severe right upper quadrant pain, and is a potentially life-threatening complication, if the tumor ruptures. Urgent intervention for control of bleeding may be needed, in addition to transfusion and pain control. If measures such as transarterial embolization are unsuccessful, emergency surgery may be required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pathologic fracture &mdash; A pathologic fracture is a bone fracture that occurs within a preexisting lesion such as a skeletal metastasis or a primary bone tumor.",
"      <br/>",
"      <br/>",
"      Patients describe the sudden onset of back or limb pain, with or without antecedent trauma. Surgical stabilization of long bone fractures, if feasible and consistent with the overall goals of care, may relieve pain and should be considered. Vertebral collapse may be treated conservatively with analgesics or with an intervention, specifically vertebroplasty or kyphoplasty; surgery is typically considered only rarely and typically to address associated neurological impairment. Radiation therapy is usually considered for all pathologic fractures and often augments pain control over a period of weeks or longer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=see_link\">",
"       \"Radiation therapy for the management of painful bone metastases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of the complications of multiple myeloma\", section on 'Skeletal lesions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Obstruction/perforation",
"      </span>",
"      of a hollow viscus &mdash; Obstruction of a bile duct, ureter, or bowel lumen by an intraabdominal or pelvic cancer or retroperitoneal fibrosis can also present with acute severe pain. Relief may be obtained urgently through percutaneous decompression, stenting, or occasionally surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17735?source=see_link\">",
"       \"Exocrine pancreatic cancer: Palliation of symptoms\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=see_link\">",
"       \"Small bowel obstruction: Causes and management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"       \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=see_link\">",
"       \"Clinical manifestations and diagnosis of retroperitoneal fibrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Associated with antineoplastic treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pain can be associated with all types of antineoplastic therapy, including chemotherapy, hormonal therapy, immunotherapy, and radiotherapy (RT) (",
"    <a class=\"graphic graphic_table graphicRef61879 \" href=\"UTD.htm?37/43/38588\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Oral mucositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common acute painful disorder associated with antineoplastic therapy is oral mucositis. Chemotherapy-associated mucositis can affect the mucosa throughout the entire gastrointestinal tract. However, pain most often results from oral mucositis (stomatitis), which typically becomes clinically evident during the first week after chemotherapy administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link\">",
"     \"Oral toxicity associated with chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence varies with the drug regimen and dose, the use of concurrent therapies (especially RT), and host factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High doses of chemotherapy that are part of a conditioning regimen for hematopoietic stem cell transplantation cause noninfectious mucositis in approximately 70 percent of patients by killing cells with high mitotic rates. Ulceration of the oropharyngeal mucosa begins several days following initiation of the conditioning regimen. Initial symptoms may consist of mild or moderate burning discomfort, but this often progresses to the point where mucositis interferes with talking, eating, and swallowing. Significant pain requiring opioid use persists in one-half of patients at three weeks after transplant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=see_link&amp;anchor=H598154#H598154\">",
"       \"Supportive care after hematopoietic cell transplantation\", section on 'Mucositis and nutritional support'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Standard doses of many common chemotherapeutic agents can also cause mucositis (",
"      <a class=\"graphic graphic_table graphicRef68013 \" href=\"UTD.htm?40/47/41724\">",
"       table 4",
"      </a>",
"      ). The frequency and severity are both drug- and dose-dependent. The three most commonly used agents associated with oral mucositis are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (FU), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link&amp;anchor=H2#H2\">",
"       \"Oral toxicity associated with chemotherapy\", section on 'Mucositis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mucositis develops in nearly all patients receiving RT to the head and neck region. RT-induced mucositis is similar qualitatively to that induced by chemotherapy. It usually develops two to three weeks after starting treatment. The Incidence and severity of RT-induced mucositis depend on the field, total dose and duration of RT, and the use of concomitant chemotherapy.",
"      <br/>",
"      <br/>",
"      Although newer radiotherapy approaches such as 3-D conformal RT (3D-CRT) and intensity-modulated RT (IMRT) may reduce the incidence, mucositis remains a common problem in patients treated for head and neck cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"       \"Management of late complications of head and neck cancer and its treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H10#H10\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Mucositis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pain due to mucositis may be more severe or prolonged when the ulcers become superinfected with bacteria or fungus, and in the setting of graft-versus-host disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment strategies for established mucositis are not cause-specific. Despite years of research, management remains empiric and focused on symptom control. Adequate analgesia can sometimes be provided topically (using viscous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    candies), but most patients require systemic opioid-based analgesia.",
"   </p>",
"   <p>",
"    A variety of topical mucosal coating agents are available, including",
"    <span class=\"nowrap\">",
"     kaolin/pectin,",
"    </span>",
"    Orabase&reg;,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , oral antacids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38865?source=see_link\">",
"     maltodextrin",
"    </a>",
"    (Gelclair&reg;), and compounded mixtures that contain coating agents often in combination with topical anesthetics. As an example, FIRST mouthwash BLM is a commercially available preparation that includes diphenhydramine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    and Maalox. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link&amp;anchor=H23#H23\">",
"     \"Oral toxicity associated with chemotherapy\", section on 'Mucosal coating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Chemotherapy induced neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many chemotherapeutic agents are neurotoxic. Acute neuropathic pain in patients treated with chemotherapy may manifest as a polyneuropathy, or less commonly, a mononeuropathy.",
"   </p>",
"   <p>",
"    Acute chemotherapy-related polyneuropathy was first described in patients treated with the vinca alkaloid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    . Other agents with a high incidence of polyneuropathy include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    . All of these drugs can produce acute paresthesias and dysesthesias. Although they can present acutely (eg, oxaliplatin-induced pharyngolaryngeal spasm), the onset of pain associated with neuropathy in patients treated with these agents is more often insidious. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link&amp;anchor=H16#H16\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Acute neurotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy-induced neuropathic pain usually gradually improves after the treatment is stopped or the dose is reduced; occasionally, neuropathic pain becomes chronic. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Chemotherapy-related neuropathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Rare overall, acute chemotherapy-related mononeuropathy is best described with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    . Orofacial pain (particularly jaw pain) is the most common manifestation, with multiple sites affected in the distribution of the trigeminal and glossopharyngeal nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/2\">",
"     2",
"    </a>",
"    ]. Other nerves, including the recurrent laryngeal, optic, and auditory nerves, may also be affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other chemotherapy-related acute pain syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific chemotherapeutic agents and hormone agents are associated with a variety of other acute pain syndromes, examples of which are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef53180 \" href=\"UTD.htm?36/63/37884\">",
"     table 5",
"    </a>",
"    ). Patient education and reassurance may be the only intervention necessary in many cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Radiation plexopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute, transient brachial plexopathy can occur after RT that involves a nerve plexus (",
"    <a class=\"graphic graphic_table graphicRef61879 \" href=\"UTD.htm?37/43/38588\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/3\">",
"     3",
"    </a>",
"    ]. Mimicking the syndrome known as acute brachial plexitis (brachial neuritis), this disorder is characterized by pain, paresthesias, and weakness in the shoulder, arm, and hand. The syndrome is usually self-limited but may cause persistent pain or dysfunction. Newer methods of RT appear to have substantially reduced the incidence of this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link\">",
"     \"Brachial plexus syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of peripheral nerve irradiation\", section on 'Transient brachial plexopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Radiation enteritis and proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing abdominal irradiation may experience cramping, nausea, and vomiting (radiation enteritis). The corresponding syndrome in those receiving pelvic irradiation (radiation proctitis) includes painful tenesmus with diarrhea, mucus discharge, and bleeding. Newer RT methods such as 3D-CRT have reduced the incidence and severity of these painful syndromes, but they have not eliminated the risk of bowel toxicity when the RT field includes the intestinal viscera. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link&amp;anchor=H14#H14\">",
"     \"Gastrointestinal toxicity of radiation therapy\", section on 'Radiation enteritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms can occur within hours after the onset of RT, but they more often develop several weeks into therapy. Specific factors that increase the risk for RT-related bowel toxicity include older age, concomitant chemotherapy, and at least in the setting of rectal cancer, the use of postoperative rather than preoperative RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H12#H12\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Versus adjuvant chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHRONIC PAIN SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately three-fourths of cancer patients who have chronic pain have nociceptive (somatic and visceral) or neuropathic syndromes that represent direct effects of the neoplasm (",
"    <a class=\"graphic graphic_table graphicRef57573 \" href=\"UTD.htm?23/33/24093\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=see_link&amp;anchor=H8#H8\">",
"     \"Assessment of cancer pain\", section on 'Inferred pathophysiology (types of cancer pain)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of chronic pain in cancer patients are antineoplastic treatments (",
"    <a class=\"graphic graphic_table graphicRef75564 \" href=\"UTD.htm?41/61/42971\">",
"     table 7",
"    </a>",
"    ), and disorders that are unrelated to the disease or its treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tumor-related somatic pain syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor involvement of bone, joints, muscle, or connective tissue can cause persistent somatic pain (",
"    <a class=\"graphic graphic_table graphicRef57573 \" href=\"UTD.htm?23/33/24093\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Multifocal bone pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone metastases are the most prevalent cause of chronic pain in cancer patients. Skeletal metastases are a common manifestation of distant disease spread from many types of solid cancers, especially those arising in the lung, breast, and prostate.",
"   </p>",
"   <p>",
"    The pain associated with bone metastases may be due to direct invasion, secondary pathologic fracture, or damage to adjacent structures. Although the factors that convert a painless to a painful bone metastasis are not known, some combination of direct nociceptor activation by tumor, mechanical distortion related to microfracture, or local release of growth factors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemical mediators, may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local field external beam RT is a well-recognized and effective palliative modality for painful bone metastases; pain relief is seen in 80 to 90 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=see_link\">",
"     \"Radiation therapy for the management of painful bone metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the majority of patients with multifocal bone pain have widespread bony metastases, hematologic malignancies can rarely produce painful bone marrow expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/7\">",
"     7",
"    </a>",
"    ]. This is presumably caused by nests of rapidly growing cells in the marrow.",
"   </p>",
"   <p>",
"    In addition, a rare paraneoplastic form of renal phosphate wasting called oncogenic osteomalacia can cause osteomalacia, multifocal bone pain, and fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/8\">",
"     8",
"    </a>",
"    ]. This rare syndrome is most often associated with mesenchymal neoplasms, and complete tumor removal can lead to rapid correction of the biochemical derangements, remineralization of bone, and symptom improvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H22#H22\">",
"     \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'Tumor-induced osteomalacia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vertebral pain&nbsp;syndromes &mdash; The most common sites of bone metastases are the vertebrae. Specific syndromes may evolve from lesions involving different spinal levels (",
"      <a class=\"graphic graphic_table graphicRef62926 \" href=\"UTD.htm?15/25/15771\">",
"       table 8",
"      </a>",
"      ). Back pain that develops at any level from vertebral metastases may signal epidural extension, which is associated with the serious complications of spinal cord or cauda equina compression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"       \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Neoplastic epidural spinal cord compression (ESCC) is a common complication of cancer that can cause pain and potentially irreversible loss of neurologic function. Most often, ESCC is caused by posterior extension of a vertebral body metastasis into the epidural space (",
"      <a class=\"graphic graphic_figure graphicRef81204 \" href=\"UTD.htm?4/51/4918\">",
"       figure 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      ESCC almost always presents initially as back or neck pain. Because pain usually precedes neurological impairment by weeks or months, it is crucial to diagnose epidural disease extension in patients when pain is the sole complaint so that effective treatment may be started to prevent or retard the progression of neurologic impairment. For most patients, magnetic resonance imaging (MRI) is the preferred approach to evaluate the epidural space. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\", section on 'Radiologic confirmation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For most patients, RT represents first-line definitive treatment for ESCC. Glucocorticoid treatment is useful to temporarily improve pain and neurological functioning, often providing a window of time during which RT can be provided. Surgical decompression is considered if the tumor type is typically radioresistant and the lesion is high grade, if the neurologic status is deteriorating during RT, if ESCC occurs in a previously irradiated field, if the lesion is posterior and can be easily extirpated, or if a tissue diagnosis is needed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=see_link\">",
"       \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pelvic and hip metastases &mdash; Pelvic metastases may involve the ilium, ischium, pubis, or sacroiliac areas. In addition to local pain, tumor invasion of the hip joint may present as hip or inguinal pain upon walking or as pain in the knee or thigh. Injury to structures just inside the pelvic ring can result in related syndromes, such as a malignant piriformis syndrome (pain in the buttock",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sciatic distribution, often with exacerbation during internal rotation of the hip) or a painful plexopathy (",
"      <a class=\"graphic graphic_table graphicRef57573 \" href=\"UTD.htm?23/33/24093\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=see_link&amp;anchor=H31#H31\">",
"       \"Overview of lower extremity peripheral nerve syndromes\", section on 'Compression/trauma in the sciatic notch/gluteal region'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Sacral syndrome is associated with the destruction of the sacrum due to neoplastic infiltration. It is characterized by severe focal pain radiating to the buttocks, perineum, and posterior thigh [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/9\">",
"       9",
"      </a>",
"      ]. Involvement of the lateral hip rotators makes movement at the hip painful.",
"      <br/>",
"      <br/>",
"      These lesions are typically treated with RT, but interventional pain strategies or surgery may be considered in some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Base of skull metastases &mdash; Neoplastic injury to the base of the skull may occur from the local extension of a nasopharyngeal cancer or from skeletal metastases involving this area, usually due to breast, lung or prostate cancers [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Depending on their location, base of skull metastases may cause specific pain syndromes (",
"      <a class=\"graphic graphic_table graphicRef64650 \" href=\"UTD.htm?22/59/23484\">",
"       table 9",
"      </a>",
"      ). In most situations, the responsible lesion is readily identifiable on axial CT imaging with bone windows or MRI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Soft tissue pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcomas can arise in muscle, as can metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In either case, pain at the local site of involvement is common.",
"   </p>",
"   <p>",
"    Muscle pain may also be due to muscular cramps, which in cancer patients can be associated with neural injury (eg, radiculopathy or plexopathy) or caused by a biochemical abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/16\">",
"     16",
"    </a>",
"    ]. Biochemical abnormalities such as hypercalcemia or hyponatremia may be the result of a paraneoplastic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Somatic chest wall pain is common among patients with lung cancer or mesothelioma, and can be due to direct tumor infiltration of the ribs, intercostal spaces, or parietal pleura (",
"    <a class=\"graphic graphic_table graphicRef57573 \" href=\"UTD.htm?23/33/24093\">",
"     table 6",
"    </a>",
"    ). The pain usually is worsened by deep inspiration. A malignant intercostal mononeuropathy may accompany this lesion and yield a syndrome that has mixed nociceptive and neuropathic features.",
"   </p>",
"   <p>",
"    Soft tissue pain may also be caused by a paraneoplastic disorder (eg, hypertrophic osteoarthropathy, (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Paraneoplastic syndromes'",
"    </a>",
"    below)).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tumor-related visceral pain syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral pain can be caused by obstruction of any hollow viscus or injury to another pain-sensitive visceral structure such as the visceral pleura, hepatic capsule, or peritoneum (",
"    <a class=\"graphic graphic_table graphicRef57573 \" href=\"UTD.htm?23/33/24093\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/1\">",
"     1",
"    </a>",
"    ]. These syndromes are particularly common in patients with gastrointestinal and gynecologic malignancies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic distention syndrome &mdash; Pain-sensitive structures in the region of the liver include the hepatic capsule, vessels, and biliary tract [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/17\">",
"       17",
"      </a>",
"      ]. Stretching of the hepatic capsule by a primary hepatoma or intrahepatic metastases can cause chronic cancer pain, which is commonly described as dull, right sided subcostal pain. If the superior aspect of the capsule is involved, diaphragmatic irritation may lead to referred pain to the top of the ipsilateral shoulder.",
"      <br/>",
"      <br/>",
"      Pain also may result from injury or invasion of the porta hepatis, with or without biliary duct obstruction. This pain may be referred to the ipsilateral scapular region.",
"     </li>",
"     <li>",
"      Midline retroperitoneal syndrome &mdash; Tumor invasion of the pancreas or other subdiaphragmatic midline structures (eg, with retroperitoneal lymphadenopathy) may produce pain by injuring the deep somatic tissues of the posterior abdominal wall or by invasion of the celiac plexus [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. Pain is experienced in the epigastrium, low thoracic region of the back, or both. It is often described as a dull ache or a \"boring\" pain, that is worse when lying down and relieved by sitting up.",
"     </li>",
"     <li>",
"      Chronic intestinal obstruction &mdash; Diffuse abdominal pain may be related to chronic intestinal obstruction from either an abdominal neoplasm or scarring [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/21\">",
"       21",
"      </a>",
"      ]. The common cancers that cause intestinal obstruction are ovarian (up to 42 percent of cases) and colorectal (up to 24 percent of cases) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/22\">",
"       22",
"      </a>",
"      ]. In such cases, pain may be related to distension proximal to an obstructed bowel segment, mural ischemia, or tension on the mesentery.",
"      <br/>",
"      <br/>",
"      Pain may be continuous or colicky, and may be referred to the dermatomes represented by the spinal segments supplying the affected viscera. Nausea, vomiting and constipation are important associated symptoms. Abdominal radiographs taken in both the supine and upright positions may demonstrate the presence of air-fluid levels and intestinal distention. CT or MRI usually reveals the extent of the intraabdominal neoplasm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=see_link\">",
"       \"Small bowel obstruction: Causes and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peritoneal carcinomatosis &mdash; Carcinomatous seeding of the peritoneum leads to peritoneal inflammation, mesenteric tethering, malignant adhesions, and ascites, all of which can cause pain. Cancers of the ovary, colorectum and stomach are frequent causes of this syndrome. Pain may be diffuse or focal, sharp or crampy, and worse postprandially. Abdominal distention, nausea and constipation are common. CT may reveal evidence of ascites, omental infiltration,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peritoneal nodules [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39928?source=see_link\">",
"       \"Malignancy-related ascites\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malignant perineal pain &mdash; Malignancy-related perineal pain is most often associated with tumors of the colon or rectum, female reproductive tract, and distal genitourinary system. The pain may be exacerbated by sitting or standing, and there may be a component of tenesmus or tenesmoid pain, or intermittent severe pain consistent with bladder spasms [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/24\">",
"       24",
"      </a>",
"      ]. Some patients describe a discrete syndrome that is characterized by discomfort or pain that occurs rapidly after standing and disappears in other positions; this symptom complex mimics an idiopathic tension myalgia syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"       \"Causes of chronic pelvic pain in women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adrenal pain syndrome &mdash; Adrenal metastases (which are most commonly seen in non-small cell lung cancer) can produce unilateral flank pain which may radiate into the ipsilateral upper and lower quadrants of the abdomen [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/25\">",
"       25",
"      </a>",
"      ]. Severe acute pain may result from adrenal hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"       \"Clinical presentation and evaluation of adrenocortical tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=see_link\">",
"       \"Role of imaging in the staging of non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ureteral obstruction &mdash; Gastrointestinal, genitourinary and gynecological cancers are the most common causes of ureteral obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/27\">",
"       27",
"      </a>",
"      ]. Although these patients may present acutely, others present subacutely with flank pain which radiates to the inguinal region. Pain is often colicky, ie, intermittent and wave-like. When severe, pain due to ureteric obstruction may be associated with nausea and vomiting. Imaging studies may confirm the nature of the syndrome by demonstrating ipsilateral hydronephrosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Directly related to cancer'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"       \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Tumor-related neuropathic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathic pain syndromes that are directly caused by neoplastic invasion may involve the spinal cord, nerve roots, plexuses, or peripheral nerves (",
"    <a class=\"graphic graphic_table graphicRef57573 \" href=\"UTD.htm?23/33/24093\">",
"     table 6",
"    </a>",
"    ). About 40 percent of patients with chronic cancer-related pain have a neuropathic pain syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Leptomeningeal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any solid or hematological neoplasm can potentially infiltrate the leptomeninges, but the common tumors are lung and breast cancer, lymphoma and leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical presentation is variable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients have headache, which may or may not have characteristics typical for intracranial hypertension (generalized aching or throbbing that is worse in the morning and with Valsalva maneuvers, and sometimes associated with nausea and vomiting). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Others experience nonspecific back pain, or pain in a radicular distribution that can affect any level of the neuraxis.",
"     </li>",
"     <li>",
"      These variable pains may be accompanied by an equally diverse set of neurological complications, including seizures, cognitive impairment, hemiparesis or hemisensory syndromes, spinal cord syndromes, or any combination of motor or sensory disturbance consistent with a cranial neuropathy or radiculopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the variable presentation, leptomeningeal metastases can mimic any type of pain syndrome or neurologic disorder, and should be suspected whenever pain or neurological impairment progresses and eludes initial diagnosis.",
"   </p>",
"   <p>",
"    The diagnosis of a leptomeningeal neoplasm is made by the finding of malignant cells on lumbar puncture. T1-weighted, gadolinium-enhanced cranial and spinal cord MRI may identify or raise suspicion for leptomeningeal spread, and can be positive even if the cerebrospinal fluid is initially negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Cranial neuralgias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy-related cranial neuralgias can develop from metastases involving the base of the skull or the leptomeninges, or from cancers that arise in the soft tissue of the head, neck, or sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glossopharyngeal neuralgia &mdash; Glossopharyngeal neuralgia is characterized by paroxysmal unilateral severe, stabbing or lancinating pain in the throat or neck which may radiate to the ear and mastoid regions. Typical triggers include chewing, swallowing, coughing, speaking, yawning, certain tastes, or touching the neck or external auditory canal. The syndrome can occur in a pattern of episodes lasting weeks to months, alternating with longer periods of remission.",
"      <br/>",
"      <br/>",
"      Injury to the ninth cranial nerve is most often caused by leptomeningeal metastases, or from primary tumors or metastatic deposits that involve the jugular foramen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of craniofacial pain\", section on 'Glossopharyngeal neuralgia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trigeminal neuralgia &mdash; A syndrome that mimics idiopathic trigeminal neuralgia may be caused by tumors of the middle or posterior cranial fossa. This pain may be labeled a painful trigeminal neuropathy. However, because it most often presents with \"electric shock-like\" or stabbing paroxysms that are similar to the symptoms seen in the idiopathic syndrome, it may be called a malignant, or tumor-related, trigeminal neuralgia. If a lesion that involves the trigeminal nerve produces different qualities of pain, such as a constant aching or burning in the face, it is more appropriate to describe the syndrome as a painful trigeminal neuropathy rather than a malignant trigeminal neuralgia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link&amp;anchor=H6#H6\">",
"       \"Trigeminal neuralgia\", section on 'Clinical features'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Many patients with tumor-related trigeminal neuralgia are treated, at least initially, for an idiopathic process. Over time, however, tumor growth leads to symptoms and signs that raise suspicion as to the nature of the disorder (eg, change in the quality of the pain or the development of neurological deficits on examination) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/31\">",
"       31",
"      </a>",
"      ]. Imaging of both the brain and skull base may be necessary to characterize or exclude a mass lesion as the cause of the pain and associated features. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link&amp;anchor=H4#H4\">",
"       \"Trigeminal neuralgia\", section on 'Etiology and pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Radiculopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any malignant process that compresses, distorts, or inflames nerve roots may cause a painful radiculopathy. If multiple nerve roots are affected, it is called a polyradiculopathy. A painful radiculopathy may result from leptomeningeal metastases, intradural tumor (particularly meningioma, neurofibroma, and ependymoma) or tumor in the epidural space. The latter situation is most common and may arise via posterior extension of a tumor from a vertebral body metastasis, or growth into the intervertebral foramen from a paraspinal site of disease (",
"    <a class=\"graphic graphic_figure graphicRef81204 \" href=\"UTD.htm?4/51/4918\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radicular pain may be continuous or intermittent, aching or sharp, or dysesthetic (eg, burning or electrical-like) in quality; it may or may not be associated with neurological signs. When located in the thoracic level and bilateral in distribution, the pain may be experienced as a tight band across the chest or abdomen, a presentation that signals a relatively high likelihood of associated epidural disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\", section on 'Pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A high index of suspicion for a malignant cause of radiculopathy or polyradiculopathy should lead to a spinal MRI. If the patient has known vertebral metastasis or paraspinal disease, this test can be done without contrast enhancement; if infiltration of nerve roots is suspected, then a study with and without the injection of contrast is more informative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Plexopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor-related plexopathies may involve the cervical, brachial, or lumbosacral plexus (",
"    <a class=\"graphic graphic_table graphicRef65913 \" href=\"UTD.htm?12/34/12844\">",
"     table 10",
"    </a>",
"    ). Pain is the usual presenting symptom.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical plexopathy &mdash; A malignant cervical plexopathy may be due to a head and neck tumor, or to metastatic deposits that originate in the cervical lymph nodes. The pain, which is often described as aching or burning, may be experienced in the periauricular, postauricular, or anterior regions of the neck, or be referred to the lateral aspect of the face, head or shoulder.",
"      <br/>",
"      <br/>",
"      If there is involvement of the superior cervical (stellate) ganglion of the sympathetic chain or of the sympathetic nerves adjacent to the carotid artery, a Horner's syndrome (ipsilateral miosis, ptosis, and anhidrosis) may be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=see_link\">",
"       \"Horner's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brachial plexopathy &mdash; Brachial plexopathy may present with shoulder, arm or hand pain, with or without neurological deficits or a Horner's syndrome.",
"      <br/>",
"      <br/>",
"      The usual cause of a malignant brachial plexopathy is local extension of a primary or metastatic tumor; cancers of the lung or breast, and lymphomas are the most common etiology [",
"      <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/32\">",
"       32",
"      </a>",
"      ]. Primary brachial plexus tumors, such as schwannomas or neurofibromas, are uncommon, and most occur as solitary tumors. These rarely cause symptomatic plexopathies. However, multiple tumors occur in patients with neurofibromatosis type 1, and these are more likely than solitary tumors to present with pain or clinical deficits.",
"      <br/>",
"      <br/>",
"      Initial signs and symptoms vary based upon anatomic location (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link\">",
"       \"Brachial plexus syndromes\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When the inferior plexus is involved first, as occurs with tumors of the lung arising in the region of the superior sulcus (Pancoast tumors), pain typically begins in the elbow and gradually spreads to involve the medial arm and hand. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=see_link\">",
"       \"Pancoast's syndrome and superior (pulmonary) sulcus tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the superior aspect of the plexus is injured first, as occurs when tumor arises from cervical lymph nodes and grows inferiorly, the pain typically starts in the shoulder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pain is classically followed by paresthesias in the distribution innervated by the involved nerves (",
"    <a class=\"graphic graphic_figure graphicRef50576 \" href=\"UTD.htm?34/25/35222\">",
"     figure 2",
"    </a>",
"    ). Weakness and sensory loss follow. Ultimately, a panplexopathy may develop, with pain and dysfunction that affects the entire limb.",
"   </p>",
"   <p>",
"    Among patients who have been previously treated for a malignancy, the differential diagnosis of a new brachial plexopathy includes recurrent tumor and radiation injury. In the setting of a known neoplasm and radiation therapy, distinguishing between cancer recurrence and radiation-induced plexopathy can be challenging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H23#H23\">",
"     \"Brachial plexus syndromes\", section on 'Radiation-induced'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H29\">",
"     'Postradiation pain syndromes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis of neoplastic versus radiation-induced brachial plexopathy is suggested by the symptoms and signs, and electrodiagnostic findings, and is confirmed by imaging, or in some cases, by biopsy. In general, radiation-induced plexopathy is less painful than neoplastic brachial plexopathy; the upper plexus is more commonly involved, there often is relatively intense paresthesias, and radiation changes in the skin and other soft tissues are evident (eg, poikiloderma, telangiectasias, atrophy, hyperpigmentation, and lymphedema). Radiation is less likely to be associated with a Horner's syndrome than plexopathy related to tumor recurrence.",
"   </p>",
"   <p>",
"    The diagnosis of a radiation-induced rather than neoplastic plexopathy is supported by the presence of so-called myokymic discharges on electromyography. These are relatively specific for radiation-induced injury, but are not a universal feature, and their absence does not exclude the diagnosis.",
"   </p>",
"   <p>",
"    MRI or CT scan of the plexus can usually establish the diagnosis. Occasionally, biopsy is needed. Because tumors adjacent to the spine may be responsible for a brachial plexopathy, MRI of the epidural space may be needed. Imaging of the chest by CT or MRI is most useful to detect a pulmonary tumor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lumbosacral plexopathy &mdash; Malignant lumbosacral plexopathy is primarily associated with colorectal, cervical, and breast cancers, sarcomas, lymphomas, and sacral chordomas. Neoplastic invasion typically presents with severe and progressive pain. The distribution of the pain and associated signs and symptoms depends on the site of anatomic involvement (",
"      <a class=\"graphic graphic_table graphicRef65913 \" href=\"UTD.htm?12/34/12844\">",
"       table 10",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic evaluation of a patient with a lumbosacral plexopathy is described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=see_link\">",
"     \"Lumbosacral plexus syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Peripheral mononeuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painful peripheral mononeuropathies can result from direct tumor invasion of a peripheral nerve. A classic example is malignant intercostal neuropathy complicating a chest wall tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Paraneoplastic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic syndromes are a heterogeneous group of disorders in cancer patients that are caused by substances released by a tumor or produced in reaction to it. These substances can be hormones or other compounds, including antibodies or other compounds produced through immune responses. Paraneoplastic disorders are not caused by direct tumor invasion, metabolic and nutritional deficits, infections, coagulopathy or side effects of cancer treatment.",
"   </p>",
"   <p>",
"    Paraneoplastic syndromes most commonly affect the nervous system, but can affect many tissues. Some examples of painful paraneoplastic syndromes are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef75839 \" href=\"UTD.htm?30/37/31323\">",
"     table 11",
"    </a>",
"    ), and two are described in more detail below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subacute sensory neuronopathy &mdash; One of the best characterized painful neurologic paraneoplastic syndromes is subacute sensory neuronopathy (sensory ganglioneuropathy), a rare condition that is related to inflammation of the dorsal root ganglion. Like many other neurologic paraneoplastic syndromes, it is most common in patients with small cell lung cancer.",
"      <br/>",
"      <br/>",
"      The sensory deficits typically begin with loss of vibratory sensation and joint position sense following by impairment in pain and temperature sensation. Patients frequently complain of the sensation of \"pins and needles\" or \"electric shocks\". The symptoms may initially affect one extremity but, in a few weeks or months, they usually progress to involve other extremities, the face, abdomen, or trunk. A severe sensory ataxia may prevent walking or even self-care. In a subset of patients, hyperalgesia and spontaneous pain remain the prominent symptom, and sensory ataxia is mild or even absent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=see_link&amp;anchor=H8#H8\">",
"       \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\", section on 'Subacute sensory neuronopathy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other, more prevalent paraneoplastic polyneuropathies comprise axonopathies that may accompany any tumor type but are often associated with plasma cell dyscrasias. The pain associated with these types of neuropathy begins in the feet symmetrically and gradually ascends as the lesion progresses. All of these paraneoplastic neuropathies can be the initial manifestation of an underlying malignancy and their occurrence should prompt a search for an occult cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=see_link&amp;anchor=H4#H4\">",
"       \"Paraneoplastic syndromes affecting peripheral nerve and muscle\", section on 'Chronic sensorimotor neuropathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertrophic osteoarthropathy &mdash; Hypertrophic osteoarthropathy is a syndrome characterized by abnormal proliferation of the skin and osseous tissue at the distal parts of the extremities. The secondary form is usually associated with lung cancer. Clinical features include digital clubbing (",
"      <a class=\"graphic graphic_figure graphicRef52839 \" href=\"UTD.htm?42/58/43951\">",
"       figure 3",
"      </a>",
"      ), periostosis of tubular bones (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57502 \" href=\"UTD.htm?4/63/5119\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70330 \" href=\"UTD.htm?10/43/10942\">",
"       image 2",
"      </a>",
"      ), and synovial effusions, which are most prominent in the large joints. Periostosis is usually accompanied by pain on palpation of the involved area. Some patients present with a painful arthropathy in advance of clubbing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link&amp;anchor=H13#H13\">",
"       \"Malignancy and rheumatic disorders\", section on 'Hypertrophic osteoarthropathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new, changed, or progressive headache in a patient with a history of cancer should be evaluated first with a thorough neurological examination, and then with imaging studies if the diagnosis of an intracranial mass lesion is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pain related to antineoplastic treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy (including glucocorticoid therapy, hormonal therapy, and biological agents, radiation therapy, and surgery) each may be associated with a group of chronic pain syndromes (",
"    <a class=\"graphic graphic_table graphicRef75564 \" href=\"UTD.htm?41/61/42971\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Chemotherapy-related neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although painful peripheral neuropathy resulting from cytotoxic therapy usually subsides over time, some patients develop persistent pain. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Chemotherapy induced neuropathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The pain is similar to other axonopathies, with initial involvement of the feet and distal legs, followed by the hands and arms. The severity of the pain and the presence and degree of neurologic impairment vary widely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link\">",
"     \"Neurologic complications of platinum-based chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, patients develop a persistent Raynaud's phenomenon; this has been observed in approximately one-third of cancer patients with testicular tumors treated with regimens containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\", section on 'Raynaud's phenomenon'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Bone complications and glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic use of glucocorticoids may cause avascular necrosis of the femoral or humeral head, which is typically heralded by a painful arthropathy. Radiologic changes on MRI or CT studies may not appear for a few months after the initial report of pain.",
"   </p>",
"   <p>",
"    Steroids also accelerate osteoporosis, which may predispose to vertebral compression fractures associated with acute or chronic back pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H17#H17\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Osteonecrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Antiandrogens and gynecomastia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painful gynecomastia develops in the majority of men receiving therapy for antiandrogens alone for advanced prostate cancer unless prophylactic radiotherapy is administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H28#H28\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Gynecomastia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Postsurgical pain syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-defined pain syndromes may occur after the surgical excision of cancer. The best characterized include postmastectomy pain syndrome, post-radical neck dissection pain syndrome, post-thoracotomy pain syndrome, postoperative frozen shoulder, post-surgery pelvic floor pain, stump and phantom limb pain following amputation, and phantom breast pain (",
"    <a class=\"graphic graphic_table graphicRef70349 \" href=\"UTD.htm?34/22/35180\">",
"     table 12",
"    </a>",
"    ). These syndromes are predominantly neuropathic and presumably related to nerve injury at the time of surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link&amp;anchor=H510013959#H510013959\">",
"     \"Mastectomy\", section on 'Pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link&amp;anchor=H510014056#H510014056\">",
"     \"Mastectomy\", section on 'Phantom breast syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Pain and phantom sensation after limb amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pain following limb amputation may involve stump pain, phantom pain, or both. Stump pain may be due to neuroma formation several months after amputation, but a poorly fitting prosthesis, recurrent tumor, infection, or ischemia also may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phantom sensation, the sensory experience that the amputated limb is still present, occurs in most amputees. Phantom pain, which is often paroxysmal and atypical, and described by some as an intense twisting or crushing sensation, is also common [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous neurophysiologic explanations for phantom pain have been advanced, from changes at the stump to functional cortical changes. Sensory deafferentation in primates and arm amputation in humans causes cortical somatosensory reorganization; this phenomenon may explain the elicitation of phantom pain by sensory stimulation at other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a number of therapeutic approaches may help [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/36-42\">",
"     36-42",
"    </a>",
"    ], management of phantom pain remains difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Postradiation pain syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pain following RT is a late complication, and often must be differentiated from recurrent tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Plexopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced cervical, brachial or lumbosacral plexopathies may occur months to many years after RT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/43\">",
"     43",
"    </a>",
"    ]. The usual presenting signs are weakness and sensory changes. Although they cause pain, it is rarely severe. Chronic perineal pain following pelvic RT is often clinically associated with a sacral plexopathy. The pain is burning in nature and may extend anteriorly to the vagina or scrotum [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of these syndromes has declined over the years due to lower-dose regimens and better RT techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link&amp;anchor=H4#H4\">",
"     \"Complications of peripheral nerve irradiation\", section on 'Late-delayed brachial plexopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link&amp;anchor=H9#H9\">",
"     \"Complications of peripheral nerve irradiation\", section on 'Lumbosacral plexopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main differential is with a plexopathy from recurrent tumor. As noted above, in the setting of a known neoplasm and RT, distinguishing between cancer recurrence and radiation-induced brachial plexopathy can be challenging. These issues are discussed above (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Plexopathies'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic radiation myelopathy is another late complication which may develop many years following the completion of RT. Sensory symptoms, including pain, typically precede the development of progressive motor and autonomic dysfunction. The pain is usually characterized as a burning dysesthesia and is localized to the area of spinal cord damage or below this region. The neurological findings may be consistent with a transverse myelopathy, sometimes in a Brown-Sequard pattern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7190?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of spinal cord irradiation\", section on 'Late radiation-induced myelopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link&amp;anchor=H18#H18\">",
"     \"Anatomy and localization of spinal cord disorders\", section on 'Brown-Sequard (hemi-cord) syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     GI tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic enteritis and proctitis may result from irradiation to the abdomen and pelvis. Small bowel obstruction, strictures, gastroparesis and intestinal pseudo-obstruction (eg, impaired gastrointestinal motility without any anatomical obstruction), fistula formation, gastrointestinal perforation, and bleeding are all late manifestations of radiation toxicity to the gastrointestinal tract, and persistent abdominal pain often complicates these lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13975?source=see_link\">",
"     \"Diagnosis and management of chronic radiation enteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link\">",
"     \"Gastrointestinal toxicity of radiation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=see_link\">",
"     \"Chronic intestinal pseudo-obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7226?source=see_link\">",
"     \"Malignancy-associated gastroparesis: Pathophysiology and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Lymphedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema may result from RT to the breast or shoulder, or to the pelvis. Approximately one-third of cancer patients with lymphedema experience pain and tightness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/45\">",
"     45",
"    </a>",
"    ]. The pathophysiology underlying the pain is usually musculoskeletal but some patients develop stretch injuries to the plexus or nerve entrapment syndromes, and as a result, experience neuropathic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/41/21146/abstract/46\">",
"     46",
"    </a>",
"    ]. The new onset of severe or progressive pain in a lymphedematous limb suggests tumor recurrence infection, or a secondary malignancy (eg, Stewart-Treves syndrome) and requires reevaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Osteonecrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation also can cause osteoradionecrosis as a result of endarteritis obliterans in the bone. Osteoradionecrosis of the jaw may follow radiotherapy for head and neck cancers, and is associated with pain and mechanical dysfunction. Osteonecrosis of other bones occurs less often but may complicate radiation at virtually any site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822453#H3822453\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Osteoradionecrosis and soft tissue necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       \"Patient information: Managing pain when you have cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/59/11186?source=see_link\">",
"       \"Patient information: Mouth sores from cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cancer pain syndrome is defined as a clinically meaningful constellation of symptoms and signs in a patient with cancer. The identification of a specific pain syndrome in cancer patients may help to elucidate the etiology, help direct the diagnostic evaluation, clarify the prognosis for the pain or the disease itself, and guide subsequent therapeutic interventions. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cancer pain syndromes may be broadly divided into those that are acute and those that are chronic. Acute pain syndromes usually accompany diagnostic or therapeutic interventions, although some are directly related to the malignancy itself (eg, hemorrhage into a hepatocellular cancer, pathologic fracture, obstruction or perforation of a bile duct, ureter, or bowel lumen). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Acute pain syndromes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Chronic pain syndromes are usually directly related to the neoplasm itself or to an antineoplastic therapy (including chemotherapy, surgery, or radiation therapy). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Chronic pain syndromes'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Foley KM. Acute and chronic cancer pain syndromes: Oxford Textbook of Palliative Medicine, 3rd, Oxford University Press, New York 2004. p.298.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/2\">",
"      McCarthy GM, Skillings JR. Jaw and other orofacial pain in patients receiving vincristine for the treatment of cancer. Oral Surg Oral Med Oral Pathol 1992; 74:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/3\">",
"      Salner AL, Botnick LE, Herzog AG, et al. Reversible brachial plexopathy following primary radiation therapy for breast cancer. Cancer Treat Rep 1981; 65:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/4\">",
"      Portenoy RK. Treatment of cancer pain. Lancet 2011; 377:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/5\">",
"      Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/6\">",
"      Schweizerhof M, St&ouml;sser S, Kurejova M, et al. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med 2009; 15:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/7\">",
"      Beckers R, Uyttebroeck A, Demaerel P. Acute lymphoblastic leukaemia presenting with low back pain. Eur J Paediatr Neurol 2002; 6:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/8\">",
"      Jan de Beur SM. Tumor-induced osteomalacia. JAMA 2005; 294:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/9\">",
"      Feldenzer JA, McGauley JL, McGillicuddy JE. Sacral and presacral tumors: problems in diagnosis and management. Neurosurgery 1989; 25:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/10\">",
"      Papagelopoulos PJ, Mavrogenis AF, Soucacos PN. Evaluation and treatment of pelvic metastases. Injury 2007; 38:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/11\">",
"      Greenberg HS, Deck MD, Vikram B, et al. Metastasis to the base of the skull: clinical findings in 43 patients. Neurology 1981; 31:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/12\">",
"      Da Silva AN, Schiff D. Dural and skull base metastases. Cancer Treat Res 2007; 136:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/13\">",
"      Araki K, Kobayashi M, Ogata T, Takuma K. Colorectal carcinoma metastatic to skeletal muscle. Hepatogastroenterology 1994; 41:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/14\">",
"      Sridhar KS, Rao RK, Kunhardt B. Skeletal muscle metastases from lung cancer. Cancer 1987; 59:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/15\">",
"      Ferrandina G, Salutari V, Testa A, et al. Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature. BMC Cancer 2006; 6:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/16\">",
"      Siegal T. Muscle cramps in the cancer patient: causes and treatment. J Pain Symptom Manage 1991; 6:84.",
"     </a>",
"    </li>",
"    <li>",
"     Coombs DW. Pain due to liver capsular distention. In: Common problems in pain management. Common problems in anesthesia, Ferrer-Brechner T (Ed), Year Book Medical Publishers, Chicago 1990. p.247.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/18\">",
"      Grahm AL, Andr&eacute;n-Sandberg A. Prospective evaluation of pain in exocrine pancreatic cancer. Digestion 1997; 58:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/19\">",
"      Kelsen DP, Portenoy R, Thaler H, et al. Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery 1997; 122:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/20\">",
"      Sch&ouml;nenberg P, Bastid C, Guedes J, Sahel J. [Percutaneous echography-guided alcohol block of the celiac plexus as treatment of painful syndromes of the upper abdomen: study of 21 cases]. Schweiz Med Wochenschr 1991; 121:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/21\">",
"      Ripamonti C. Management of bowel obstruction in advanced cancer. Curr Opin Oncol 1994; 6:351.",
"     </a>",
"    </li>",
"    <li>",
"     Ripamonti C, Mercadante S. Pathophysiology and management of malignant bowel obstruction. In: Oxford textbook of palliative medicine, 3rd, Doyle D, Hanks GW, McDonald N, Cherny N (Eds), Oxford University Press, New York 2005. p.496.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/23\">",
"      Archer AG, Sugarbaker PH, Jelinek JS. Radiology of peritoneal carcinomatosis. Cancer Treat Res 1996; 82:263.",
"     </a>",
"    </li>",
"    <li>",
"     Stillman M. Perineal pain: diagnosis and management, with particular attention to perineal pain of cancer. In: Second International Congress on Cancer Pain - Advances in pain research and therapy, Foley KM, Bonica JJ, Ventafrida V (Eds), Raven Press, New York 1990. Vol 16, p.359.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/25\">",
"      Berger MS, Cooley ME, Abrahm JL. A pain syndrome associated with large adrenal metastases in patients with lung cancer. J Pain Symptom Manage 1995; 10:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/26\">",
"      Karanikiotis C, Tentes AA, Markakidis S, Vafiadis K. Large bilateral adrenal metastases in non-small cell lung cancer. World J Surg Oncol 2004; 2:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/27\">",
"      Russo P. Urologic emergencies in the cancer patient. Semin Oncol 2000; 27:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/28\">",
"      Taillibert S, Laigle-Donadey F, Chodkiewicz C, et al. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 2005; 75:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/29\">",
"      Nolan CP, Abrey LE. Leptomeningeal metastases from leukemias and lymphomas. Cancer Treat Res 2005; 125:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/30\">",
"      Gupta SR, Zdonczyk DE, Rubino FA. Cranial neuropathy in systemic malignancy in a VA population. Neurology 1990; 40:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/31\">",
"      Cheng TM, Cascino TL, Onofrio BM. Comprehensive study of diagnosis and treatment of trigeminal neuralgia secondary to tumors. Neurology 1993; 43:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/32\">",
"      Kori SH. Diagnosis and management of brachial plexus lesions in cancer patients. Oncology (Williston Park) 1995; 9:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/33\">",
"      Weinstein SM. Phantom pain. Oncology (Williston Park) 1994; 8:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/34\">",
"      van der Schans CP, Geertzen JH, Schoppen T, Dijkstra PU. Phantom pain and health-related quality of life in lower limb amputees. J Pain Symptom Manage 2002; 24:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/35\">",
"      Flor H, Elbert T, Knecht S, et al. Phantom-limb pain as a perceptual correlate of cortical reorganization following arm amputation. Nature 1995; 375:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/36\">",
"      Halbert J, Crotty M, Cameron ID. Evidence for the optimal management of acute and chronic phantom pain: a systematic review. Clin J Pain 2002; 18:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/37\">",
"      Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med 2002; 27:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/38\">",
"      Jaeger H, Maier C. Calcitonin in phantom limb pain: a double-blind study. Pain 1992; 48:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/39\">",
"      Huse E, Larbig W, Flor H, Birbaumer N. The effect of opioids on phantom limb pain and cortical reorganization. Pain 2001; 90:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/40\">",
"      Kern U, Altkemper B, Kohl M. Management of phantom pain with a textile, electromagnetically-acting stump liner: a randomized, double-blind, crossover study. J Pain Symptom Manage 2006; 32:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/41\">",
"      Belleggia G, Birbaumer N. Treatment of phantom limb pain with combined EMG and thermal biofeedback: a case report. Appl Psychophysiol Biofeedback 2001; 26:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/42\">",
"      Weiss T, Miltner WH, Adler T, et al. Decrease in phantom limb pain associated with prosthesis-induced increased use of an amputation stump in humans. Neurosci Lett 1999; 272:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/43\">",
"      Johansson S, Svensson H, Denekamp J. Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. Int J Radiat Oncol Biol Phys 2002; 52:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/44\">",
"      Minsky BD, Cohen AM. Minimizing the toxicity of pelvic radiation therapy in rectal cancer. Oncology (Williston Park) 1988; 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/45\">",
"      Newman ML, Brennan M, Passik S. Lymphedema complicated by pain and psychological distress: a case with complex treatment needs. J Pain Symptom Manage 1996; 12:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/41/21146/abstract/46\">",
"      Ganel A, Engel J, Sela M, Brooks M. Nerve entrapments associated with postmastectomy lymphedema. Cancer 1979; 44:2254.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2804 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21146=[""].join("\n");
var outline_f20_41_21146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE PAIN SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Directly related to cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Associated with antineoplastic treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Oral mucositis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Chemotherapy induced neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other chemotherapy-related acute pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Radiation plexopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Radiation enteritis and proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHRONIC PAIN SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tumor-related somatic pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Multifocal bone pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Soft tissue pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tumor-related visceral pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Tumor-related neuropathic pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Leptomeningeal metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Cranial neuralgias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Radiculopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Plexopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Peripheral mononeuropathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Paraneoplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pain related to antineoplastic treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Chemotherapy-related neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Bone complications and glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Antiandrogens and gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Postsurgical pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Pain and phantom sensation after limb amputation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Postradiation pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Plexopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Myelopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - GI tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Lymphedema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Osteonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2804\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2804|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/63/5119\" title=\"diagnostic image 1\">",
"      Pulmonary osteoarthropathy I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/43/10942\" title=\"diagnostic image 2\">",
"      Pulmonary osteoarthropathy II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2804|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/51/4918\" title=\"figure 1\">",
"      Spinal nerves thoracic vertebra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/25/35222\" title=\"figure 2\">",
"      Trunks and cords of the brachial plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/58/43951\" title=\"figure 3\">",
"      Clubbing of the fingers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2804|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/44/32459\" title=\"table 1\">",
"      Pain assoc interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/47/6907\" title=\"table 2\">",
"      Pain synd cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/43/38588\" title=\"table 3\">",
"      Pain synd neoplastic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/47/41724\" title=\"table 4\">",
"      Chemo agents and mucositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/63/37884\" title=\"table 5\">",
"      Pain synd chemo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/33/24093\" title=\"table 6\">",
"      Chronic pain synd cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/61/42971\" title=\"table 7\">",
"      Chronic pain synd antineo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/25/15771\" title=\"table 8\">",
"      Tumor vertebral pain synd",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/59/23484\" title=\"table 9\">",
"      Tumor skull base synd",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/34/12844\" title=\"table 10\">",
"      Plexopathies cancer pts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/37/31323\" title=\"table 11\">",
"      Paraneo pain synds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/22/35180\" title=\"table 12\">",
"      Chronic postsurg pain synd",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=related_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=related_link\">",
"      Chronic intestinal pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=related_link\">",
"      Clinical manifestations and diagnosis of retroperitoneal fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7190?source=related_link\">",
"      Complications of spinal cord irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13975?source=related_link\">",
"      Diagnosis and management of chronic radiation enteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17735?source=related_link\">",
"      Exocrine pancreatic cancer: Palliation of symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/45/23257?source=related_link\">",
"      Lumbosacral plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7226?source=related_link\">",
"      Malignancy-associated gastroparesis: Pathophysiology and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39928?source=related_link\">",
"      Malignancy-related ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=related_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=related_link\">",
"      Overview of craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/58/14250?source=related_link\">",
"      Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6583?source=related_link\">",
"      Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/59/11186?source=related_link\">",
"      Patient information: Mouth sores from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=related_link\">",
"      Role of imaging in the staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=related_link\">",
"      Small bowel obstruction: Causes and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_41_21147="Assessment for auto-HCT eligibility";
var content_f20_41_21147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment for autologous hematopoietic cell transplantation eligibility",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Detailed history and physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Including Karnofsky performance status and dental examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Laboratory studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Complete blood count with differential; chemistries with liver and renal function and electrolytes; pregnancy test as clinically indicated; serology for HIV, hepatitis B, hepatitis C, herpes simplex and varicella, and cytomegalovirus; urine for microanalysis and macroanalysis; ABO typing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow aspiration and biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chest radiograph, an electrocardiogram, and a study of cardiac function (eg, ejection fraction measured by echocardiogram or MUGA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary function test, including DLCO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disease-specific restaging studies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MUGA: multiple gated cardiac blood pool imaging; DLCO: diffusing capacity of the lungs for carbon monoxide.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21147=[""].join("\n");
var outline_f20_41_21147=null;
var title_f20_41_21148="Treatment of APL";
var content_f20_41_21148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended treatment for acute promyelocytic leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Newly diagnosed patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Induction therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ATRA 45 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        PO per day in two divided doses until CR",
"        <strong>",
"         plus",
"        </strong>",
"        an anthracycline (eg, daunorubicin or idarubicin) with or without added cytarabine. The optimal dose of daunorubicin in this setting has not been clarified (see text).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Consolidation",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Two 25-day cycles of arsenic trioxide (0.15 mg/kg IV per day for five days each week for five weeks each) followed by two cycles of the combination of daunorubicin (50 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV daily for three days) plus ATRA (45 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day orally days 1 through 7).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ATRA 45 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        PO daily on an intermittent schedule (eg, 15 days every three months or 7 days every two weeks) for one year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Follow-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PCR for the PML/RARa fusion gene on a bone marrow specimen every three to six months for two years, and then every six months for two years. Monthly monitoring of peripheral blood may be a reasonable alternative. Relapses can occur between scheduled bone marrow studies and late relapses (ie, &gt;4 years) may be observed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Relapsed disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arsenic trioxide 0.15 mg/kg per day PO for 25 consecutive doses (or five doses per week for five weeks) to second CR, followed by autologous HCT (if cells are PCR negative). Allogeneic HCT can be considered if a suitable donor is available.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These recommendations are for patients with t(15;17) or the PML/RAR-alpha fusion gene only.",
"    <div class=\"footnotes\">",
"     ATRA: all-trans retinoic acid; CR: complete remission; PCR: polymerase chain reaction; 6-MP: 6-mercaptopurine; MTX: methotrexate; HCT: hematopoietic cell transplantation.",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2011; 116:3751.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21148=[""].join("\n");
var outline_f20_41_21148=null;
var title_f20_41_21149="Disulfide linkages in IgG subclasses";
var content_f20_41_21149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disulfide linkages of the human IgG immunoglobin subclasses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 220px; height: 534px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The B-Lymphocyte System: Clinical Immunology. In: Immunologic disorders in infants and children, 5th edition, Stiehm, ER, Ochs, HD, Winelstein, JA (Eds), Elsevier, Philadelphia 2004. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21149=[""].join("\n");
var outline_f20_41_21149=null;
var title_f20_41_21150="XELOX plus bevacizumab regimen";
var content_f20_41_21150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Capecitabine and oxaliplatin (XELOX) with bevacizumab for metastatic colorectal cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bevacizumab",
"        </strong>",
"       </td>",
"       <td>",
"        7.5 mg/kg IV",
"       </td>",
"       <td>",
"        Dilute into a total volume of 100 mL normal saline* and administer the first dose over 90 minutes following oxaliplatin. If tolerated, then administer second dose over 60 minutes after oxaliplatin. If tolerated, then administer all subsequent doses over 30 minutes before oxaliplatin.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oxaliplatin",
"        </strong>",
"       </td>",
"       <td>",
"        130 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL 5 percent dextrose in water (D5W)* and administer over two hours.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Capecitabine",
"        </strong>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        850 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per dose by mouth",
"       </td>",
"       <td>",
"        Twice daily; take with water within 30 minutes after a meal.",
"       </td>",
"       <td>",
"        Evening of day 1 to morning of day 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        Oxaliplatin plus bevacizumab: MODERATE. Capecitabine: LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen. Refer to UpToDate topics on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\" and \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Oxaliplatin is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors not indicated (estimated risk of febrile neutropenia &lt;5 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Lower starting doses of oxaliplatin and capecitabine may be needed for renal impairment. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Maneuvers to prevent neurotoxicity:",
"        </strong>",
"        Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during, and for approximately 48 hours after each infusion. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes and liver and renal function every three weeks prior to treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in blood pressure, urine protein concentration, neurologic function, and risk for bleeding prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Delay treatment one week if the total white blood cell count is less than 3000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , ANC is &lt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , or the platelets count is &lt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        on day 1. If treatment is delayed for two weeks or delayed for one week on two separate occasions, reduce the doses of oxaliplatin and capecitabine by 10 to 20 percent. Subsequent treatment cycles should be delayed until ANC &ge;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelets &ge;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        In the original trial, oxaliplatin dose was decreased by 25 percent for grade 3 paresthesias and dysethesias lasting longer than seven days, and the drug discontinued for grade 4 or persistent grade 3 paresthesia/dysesthesias",
"        <sup>",
"         [1]",
"        </sup>",
"        . The US FDA-approved package insert suggests dose reduction for persistent NCI-CTC grade 2 neurosensory events (sensory alteration or paresthesias including tingling but not interfering with activities of daily living [ADLs]) and discontinuation of oxaliplatin for persistent grade 3 (objective sensory loss or paresthesias including tingling interfering with function but not ADLs) or grade 4 neurosensory events",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        A dose reduction in oxaliplatin is recommended after recovery from grade 3 to 4 gastrointestinal toxicity",
"        <sup>",
"         [2]",
"        </sup>",
"        . Recommended dose modification guidelines for capecitabine are available in the US FDA-approved package insert",
"        <sup>",
"         [3]",
"        </sup>",
"        . Doses of capecitabine that are omitted for toxicity are not replaced. The patient should resume planned treatment cycles at the modified dose. Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy, serious hemorrhage, arterial thromboembolism, nephrotic syndrome, gastrointestinal perforation, fistula formation, or reversible posterior leukoencephalopathy syndrome (RPLS)",
"        <sup>",
"         [4]",
"        </sup>",
"        . Bevacizumab should not be administered within 28 days of surgery, and it should be suspended prior to elective surgery. Refer to UpToDate topics on \"",
"        <span class=\"emphasis\">",
"         Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"        </span>",
"        \" and \"",
"        <span class=\"emphasis\">",
"         Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\".",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; INR: international normalized ratio; ANC: absolute neutrophil count; NCI-CTC: National Cancer Institute Common Toxicity Criteria.",
"     <br/>",
"     * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     &Delta; Capecitabine should be administered within 30 minutes of a meal, with each dose given as close to 12 hours apart as possible.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Cassidy J, et al. J Clin Oncol. 2004; 22:2084.",
"      </li>",
"      <li>",
"       Eloxatin (oxaliplatin). US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 28, 2011).",
"      </li>",
"      <li>",
"       Xeloda (capecitabine). US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 28, 2011).",
"      </li>",
"      <li>",
"       Avastin (bevacizumab). US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 28, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_41_21150=[""].join("\n");
var outline_f20_41_21150=null;
var title_f20_41_21151="Collection of a 24-hour urine specimen";
var content_f20_41_21151=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/41/21151/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21151/contributors\" id=\"au801\">",
"       Ronald D Perrone, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21151/contributors\" id=\"au1167\">",
"       Lesley A Inker, MD, MS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/41/21151/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21151/contributors\" id=\"se5356\">",
"       Richard H Sterns, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/41/21151/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/41/21151/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?20/41/21151?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     The following instructions will guide you in the proper collection of a 24-hour urine specimen. In some instances, you will be asked to collect two or three consecutive 24-hour urine samples.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      INSTRUCTIONS",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You should collect every drop of urine during each 24-hour period. It does not matter how much or little urine is passed each time, as long as every drop is collected.",
"      </li>",
"      <li>",
"       Begin the urine collection in the morning after you wake up, after you have emptied your bladder for the first time.",
"      </li>",
"      <li>",
"       Urinate (empty the bladder) for the first time and flush it down the toilet. Note the exact time (eg, 6:15 AM). You will begin the urine collection at this time.",
"      </li>",
"      <li>",
"       Collect every drop of urine during the day and night in an empty collection bottle. Store the bottle at room temperature or in the refrigerator.",
"      </li>",
"      <li>",
"       If you need to have a bowel movement, any urine passed with the bowel movement should be collected. Try not to include feces with the urine collection. If feces does get mixed in, do not try to remove the feces from the urine collection bottle.",
"      </li>",
"      <li>",
"       Finish by collecting the first urine passed the next morning, adding it to the collection bottle. This should be within ten minutes before or after the time of the first morning void on the first day (which was flushed). In this example, you would try to void between 6:05 and 6:25 on the second day.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If you need to urinate one hour before the final collection time, drink a full glass of water so that you can void again at the appropriate time. If you have to urinate 20 minutes before, try to hold the urine until the proper time.",
"    </p>",
"    <p>",
"     Please note the exact time of the final collection, even if it is not the same time as when collection began on day one.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      STORAGE",
"     </span>",
"    </p>",
"    <p>",
"     The bottle(s) may be kept at room temperature for a day or two, but should be kept cool or refrigerated for longer periods of time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27018511\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27018527\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/56/43905?source=see_link\">",
"      Patient information: Kidney stones in adults (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27018541\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Beyond the Basics content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27018556\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding professional level content.",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?20/41/21151?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f20_41_21151=[""].join("\n");
var outline_f20_41_21151=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           INSTRUCTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           STORAGE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
